ORIGINAL ACRST- 3107

OFFICIAL TRANSCRIPT OF PROCEEDINGS NUCLEAR REGULATORY COMMISSION

ADVISORY COMMITTEE ON REACTOR SAFEGUARDS

Title:

MEETING: 469TH ADVISORY

COMMITTEE ON REACTOR

SAFEGUARDS (ACRS)

TRO4 (ACRS)
RETURN ORIGINAL Daly
TO BJWHITE
415-7130 Starting
THANKS!

Work Order No.: ASB-300-1118

LOCATION:

Rockville, MD

DATE: Thursday, February 3, 2000

PAGES: 1 - 287

ANN RILEY & ASSOCIATES, LTD. 1025 Connecticut Ave., NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034 ACRS Office Copy - Retain Lot the Life of the Committee

DISCLAIMER

UNITED STATES NUCLEAR REGULATORY COMMISSION'S ADVISORY COMMITTEE ON REACTOR SAFEGUARDS

FEBRUARY 3, 2000

The contents of this transcript of the proceeding of the United States Nuclear Regulatory Commission Advisory Committee on Reactor Safeguards, taken on February 3, 2000, as reported herein, is a record of the discussions recorded at the meeting held on the above date.

This transcript had not been reviewed, corrected and edited and it may contain inaccuracies.

А Ц		_
1		1
1	UNITED STATES OF AMERICA	
2	NUCLEAR REGULATORY COMMISSION	
3	ADVISORY COMMITTEE ON REACTOR SAFEGUARDS	
4	* * *	
5	MEETING: 469TH ADVISORY COMMITTEE ON	
6	REACTOR SAFEGUARDS (ACRS)	
7		
8 9	U.S. NRC	
	Two Flint Flint North, Room T2-B3	
10	11545 Rockville Pike	
10 11 12	Rockville, MD	
12	Thursday, Februay 3, 2000	
13	The committee met, pursuant to notice, 8:31 a.m.	
14	MEMBERS PRESENT:	
15	DANA POWERS, Chairman, ACRS	
16	THOMAS KRESS, Member, ACRS	
17	GEORGE APOSTOLAKIS, ACRS Member	
18	MARIO BONACA, ACRS Member	
19	JOHN BARTON, ACRS Member	
2.0	JOHN D. SIEBER, ACRS Member	
21	ROBERT SEALE, ACRS Member	
2 2 2 3	WILLIAM SHACK, ACRS Member	
23	ROBERT UHRIG, ACRS Member	
24	GRAHAM WALLIS, ACRS Member	
25		
·	ANN RILEY & ASSOCIATES, LTD. Court Reporters	
	1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036	
	(202) 842-0034	

,

PROCEEDINGS
[8:31 a.m.]
CHAIRMAN POWERS: The meeting will now come to
order.
This is the first day of the 469th meeting of the
Advisory Committee on Reactor Safeguards.
During today's meeting, the committee will
consider technical aspects associated with the revised
reactor oversight process and related matters, proposed
final amendment to 10 CFR 50.72 and 50.73, proposed
regulatory guide and associated NEI document 96-07
guidelines for 10 CFR 50.59, safety evaluations, proposed
revision of the Commission's safety goal policy statement
for reactors, proposed ACRS reports.
The meeting is being conducted in accordance with
the provisions of the Federal Advisory Committee Act. Dr.

10.0

1

2

ُم ۲

4

5

6

7

8

9

10

11

12

13

14

19

20

21

22

23

24

 $2^{\circ}5$

15 nittee Act. Dr. 16 17 John T. Larkins is the designated Federal official for the initial portion of the meeting. 18

We have received no written statements from members of the public regarding today's session.

We have received a request from a representative of NEI for time to make oral statements regarding proposed revision of the safety goal policy statement.

A transcript of portions of the meeting is being kept, and it is requested that speakers use one of the

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

2

microphones, identify themselves, and speak with sufficient 1 2 clarity and volume so they can be readily heard. I want to begin the meeting by calling the 3 members' attention to their items of interest. 4 The first item in this summary should be of 5 particular interest, a congratulatory memorandum from the 6 Chairman. 7 The members are also directed to the last page of 8 the package on items of interest, which brings to their 9 attention the Regulatory Information Conference, which many 10 members have found to be of use in the past. 11 I also want to alert members to the fact that we 12 have a large number of issues to examine in the 13 reconciliation of comments. That's going to be distributed 14 to you today, fairly early, earlier than usual, and you 15 should examine it and be prepared to discuss them tomorrow. 16 I also want to call members' attention to the 17 schedule for the March meeting. We had agreed that, on 18 March 1st, in the morning, we would take training in NRC's 19 new ADAMS program and that we would start the full meeting 20 that afternoon. 21 Also, the Planning and Procedures Subcommittee is 22 planning to meet in the morning on the 29th of February and, 23

3

in the afternoon of the 29th of February, work on what we need to do in preparation for a meeting with the Commission,

24

25

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

and we're inviting other interested members to attend that 1 2 session. That's the afternoon of the 29th? MR. BARTON: 3 CHAIRMAN POWERS: Afternoon of the 29th. 4 And finally, I'd like to welcome our new large 5 member, Mario Bonaca. Members have been curious on whether 6 you're just gaining weight or you've escaped from something. 7 DR. BONACA: Gained weight. 8 CHAIRMAN POWERS: I see. 9 Are there any opening comments other members would 10 like to make on today's session? 11 [No response.] 12 CHAIRMAN POWERS: Seeing none, I will turn to the 13 first item of business, which is technical aspects 14 associated with the revised reactor oversight process and 15 related matters. 16 John Barton, I think you're going to lead us 17 through this --18 I'll try, Chairman. MR. BARTON: 19 CHAIRMAN POWERS: -- important area. 20 The purpose of the meeting is to MR. BARTON: 21 review the technical components of the reactor oversight 2.2 process, including significant determination process and 23 performance indicators. 24 In a letter dated November 23, 1999, NRR Director 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

requested the committee to review technical components of the reactor oversight process.

1

2

13

14

25

In particular, we were asked to review the updated significance determination process and plant performance indicators.

In an SRM dated December 17th, the Commission requested ACRS review the technical adequacy of the performance indicators, current and proposed, for the new reactor oversight process, which includes assessment to the extent to which the performance indicators collectively provide meaningful insights to those areas of plant operation that are most important to safety.

The plant operation subcommittee met with the staff and NEI on January 20, 2000, to discuss these issues.

The subcommittee, at that time, formulated a set of questions which were transmitted to the staff, and the staff was requested to respond to those issues at today's session.

19At this time, I will turn the meeting over to the20NRC staff, and Frank Gillespie, you have the lead here.

21 MR. GILLESPIE: I think Bill Dean is going to take 22 the lead.

23 MR. DEAN: Good morning, Dr. Powers and committee 24 members.

My name is Bill Dean. I'm the Chief of the

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

Inspection Program Branch in NRR. Under my auspices are the development and implementation of the new oversight process which we're here to talk to you about this morning.

1

2

3

4

5

6

7

8

With me today, I've got Mike Johnson, who is a Section Chief in my branch for performance assessment, and Alan Madison, who has been the task lead for the implementation of the new pilot program and revised oversight process.

9 We also have with us today a number of our staff 10 members that have been key in the development and 11 implementation of this process, and there may be some 12 opportunity this morning to have some of them weigh in and 13 provide some additional information as we go through the 14 agenda.

What we intend to do this morning, in our two hours, is to provide a brief review of the pilot program results and the readiness for start of implementation, our feedback in that regard, to cover some of the defining principles and assumptions.

We think this is important before we get into the actual detailed discussions of the performance indicators and the significance determination process, which are the two technical issues that we have brought forward to the committee for their consideration, that it would be important to go over some of the defining principles and

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

assumptions of the whole oversight process.

1

2

3

4

25

Alan and Gareth Parry will provide some discussion on the performance indicators and the significance determination process.

5 Mike Johnson will then talk about the assessment 6 process, where we pull together the results of the 7 performance indicators and the significance determination 8 process, and of course, we'll answer any -- hopefully, try 9 to answer any questions that you have.

We met with the subcommittee on January the 20th. Out of that subcommittee meeting, there was a number of questions that we have, and we believe that we've integrated the responses to those questions within our presentation. So, hopefully, we'll be able to address all of those here today.

Lastly, I guess this is a -- I don't know what number, but there's been an ongoing series of briefings for the committee on the process, and I believe the last time that we met with the full committee was in June of last year, which was right about the time that we were starting the pilot program.

22 So, here we are now. The pilot program is over, 23 and we're looking at preparing for initial implementation, 24 so it's a good time to meet with you again.

The pilot program was a six-month program. We

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

performed this program between the months of June and November of last year. It's important to note that we're still executing this process at those 9 sites at which we did the pilot program, and so, we're still gaining information and lessons learned, albeit at a much more discrete and subtle level than we did earlier in the pilot program.

1

2

3

4

5

6

7

8 I think the most important characterization of 9 this new process that we developed as a result of our pilot 10 program is that the performance indicators and the baseline 11 inspection do provide a sound framework for providing 12 oversight of licensee performance and to assure that reactor 13 safety is maintained.

Now, am I confident in saying that we've had
enough time with this pilot program to prove this premise?
The answer to that would be no, and that could probably take
us years to actually prove the premise that this program
will provide reasonable assurance for reactor safety.

But have we had enough time and have we gained enough lessons learned to demonstrate that the process has demonstrated that we can have some confidence, a good level of confidence that this process will provide reasonable assurance and that it's at a point that we can expand this process beyond the pilot program? I think the answer to that is yes.

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

DR. APOSTOLAKIS: I have a question on that. DR. SHACK: Yes, sir.

1

2

24

25

3 DR. APOSTOLAKIS: The committee has been 4 struggling with the objectives, understanding the objectives 5 of the program, and what you just said reminded me of that. 6 What exactly is the objective of the oversight process? To 7 assure safety? And we have to elaborate on that, what it 8 means. Or to make sure that the plant is operated as 9 licensed?

MR. DEAN: Well, I think you have to actually go back to the actual safety mission of the agency, and that's to assure reasonable protection of public health and safety from the operation of nuclear power plants. I mean that's our overall mission.

DR. APOSTOLAKIS: What does that mean? For example, it could mean that you have some safety goals, and as long as the goals are met, you're providing reasonable assurance.

On the other hand, when we were reviewing 50.59, we were told that the staff wanted to maintain the licensing basis. So, all changes were evaluated in that context.

We believe that this is a very key element here to understanding what you're doing.

MS. MADISON: Well, I think we've described that before, George, when we talked about the basis of the

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

program.

1

24

25

The cornerstone diagram shows as the top item on 2 there is our basic mission of the agency, and part of the 3 cornerstone of safety that we developed for this oversight 4 5 process is the protection of the public health and safety due to the operation of commercial nuclear power, and 6 underlying that, in the strategic performance area, are the 7 goals you speak of. By achieving those goals, we feel we've 8 met our mission of protecting the public health and safety, 9 and so, the cornerstones, then, have objectives that are 10 directed at achieving those goals in the strategic 11 12 performance areas.

DR. APOSTOLAKIS: Yes, but -- so, let's take the case of a plant that has a very low core damage frequency, has highly redundant systems. So, it's maybe -- core damage frequency, say, is 15 times smaller than the goal.

That means, of course, that there are system unavailabilities that are lower than the average and maybe the rate of occurrence of some initiators is lower than the average and so on.

If this process is to assure adequate protection, then in principle, you could allow this plant to raise the unavailability of those systems.

> MS. MADISON: In principle, you're right. DR. APOSTOLAKIS: Whereas if your objective was to

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

make sure that the status of that plant, the risk profile, remains the same as it was last time you checked, then you would not allow it to increase, and that is a major difference in the objectives of the problem.

1

2

3

4

5

6

24

25

MS. MADISON: In principle, you're right, George, but you have a conflict.

7 The rules and the regulations and the las are 8 still on the books, and as long as they are, we also have an 9 obligation to make sure that they're maintained, as does the 10 licensee who signed on the license, but it probably would 11 make a case for risk-informing those regulations or 12 risk-informing the license that the licensee has and coming 13 in for some changes based upon the risk characterization.

DR. APOSTOLAKIS: But what you're say, then, is 14 that the objective of the program is to make sure that the 15 risk profile -- and risk profile doesn't mean only the 16 quantitative part -- I mean the whole thing, the way that 17 it's licensed -- remains the same, as we think it is. 18 That's what you're saying, because if they want to change 19 it, they have to follow, for example, Regulatory Guide 1.174 20 and come in with a request. 21

22 So, that view would be consistent with the 50.59 23 revision, with all the regulations we have.

DR. KRESS: Suppose they came in with a change request, an exemption, and it was significant enough that

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

	12
1	they did it to 1.174 but it did change their risk status.
2	DR. APOSTOLAKIS: Yes.
3	DR. KRESS: They increased it. Would you do
4	anything to the performance indicators for that particular
5	plant? The performance indicators would stay the same as
6	they are now.
7	DR. APOSTOLAKIS: No, because it would have to be
8	plant specific.
9	DR. KRESS: I know, but they're not.
10	DR. BONACA: But in this process, that will not
11	change.
12	DR. APOSTOLAKIS: Why not? The process allows for
13	change.
14	DR. BONACA: You have certain values set for
15	unavailability, etcetera, which are really coming from
16	simply a threshold that you set.
17	DR. APOSTOLAKIS: Yes, but that's the whole point
18	of raising the issue, because if that is the view, then the
19	performance indicators would have to be plant-specific.
20	So, if you changed the licensing basis of the
21	plant, you would have to change some of the performance
22	indicators.
23	DR. BONACA: It seems to me that the only thing
24	that the process has set up right now, we identify
25	developing adverse trends. That's really what it does,
	ANN RILEY & ASSOCIATES, LTD.
	Court Reporters 1025 Connecticut Avenue, NW, Suite 1014
:	Washington, D.C. 20036 (202) 842-0034

okay? I don't see that it can quantify safety. I mean it : 1 will identify a trend if something degrades. 2 DR. KRESS: So, you would see the objective as 3 being to provide a consistency --4 DR. BONACA: Absolutely. 5 DR. KRESS: -- in the performance and not really 6 to achieve a level of risk status that's equivalent to what 7 was licensed. 8 DR. APOSTOLAKIS: It's a very key question. Maybe 9 we are surprising you with this. 10 MR. GILLESPIE: You've actually hit the right 11 This isn't a licensing program. principle for this program. 12 What we're looking at is the delta change from the condition 13 at the facility. 14 We, in fact, are kind of -- although I hesitate to 15 use the word "risk profile," because people jump immediately 16 to quantitative, you know, but in the global picture, what 17 we're looking at is departures from that kind of established 18 norm, and that's when we get more engaged. 19 Departing is not the end of the world. It just 20 means we have to understand why you're departing. 21 DR. APOSTOLAKIS: Departing from the license --22 from the profile -- the risk profile that was there when the 23 plant was licensed. License means, you know, including the 24 amendments and everything. Right? So, that's consistent, 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036

(202) 842-0034

14 then, with the spirit of 50.59. 1 2 MR. GILLESPIE: So, we're looking at a delta. We're looking at basically kind of -- you know, the 3 surrogate is a delta CDF from whatever is allowed at that 4 facility, and whatever the allowance is for that facility 5 could be different from place to place, and we know it's 6 7 different. 8 DR. APOSTOLAKIS: Right. DR. BONACA: Then there is an expectation that the 9 indicators will be capable of identifying adverse trends. 10 This is the definition that we are going to use, and I 11 12 completely agree with that. That's all that the process can do, can identify 13 adverse trends, from one inspection to the next, something 14 15 is degrading. Okay. Then, also, I would like to say that the 16 thresholds, then, are such that they should be able to 17 18 identify the adverse trends. DR. APOSTOLAKIS: This was just an issue of 19 objectives. 20 21 DR. BONACA: But you see how important it becomes. DR. APOSTOLAKIS: So, Dr. Kress, do we agree, 22 then, on which the objective is of the five you've 23 identified? 24 DR. KRESS: I'm still not sure. We hear that it's 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036

(202) 842-0034

to identify adverse trends, which would be plant-specific, also, but then we hear it's to maintain the licensing basis as it was, as licensed. I think those are two different things.

1

2

3

4

5

6

19

20

DR. APOSTOLAKIS: They are two different things, but the objective, though, is what the staff just said.

Now, the issue of trends and so -- I would say that's implementation and what you want to -- you know, information you want to get and so on, but the fundamental objective is to maintain the licensing basis.

11 MR. DEAN: Well, I would say the fundamental 12 objective of the program is to maintain the level of safety 13 that exists in nuclear power plants today.

DR. APOSTOLAKIS: Not nuclear power plants, at that plant. There's a difference. This is the key difference. If you say at nuclear power plants, you are making it generic, and what I'm saying is no, to maintain the level of safety at that plant.

DR. KRESS: At that plant.

DR. APOSTOLAKIS: At that plant.

MR. JOHNSON: George, we're not surprised by the question, because we have discussed it many times before, and we've not satisfied you, obviously, but you know, I think maybe we think about this more simplistically than you do.

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

This is an oversight process, oversight meaning, you know, going back to our early words to you on what the process was trying to do.

1

2

3

4

5

6

7

8

24

25

There's a lot to be worried about.

We have a licensing process to control -- in which we try to control the licensing basis, and changes that the license tries to make, we want to make sure that we maintain that licensing basis.

As Frank said, we have various regulatory 9 programs, and this process doesn't change those programs. 10 What this process does is steps back to say, on any given 11 day, a licensee may or may not be in compliance, full 12 compliance with their technical specifications, they may 13 have things that happen, you know, expected things that go 14 on at a plant, and so, the role of the regulator and the 15 role of this process is to step back and look at those 16 things and changes in those types of things that happen at 17 plants, to ask ourselves, is it okay, is it some nominal 18 deviation from what is normally expected in terms of the 19 performance of the plant, or do we need to go further and 20 dig down and check, for example, to make sure that, with 21 respect to issue A, they're in compliance with their 2.2 licensing basis. 23

DR. APOSTOLAKIS: Right.

MR. JOHNSON: So, it's an oversight process.

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

DR. APOSTOLAKIS: Sure. But you said of that plant. These are key words. The whole process is focused on that plant, and if you do that, you are consistent with the body of regulations.

1

2

3

4

5

6

7

8

See, we can take an extreme case and say, okay, as long as the core damage frequency is less than 10 to minus 4 -- let's limit ourselves to that -- the oversight process says it's okay.

Now, we know there are many plants whose CDF is less than that, much less than that. You wouldn't let them raise the CDF up to the goal just because they keep being below the goal.

This is not the role of this, because then why do we have Regulatory Guide 1.174? Why do we have all the other regulations?

So, it's really a plant-specific process to make sure that the level of safety at that plant is maintained, and if there is any change, you would like to know it, adverse change.

I think we agree, actually.
MR. JOHNSON: Yes, I think we agree.
DR. APOSTOLAKIS: But this is so fundamental,
because it then tells us how we should treat the thresholds,
performance indicators, although we should make a
distinction between the two.

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

MS. MADISON: I think you have to be careful with 1 the term "plant-specific." It is a program that looks at 2 specific plants and looks at individual plants, but it is 3 not -- does not carry plant-specific thresholds. 4 DR. APOSTOLAKIS: 5 Sure. MS. MADISON: There are some plant-specific 6 indicators -- or type indicators, not necessarily 7 plant-specific indicators. There are plant-type indicators. 8 And the same with the inspection program. The 9 inspection program may be tailored somewhat to the plant, 10 but is ia fairly generic program industry-wide. 11 DR. APOSTOLAKIS: But that's why we're having this 12 discussion, because we really have to agree on clear 13 objectives and then discuss the implications of the 14 objectives, because if the objective is to maintain the 15 level of safety at that plant, then the thresholds must be 16 plant-specific. 17 That doesn't mean you have necessarily a different 18 number for each plant, but you start with that premise, and 19 then you may decide that, for certain performance 20 indicators, you can live with more generic-type thresholds, 21 but this is really key. 22 We've been discussing this and we're trying to 23 understand what's going on. 24 MR. DEAN: Let me cover some other objectives, 25 ANN RILEY & ASSOCIATES, LTD.

Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

though, that I think are important to make sure that we 1 understand, you know, why is it that we even entered into an 2 effort to try and revise the oversight process, and 3 certainly, we've gotten some clear direction from the 4 Commission based on feedback from a number of stakeholders, 5 external stakeholders, both industry and public 6 stakeholders, that there were some concerns and problems 7 with our existing oversight process, and the Commission 8 asked us to develop a process that was more risk-informed, a *ं* 9 process that was more objective, more predictable as to what 10 actions that the NRC would take for given performance 11 declines, and something that was more understandable to the 12 public and more scrutable, and so, that has been a lot of 13 our defining principles as to how we're trying to revise 14 15 this process.

We have a focus on risk-significant issues, and I 16 think that the early returns from the pilot program is that 17 -- from a licensee's perspective -- is that we have been 18 able to successfully focus not only our attention but the 19 licensee's attention on those issues that are the most 20 risk-significant at that plant, and that should be the 21 appropriate allocation of our efforts and resources, to 22 focus on those things that are most risk-significant at the 23 plant. 24

With respect to the oversight process and is it

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

25

adequate to support initial implementation at all plants, as I mentioned earlier, I think that we've gotten diminishing returns from the pilot program.

1

2

3

Like I said, we're still executing the process at 4 5 all the pilot sites, and we are still getting some indications of issues that need refinement, but we're 6 talking about much more subtle and discrete issues and not 7 major changes that we made early in the pilot program, where 8 we made substantial changes to the performance indicator 9 program, to the significance determination process, and key 10 elements like that. 11

So, we believe we're at a point where we need to increase the volume and the scope in order to fully exercise the process and gain additional lessons learned so that we can further define and refine the process.

16 DR. APOSTOLAKIS: Do you have an estimate of the 17 reduction in unnecessary burden?

18 MR. DEAN: Do I have an estimate? That would be 19 something that I think would probably be better left to 20 industry to provide some comment on that.

21 MR. GILLESPIE: I don't want the staff to get put 22 in a box, so I'm going to jump in here.

23 Reduction in regulatory burden, in the case of 24 this program, can be viewed in different lights. It could 25 be viewed in fewer inspection hours, which in general the

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

pilot says didn't happen.

1

2

3

4

25

Good performers are still going to get inspected in the future, probably as much as good performers did in the past.

5 One of the things industry very much wanted out of 6 a new system was stability and predictability, and one of 7 the things this new process builds is stability and 8 predictability.

9 Utilities wanted to say we know where we stand 10 without waiting every 18 months for a SALP report. What is 11 the value in regulatory burden to a stable and predictable 12 system on Wall Street to a utility? Only they can predict 13 that.

But they were very vehement in the beginning that that was one of the most, if not the most important objective to where they were driving.

So, it isn't a question of, you know, is it 10 less inspection hours or are we doing this much less or do they get a licensing action through faster.

The question on regulatory burden is truly one of what's the value of a stable predictable system where everyone knows the ground rules, and that's more of a social value, but they can turn it into dollars and sense on their end.

DR. BONACA: The only objective portion of the

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

process is the performance indicators. I mean you have not established a pass/fail system or the baseline inspection, nor have you established how baseline inspections and performance indicators will be integrated into an overall cornerstone assessment.

1

2

3

4

5

6

7

So, I'm just saying yes, you have a more objective set, but the only objective set is the indicators.

I believe That's not totally true. 8 MR. DEAN: that we have objectivity that's imbued in various elements. 9 A significance determination process is an objective look 10 based on the principles of Req. Guide 1.174 in terms of 11 ascertaining risk characterization of our inspection 12 finding, is an attempt to try and make those inspection 13 findings more objective in nature and being able to convey 14 to the licensees and to the public what is it about this 15 issue that is of risk significance. 16

DR. BONACA: I'm only saying that, you know, Wall 17 Street was mentioned, and they're not going to look at the 18 safety significance. They're going to look at greens, and 19 if you have all indicators in the initiators are green, 20 that's a lot of statement coming from the performance 21 indicators, and there isn't a process that says it's green 22 but it's not really green because, if you average it and 23 integrate it with this other information, it should be, 24 really, a yellow or something. 25

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

MR. GILLESPIE: From a safety kind of perspective, 1 one of the nice parts about this process was we don't try to 2 aggregate it into a single score, and in fact, that's what a 3 lot of our public groups really kind of like, because it's a 4 5 profile, so that you don't get -- and one of the -- maybe one of the deficiencies in what AEOD was doing earlier on 6 was they were trying to deal with LER's, enforcement items, 7 and aggregate it all, but they weren't mutually exclusive, 8 and so, one could outweigh the other. In fact, you could 9 10 show good performance on the aggregate, even though the agency is very worried over here. 11

12 So, we have deliberately left this as a profile, 13 but people can see both whites in PI's and in inspections. 14 Inspections are like PI's. They're divided into 15 cornerstones, and now they're graded also as a structure.

16

MR. DEAN: We'll talk about that in a minute.

The last bullet on this slide in terms of implementing an ongoing self-assessment process -- you know, are we done making changes? No. Obviously, we've made notable improvements to address the concerns raised by the Commission.

We have made a process that's more objective and scrutable and understandable and risk-informed, and there's still been a lot of what I would consider to be appropriate stakeholder skepticism, both internal and external, with

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

respect to the long-term efficacy of this process, and we 1 have to make sure that we address that skepticism, and we 2 believe the way to do that is to expand this program to get 3 more input and more experience on a broader scale, and so, 4 that's why we believe -- and we've changed our -- I think, 5 if you go back six or seven months ago, we talked about the 6 next phase of this process, implementation, would be full ; 7 implementation, and that's really not the right connotation, 8 and we've changed that to say the next phase really is 9 10 initial implementation.

We've tested out the principles and the major processes through the pilot program.

Now we're ready to move to an initial implementation phase where we recognize that we're going to gain lessons and that we need to come back and revisit this process after we gain about a year's worth of experience and go through a significant assessment as to what has this year's worth of information told us about implementing this process at all sites.

So, we think we're ready to move into something called initial implementation but not full implementation where you would have the concept that this process is now a rigid, etched-in-granite process, okay? There's still some dynamics that are going to be involved here, and we have to make sure that we continue to provide an appropriate

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

1 2

3

4

5

6

14

25

self-assessment of this process.

I just wanted to spend a few minutes revisiting some of the defining principles and assumptions, and one of them gets to this discussion that we've already had, George, and that is that thresholds -- you know, the whole concept of thresholds, okay?

This program establishes thresholds both in performance indicator space and inspection space that, below which, only minimal NRC interaction is warranted, in effect that when you have plants that have green performance indicators and green inspection findings, that the appropriate level of NRC regulatory interaction is the execution of our baseline inspection program, okay?

So, what does that mean?

Does green mean good? Green does not mean good, and it shouldn't be equated to good.

What green means is that performance, as determined by the indicators, performance indicators, inspection findings, is acceptable to the extent that our regulatory oversight of a baseline inspection program is the appropriate regulatory oversight.

22 MR. BARTON: Bill, is that defined someplace? 23 Will I find those words, green means just what you said? 24 Somewhere in this process --

MR. DEAN: Yes. If you go all the way back to the

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

technical framework of this process back in 99-007 --1 All right. 2 MR. BARTON: MR. DEAN: We can help define where that is. 3 That will be in the program MR. JOHNSON: 4 implementation documents. 5 For example, it will be in the SDP manual chapter 6 that you haven't seen -- or you may have seen. I quess that 7 version is out. It will be in the new performance indicator 8 manual chapter. We're very clear about what those terms 9 10 mean. Okay. Thank you, Mike. MR. BARTON: 11 This is a clear paradigm shift. That MR. DEAN: 12 is an area that our inspectors still feel some discomfort 13 with, that there is, within the process, what we call a 14 licensee response band where issues that emerge within this 15 band of performance are issues that are best turned over to 16 the licensee, they're of very low risk significance or 17 below, that these are issues that should be entered in a 1.8 licensee's corrective action program and dealt with in 19 construct with all the other issues that licensees 20 themselves identify and put in their corrective action 21 program, and that the NRC should not be driving resolution 22 of these issues just because they're issued identified by 23 the NRC. 24 MR. BARTON: A key part of the new process is 25

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

reliance on the old violations being put into the licensee's corrective action process and that process being an effective means to get to the root cause and fix them. Where in this new oversight process are we doing an assessment of the licensee's corrective action programs?

6 MR. DEAN: We'll get to that. That's a good 7 question, and we'll build to that.

1

2

3

4

5

8 DR. APOSTOLAKIS: Now, regarding the thresholds, 9 first of all, I think we have to distinguish between 10 establishing the performance indicators, the establishment 11 of performance indicators and the establishment of the 12 thresholds.

Perhaps the indicators can be generic, but with the thresholds, again I have a problem, because as I recall, you looked at data over the five -- past five years for a particular indicator and then you plotted them and you took the 95th percentile, the highest value of the -- that performance indicator over plan, so you took the 95th percentile as a threshold.

Now, coming back to the objective, if the objective of the process is to make sure that the safety level at plant X is maintained, then if that plant X happened to be very good with respect to this indicator -say it was down to the 10th percentile of that curve -- by establishing a threshold at the 95th percentile, aren't you,

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

in effect, allowing that plant to raise that indicator all the way and then it will still be green, and then how is that consistent with the notion that I'm trying to oversee -- that I'm trying to convince myself that the safety level of that plant has not changed?

1

2

3

4

5

6 See, this is where my problem -- the conceptual 7 problem is.

MS. MADISON: But are you saying, George, that if a plant is performing in the top 10 percentile, that we should never let them slip below that, that for some reason our regulations should be written such that they can't be anything less than in the top 10 percentile once they've established themselves there?

Because by establishing a threshold -site-specific threshold based upon their top 10 percent performance during that period of time, that's what you're saying, that we would take action if they slipped below --

DR. APOSTOLAKIS: Yes. If your objective is that the safety level is maintained, you shouldn't allow them to slip.

MS. MADISON: But in a generic sense is our objective, and that's why the four outcome measures were meant in a generic sense, that an industry-wide, industry performance should be maintained in a safe manner, the maintenance of safety industry-wide, and I don't think we

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

29 have the regulations to say that a licensee must perform in 1 the top 10 percent or an excellent manner. 2 Our regulations all lead to licensees performing 3 in an adequate, in a safe enough manner. 4 MR. BARTON: George, i think there is a difference 5 between the old process and new process as a licensee would 6 7 perceive it. In the old process, there was incentives to 8 improve performance and raise standards. Whether anybody 9 wants to admit to that or not, I think the SALP process had 10 that ingrained in it. 11 I think the new process takes away those 12 incentives to increase performance, to be an excellent 13 performer. 14 Jack, do you agree? 15 DR. APOSTOLAKIS: Maybe you're saying the same 16 17 thing with different words. I'm not picking one side, not yet. All I'm saying 18 is your thresholds should be consistent -- the establishment 19 of the thresholds should be consistent with your objectives. 20 So, if we agree that the objective is to make sure 21 that the level of safety at that plant is maintained, then 22 the thresholds have to be plant-specific. There's no way 23 around it. 24 DR. KRESS: There is one way around it, George. 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036

(202) 842-0034

DR. APOSTOLAKIS: If, on the other hand, Alan is 1 2 right and you want to look at the population of plants and make sure that things don't change, then again -- then the 3 question would be different. Why do you rely only on the 4 95th percentile? 5 DR. KRESS: Let me throw out a suggestion, George. 6 Let's presume that what we're talking about is the 7 derivative of a PI. We want to know whether it's increasing 8 and whether that increase is such that we begin to be 9 concerned about it. 10 Now, let's take your really good plant, at the 11 12 10th percentile. Now, let's say it goes through a derivative; it's 13 degrading in performance for, say, one or more of the 14 indicators. 15 Now, how can we look and see whether that 16 derivative is of concern to us? 17 Well, it depends on the performance indicator. 18 If that derivative is such that it extends in time 19 so it crosses some threshold, then you have a measure that 20 this derivative -- a threshold away from its base case --21 you have a measure of this derivative, because you know it 22 crossed the threshold. 23 That means it increased a certain amount over a 24 given amount of time. 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014

30

Washington, D.C. 20036 (202) 842-0034

So, the question is now would you have the same 1 derivative measure if you put that threshold higher and 2 higher and higher and higher? 3 In fact, you could put it all the way up to the 95 4 percentile, and it depends on whether the degraded 5 performance has an effect on this derivative sufficiently to 6 drive it all the way up to the 95. 7 Now, that's the issue, to me. 8 If a degrading performance that is of concern to 9 me drives that derivative so that the value gets above the 10 95, then I've got the derivative for all plants, and I can 11 use a plant-wide set of thresholds and not be 12 plant-specific. 13 If that derivative is not sufficient to hit my 14 concern level before it gets up to that 95, then I have a 15 problem. Then I need plant-specific ones. 16 Do you understand the difference? 17 DR. APOSTOLAKIS: I still don't know why the 95th 18 percentile should play such a major role. 19 DR. KRESS: I could have picked any. That's 20 arbitrary. I could have picked any threshold, is my point. 21 DR. APOSTOLAKIS: But this is industry-wide. 22 DR. KRESS: Yes. 23 DR. APOSTOLAKIS: And my objective was stated as 24 one of maintaining the level of safety at that plant. 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036

(202) 842-0034

DR. KRESS: Suppose we were interested in the derivative and that a degraded performance, whatever caused this performance indicator to go, actually puts it way beyond the 95, you know, triples it.

DR. APOSTOLAKIS: Sure, then bells will ring.

DR. KRESS: Well, that's what I'm saying. It depends on the magnitude of the derivative and how far it will go, and I'm not sure we know that.

5

20

9 They have an implied assumption that, if it trips 10 this threshold that we have set, that that is -- that you 11 will find the derivative for that particular plant. Even 12 though it started real low or even if it started high, 13 you'll still get the derivative.

Now, I don't know if that's true or not, because I don't know enough about the relationship between our concern level and the thresholds and the derivative, but it's possible that you could have a set of thresholds for all plants and not have them plant-specific, although you begin to get a little concerned about that.

DR. APOSTOLAKIS: I'm still not convinced.

MR. DEAN: I'd like to share on insight with you, George, that may or may not help give you a little bit of a sense of confidence, but you know, the fact that -- an outgrowth of the fact that we are publishing on our web-site these performance indicators on a quarterly basis and it's

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

there for God and country to see, you know, whether a plant is the green band or the white or the yellow has provided a tremendous incentive for licensees to assure that their performance is such that they do not have indicators trip thresholds, okay?

1

2

3

4

5

6 They do not want to be seen as an outlier, and so, 7 what a number of licensees have done within the pilot 8 process is, within that green band, have established their 9 own thresholds for performance, as they train within the 10 green band.

Now, we're not training within the green band, 11 okay? We have an objective threshold, green/white, that we 12 judge to be an appropriate threshold for which we change our 13 level of engagement in regulatory oversight, but licensees 14 are tracking and trending within those bands and are 15 responding when they start to see thresholds creep up, to 16 maintain themselves, and not to go up and ride along that 17 95th percentile performance level. 18

DR. APOSTOLAKIS: I guess what I'm saying is that maybe we ought to be doing something like that, not the licensees, leave it up to the licensees, I mean just as a matter of consistency.

DR. BONACA: Well, the licensees have been doing this for a long time, because I mean many of these indicators are the INPO indicators that were -- and they

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

didn't go through, you know, a very elaborate derivation of it, but they were very similar.

First of all, I support the perspective that Dr. Kress is pointing out. I mean I do believe the point he's making is correct.

The concern I have is that thresholds may be high 6 enough that it will be a long way before you get there, and 7 so, therefore, you will not be able to see much, 8 particularly because, already, for 10, 15 years, the 9 licensees have been looking at the INPO, and therefore, they 10 are striving to be well below values which are below that, 11 which says, then, the threshold may be inscrutable, 12 inscrutable in the sense that they don't provide you a way, 13 really, of seeing, but I'm sure we'll talk about that at 14 some point. 15

16

23

24

25

1

2

MR. DEAN: Yes, we will.

DR. BONACA: Because what is being published in internet, you're saying, really is only the performance indicators and not the cornerstone performance indicators.

20 MS. MADISON: We're publishing the performance 21 indicators, as well as the inspection findings, which cover 22 the whole cornerstone.

DR. BONACA: So, you publish that, too. MS. MADISON: Yes. DR. BONACA: Now, here you're talking about an SDP

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

green. We haven't seen that. I don't understand exactly
 how that works.

3 DR. APOSTOLAKIS: Before we leave the thresholds,
4 one last point.

5 Why, then, if this is the thinking, did the staff 6 feel that it was necessary in establishing the threshold 7 between green and white, that you had to distinguish between 8 some plant types? In the electric power, I think you had 9 something there. I don't remember now which one it was.

MS. MADISON: We had to distinguish between plant types because of the safety systems involved, because BWRs and PWRs don't necessarily have the same safety system. NPO did the same thing in their indicators, and we mimicked that to have the same four safety systems at each plant type.

16 DR. APOSTOLAKIS: Wasn't there also a distinction 17 between plants with different numbers of diesels?

MS. MADISON: Yes.

18

DR. APOSTOLAKIS: So, different kinds of redundancy, then.

So, why would that apply to a threshold between green and white and not -- well, a higher threshold and not at the baseline? What is the logic? Why are we departing from the idea of a generic threshold at that level, but at the lower level we don't?

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

This is Gareth Parry from the staff. MR. PARRY: 1 The reason we made that distinction or the reason 2 we did it for the green/white threshold is because of the 3 way we established the thresholds, which was to use 4 historical data to determine that threshold, as you've 5 describe it, and that's based on a single-train 6 unavailability figure. 7 This is going to be part, I think, of a somewhat 8 longer discussion later, I guess. 9 DR. APOSTOLAKIS: Okay. 10 MR. PARRY: Let's come back to this. 11 MS. MADISON: We will come back to this. 12 DR. APOSTOLAKIS: Okay. 13 MR. DEAN: Another principle I wanted to discuss 14 real briefly was the fact that, to obtain a level of 15 adequate assurance of performance, that we need both the 16 performance indicators and the inspection results. 17 When we go out and make presentations to the 18 public or to other stakeholders about this process, there's 19 a tendency to latch onto the performance indicators as being 20 the end-all and be-all, and they're not, okay? 21 They're a complementary set of indicators, 22 information by which we need both of those to be able to 23 judge -- adequately judge performance at a plant. 24 The revised oversight process, in utilizing these 25 ANN RILEY & ASSOCIATES, LTD.

Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034 performance indicators and these inspection findings, has developed a process whereby our assessment of license performance is more of a continual and ongoing assessment process, as opposed to -- for example, we mentioned earlier about the SALP process, where maybe every 18 or 24 months, you would get a package that gave you an assessment of plant performance.

1

2

3

4

5

6

7

8 So, we have embodied in this new process a much 9 more continuous and ongoing assessment whereby every 10 quarter, as we get new performance indicator information and 11 as we update our inspection finding plant issues matrix, 12 that you get an additional set of information by which you 13 can add that onto your previous information and use that to 14 judge on a more continuous basis licensee performance.

The performance indicators obviously have a much more major role into this process than they did in the past. Performance indicators in the past were really used more to perhaps provide a level of support or a confirmatory tool, as you will, for decisions when we got into the senior management meeting process.

We would look at, well, what do the performance indicators say and do they jibe with what our inspection findings told us, which is really what we based our assessment on licensee performance on, really was inspection findings.

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

So, now we have integrated performance indicators to provide some at least more objective tools in that area.

1

2

3

4

5

The issue of cross-cutting areas -- and this gets back to the earlier question about performance -- problem identification and resolution.

Within this process, I think as you're all aware, 6 that we've identified three areas that we consider to be 7 cross-cutting areas, that they find their way into all the 8 cornerstones of safety in terms of contributing to the 9 attributes, and that would performance -- problem 10 identification resolution, human performance, and safety 11 conscious work environment, and it's important to note that, 12 in the revised oversight process, we're assessing 13 performance in the cornerstones. 14

15 I've heard mentioned a couple times an overall 16 assessment of the cornerstones. We're not providing an 17 overall assessment of the cornerstones like we did with an 18 overall assessment in the SALP process of a functional area, 19 okay?

20 What we're doing is we're identifying issues 21 within a safety cornerstone, assessing that issue more 22 discretely or assessing that performance indicator, which is 23 an indicator of performance within that cornerstone, and 24 dealing with those issues on a more discrete basis, and as 25 those issues emerge with either a higher threshold being

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

crossed or as you get more issues within that cornerstone, then what you see is an analogous NRC regulatory response -a greater level of inspection, supplemental inspection, more focused team inspections, as you see higher thresholds being crossed or as you see more thresholds being crossed within the cornerstone, but we are not, in this process, trying to, quote/unquote, assess a cornerstone like we did assess a functional area with our more subjective process in the 8 past.

1

2

3

4

5

6

7

9

10

DR. BONACA: Let me just ask a question.

There is clearly a perception on the part of the 11 industry that -- I quote here a statement in the NEI 99-02, 12 a draft of it, regulatory assessment performance indicator 13 quideline, where it says that a green performer from 14 performance indicators only -- a green performer will be 15 allowed to identify and correct perceived problems, which 16 means essentially that the NRC action or interaction or 17 intervention is going to be determined by the performance 18 indicators. 19

The interaction is determined, as MR. DEAN: NO. 20 21 we mentioned earlier, on the completely integrated set of performance indicators and inspection. 22

DR. BONACA: Well, I think we will have to ask the 23 industry later on if it is the same conclusion they have 24 documented here in this draft, because when I read that, it 25

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

says that the performance indicators being in the green may, in fact, be an impediment to the staff to look at other things or to take action based on cross-cutting issues.

1

2

3

12

13

14

15

16

24

25

It's always been advertised that the 4 MS. MADISON: performance indicators, from the beginning of developing 5 this program in SECY 99-007, that the performance indicators 6 could not stand alone, that the had to be supported and 7 supplemented by baseline inspection program and that just 8 because performance indicators are indicating good 9 performance did not mean that we wouldn't react or wouldn't 10 take action based upon inspection findings. 11

DR. BONACA: Even if everything was green.

MS. MADISON: Even if everything is greener than green in the performance indicators, if there are indications in the inspection program, then we'll take action based upon that.

DR. SHACK: Are they weighted the same? That is, if you go through an inspection and you go through an SDP and you come up with a white, is that a white like a performance indicator white?

MS. MADISON: Yes, that's the purpose, and I'm going to try to explain a little bit of that during the SDP, and Mike will go into it more in the assessment program.

MR. DEAN: The intent was to try and brace our thresholds on the guidance that's contained within Reg.

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

Guide 1.174 and try and make the performance indicator thresholds analogous to the inspection finding thresholds.

1

2

23

24

25

- -

Now, is it exact across the board? You know, obviously not, but I think that we've come pretty close in trying to make them similar so that a white here and a white here are equivalent.

7 MR. BARTON: That's an important point, because 8 under the current process, you could have good PI's and 9 still be in trouble.

10 MR. DEAN: Oh, yes. Matter of fact, I'll give you 11 a good example. This came up, matter of fact, in a 12 discussion last night.

I was up in New Jersey last night, matter of fact, 13 speaking to the public on the new oversight process, and the 14 issue came up about the complementary nature of inspections 15 and PI's and could something be evaluated as green in PI's 16 and potentially mask a potential problem, and in fact, in 17 New Jersey, we've had recent incidents where, in the 1.8 emergency preparedness area, the performance indicator has 19 been green, it's shown good performance over the last year 20 in terms of EP performance, but that there have been several 21 actual events at Salem where you have had some problems in 22

MR. BARTON: -- misclassification.
MR. DEAN: -- misclassification of events, and

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034 that was evaluated through our inspection program and determined to be a white issue, even though the green performance indicator in EP would show that -- you know, give you an indication that performance in that area was acceptable.

1

2

3

4

5

6

MR. BARTON: So, what does that tell me?

MR. DEAN: So, what's that telling you, is that 7 that's a good example of where the PI's and the inspection 8 process are complementary in nature, the fact that the 9 performance indicator is not the overall indicator of 10 performance in that area, it's an indicator of performance 11 with a specific aspect within that cornerstone but that our 12 inspection program is complementary or supplementary to what 13 we get from the performance indicators and that we may have 14 issues emerge that a performance indicator doesn't give us 15 the same information that our inspection does. 16

MR. BARTON: What does the public see in that case? What's on the internet?

MR. DEAN: What they would see is they would see, underneath that cornerstone, okay, if you're familiar with our web-site, you know, the single page, you have the cornerstones and the PI's underneath that cornerstone, and then, below that are the inspection findings, and what they would see is, under that inspection finding, the block for that current quarter, when that inspection finding emerged,

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

would be colored white, and then they could click onto that box and it would take them right to that description of what that inspection finding was as to why we characterized it as a white issue.

5

6

1

2

3

4

DR. BONACA: The performance indicator was green. MR. DEAN: That's right.

7 DR. BONACA: So, you would have not only a white, 8 you would have a performance indicator of green and then you 9 would have an assessment white.

10MR. DEAN: An inspection finding of white, that's11correct.

MS. MADISON: And they would both be inputs into the assessment program, as Michael described, and the same action would be taken for a white inspection finding as a white performance indicator.

16 MR. DEAN: Before I move off the slide, I want to 17 make one other point, and that has to do with the problem 18 identification and resolution.

We recognize that, in establishing this band of performance and backing away a little bit, as you will, from focusing on these low-level issues and trying to drive their resolution, that we have to rely on a licensee's ability to identify and resolve their problems more substantially than we have in the past.

25

In order to provide us with some level of

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

assurance that a licensee does have an effective problem 1 identification and resolution process, we have embedded in 2 every inspectable area a portion of that inspection 3 procedure has to focus on problem identification and 4 5 resolution activities associated with that inspectable area, and that's a substantial change from our previous inspection 6 program, where we may do, every couple of years, perhaps, a 7 programmatic review of a licensee's problem identification 8 and resolution or their corrective action program. 9

We have now embedded that in each and every inspection procedure, as well as having a periodic annual inspection that looks at problem identification and resolution from a broader perspective.

14 So, we are spending a lot of our inspection 15 resources and effort to look at problem identification and 16 resolution, much more than we did in the past.

DR. BONACA: In your guidance to the resident inspectors, you specify that, if you have a number of misclassifications, that would correspond to a white? Is there a criterion for determining that?

21 MS. MADISON: It's in the significance 22 determination process for emergency preparedness.

DR. BONACA: Well, that still leaves it to the -you don't have a head count. I'm trying to understand how objective that process is.

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

MR. DEAN: We're going to talk a little bit about the significance determination process later. So, hopefully, we'll be able to address that.

1

2

3

4

5

6

7

The last point I want to make before we start talking about some of the technical aspects of the program is that the oversight process is intended to be indicative within the licensee response.

8 I think we've talked about that already several 9 times, that we are backing away from having a more 10 diagnostic approach for those very low-level, low 11 significant issues, and that's a purpose of our 12 risk-informed baseline inspection program.

It's intended to be indicative, are we getting 1.3 indications of problems whereby, if we do see issues that 14 are crossing risk-significant thresholds, that would then 15 engender additional or supplemental inspection, which is 16 designed to be more diagnostic in nature, it's intended to 17 be looking at what is the root cause that the licensee has 18 conducted say about that issue, what have they done in terms 19 of looking at extent of condition. 20

And as you see more thresholds being crossed or higher thresholds being crossed, that supplemental inspection becomes much more independent in terms of its level of diagnostics, and the oversight that's based on our action matrix -- as I have stated several times, the action

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

matrix is one of the tools that we have in place to help make our process more predictable and understandable as to why it is we're taking the actions that we are taking and that a licensee or the member of the public can predict and understand why it is we're doing whatever sort of inspection or regulatory response, whether it be a 50.54(f) letter or 6 an order -- they can understand what performance issues have led to us taking that action. 8

1

2

3

4

5

7

So, that's one of the major intents of the action 9 10 matrix.

Can you explain the first DR. APOSTOLAKIS: 11 I don't understand it. "The oversight process 12 sentence? will be indicative within the licensee response band." What 13 does that mean? 14

I guess what that's referring to is 15 MR. DEAN: that the performance indicators, okay, provide indications 16 of performance, are not measuring performance, but they 17 18 provide you indicators.

The inspection program is designed to identify 19 indications of potentially poor performance that have some 20 risk significance, and so, the process, as long as a 21 licensee is within the green band, their performance 22 indicators and the inspection findings are characterized as 23 green, then our process in that realm is more of an 24 indicative process. 25

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

We're looking for indications of potential poor performance.

1

2

16

17

18

21

22

23

24

25

Once you emerge from the green band, you cross a threshold, whether it's a performance indicator or whether it's an inspection finding.

Our process now is designed to be more diagnostic with respect to that issue or with respect to that cornerstone, if you have a degraded cornerstone, if you have several issues within a cornerstone that cross thresholds.

10 So, now we move into more of a diagnostic, trying 11 to understand why is this happening, why did you have issues 12 that caused you to cross this PI threshold or cross this 13 risk significance threshold for the inspection findings?

14 So, there's a shift in our focus of what we're 15 trying to understand about licensee performance.

DR. APOSTOLAKIS: By the way, again, for my education, when the inspectors perform the inspection, are they using generic criteria or plant-specific criteria?

MR. DEAN: In terms of assessing the significance of the issue?

DR. APOSTOLAKIS: Yes.

MR. DEAN: We're going to talk about the significance determination process, but there is, I think, a -- you know, your concern about generic thresholds and so on.

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

I believe that our significance determination 1 process and the tools that we have for the inspectors to use 2 are much more plant-specific in terms of looking at, you 3 know, what mitigating systems are available and so on and so 4 5 forth. DR. APOSTOLAKIS: Right. So, the ADP is 6 7 plant-specific. MR. DEAN: Yes. 8 MR. BARTON: Yes, it is, George. 9 CHAIRMAN POWERS: We've asked in that regard why 10 it is -- it's plant-specific, but it appears to me that they 11 have gotten that plant specificity by looking at the IPE 12 submittals. 13 DR. APOSTOLAKIS: That's right. 14 CHAIRMAN POWERS: And those IPE submittals are 15 now, what, eight years old? 16 At the time they came out, the committee was 17 acquainted with some substantial concerns on whether the 18 analyses in the submittal represented a complete set of 19 accidents and whether the IPE was, indeed, faithful to the 20 21 plant design. Since that time, anecdotal accounts suggest that 22 several of them weren't. 23 How do you correct for that? 24 MR. DEAN: Alan is going to specifically address 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

that issue and the concern, and I think we're probably ready 1 to get into Alan's discussion. 2 We'll start with the PI's first, right, Alan? 3 DR. APOSTOLAKIS: I don't think I got an answer to 4 my question. 5 During the inspection, in an inspectable area, the 6 inspector has industry-wide criteria in his mind or the 7 history of this plant and how things were done --8 MS. MADISON: The simple answer to your question 9 is yes, both. They're going to have to use some 10 industry-wide guidance. 11 There's industry-wide standards that they'll be 12 looking at, but there are plant-specific implementation 13 standards that they'll also be concerned with and 14 plant-specific design characteristics that they'll be 15 looking at when they're doing their inspection. 16 So, the inspection program has both elements in 17 it, both the generic, both industry-wide-type concerns, as 18 well as a plant-specific focus. 19 DR. APOSTOLAKIS: So, in my mind, then, the only 20 part of the whole process that uses generic numbers is the 21 thresholds for the performance indicators. Everything else 22 is more or less plant-specific. It doesn't mean you ignore 23 the industry, the rest of the industry. 24 MR. DEAN: In a general sense, that's accurate. Ι 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters

1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

will say, for example, in the significance determination 1 2 process, for example, initiating event frequencies are basically generic, industry-wide initiating event 3 frequencies, and a specific plant may have a different 4 factor built into their IPE that may emerge as you get 5 further into the risk analysis of an issue, but you know, 6 there's generic aspects to the significance determination 7 process, although that process, I believe, is much more 8 aligned towards the plant-specific design. 9

DR. SHACK: The inspector will be looking for all, 10 essentially, violations of the licensing basis, just the way 11 It's the SDP that suddenly becomes different. 12 he does now.

MR. DEAN: Yes, what do you do with those findings and issues. Do we have something -- a compliance issue that is significant? If it's not a significant issue, we turn that over to the licensee, they are still required to comply 16 with the regulations. 17

It's just that we will not expend a lot of our 18 effort to drive resolution of that. We'll come back and 19 revisit it as part of our corrective action program reviews, 20 21 but it's not --

DR. APOSTOLAKIS: So, it confirms what I said. It 22 23 is plant-specific.

DR. SHACK: But what he's looking for is essentially a violation of the licensing, which I guess is

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

50

24

25

13

14

1

2

3

4

plant-specific, yes.

MS. MADISON: Well, we've changed the focus a little bit, and we're trying to focus them on risk significance rather than violations, and in fact, that has occurred during the pilot program. 5

Some of the issues -- some of the significant 6 issues that have been raised have not been necessarily 7 violations of regulations, but they have risen to a level of 8 significance that we were concerned -- and the licensee was . 9 concerned with the issue. 10

11

MR. DEAN: Alan?

MS. MADISON: We're going to talk first about 12 performance indicators and then about the significance 13 determination process, and we're going to try to address a 14 couple of the questions that you had in these areas. 15

A little bit later, Gareth Parry -- in fact, in a 16 few moments, I hope, Gareth Parry is going to be talking 17 about George's specific issue on plant-specific thresholds. 18

DR. APOSTOLAKIS: I'm not trying to be a bad guy. 19 MS. MADISON: No, no, we're trying to address your 20 questions. 21

When did you change, George? MR. BARTON: 22 DR. APOSTOLAKIS: I'm really troubled by this. 23 I just wanted to highlight a couple MS. MADISON: 24 of things about the performance indicators and the 25

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

thresholds.

1

The purpose of that green/white threshold was to indicate or identify licensee performance below which we needed to start getting involved as an agency, we needed to start getting, as Bill said, more diagnostic rather than indicative, and instead of turning the problems back over to the licensee, focusing on them ourselves and trying to determine more of the why's.

9 We're not -- within that green band, as long as 10 it's above that green/white threshold, we're not ranking, 11 we're not trending within that green band, although some 12 licensees are, and in fact, in some of the performance 13 indicators, we don't think it's appropriate, necessarily, to 14 trend, especially like in the barrier areas, because they're 15 more data point-type indicators.

Again, one of the other things to focus on is they are indicators, they're not measures, and in some cases, we don't have a real clear tie to risk some of these indicators. So, we're not looking at them as a straight-line-type measurement of performance.

The green/white threshold, as we've been talking about -- we initially set that trying to come up with like a 95-percent performance area, but it's really focused on -with the concept that we have looked at industry as a whole and feel that industry as a whole is performing safely.

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

Now we're looking for outliers, folks that are outlying from nominal performance, and the development of that threshold, then, was based upon this 95-97 history, saying if that's a safe history, then where were the outliers in that time period and where would we establish a threshold to capture those outliers in the future?

1

2

3

4

5

6

CHAIRMAN POWERS: If I have a plant that, because 7 of a design characteristic, some peculiar feature of it 8 causes me to be in this upper 5 percent, and there's nothing 9 I can do about it, it's a design feature, it has been 10 accommodated and corrected with some compensatory action, 11 presumably, in the licensing process and it's fully 12 documented, everybody understands that, do I still end up 13 getting a white? 14

MS. MADISON: It's a good point. We haven't seen that, actually, in the reactor safety areas, but we're likely to see that in some of the non-reactor areas, and we're addressing that by -- our proposal for addressing that is we recognize that performance.

For example, in the security area, where comp measures may account and provide backup for some security equipment, but we do need to, for the public's scrutiny and to maintain a stable program, we will identify that as a white issue or a white performance indicator, but we'll note what actions are being taken by the licensee and by the

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

1 agency to address that issue.

1	
2	CHAIRMAN POWERS: I think you're inviting
3	difficulties here. You have set your thresholds for
4	green/white so high, 95th percentile high, that you've given
5	white, which on reading the words is not particularly bad
6	it's only requiring some additional attention, whatnot, it
7	has not impacted the public's health and safety the least
8	little bit you are drawing attention to it.
-9	A white in a field of green stands out, especially
10	since there's no gradation in the greens, and I think you
11	invite trouble if you ask people to look at the asterisk
12	that said this is okay.
13	I don't think it will be captured. I think you
14	invite difficulty to that plant.
15	MS. MADISON: And we'll have to look at that,
16	Dana.
17	MR. GILLESPIE: I think one of the important
18	aspects is what Alan said, is none of the existing plants
19	seem to have the problem. So, we want to be careful that we
20	don't try to fix something that's not a problem.
21	Now, if someone builds a new plant and does it,
22	well, that's okay, but we've got a number of years to deal
23	with that, quite honestly.
24	So, you know, we're trying to get a process in
25	place, and this really hasn't become an issue, and even in
	·
,	ANN RILEY & ASSOCIATES, LTD.
	Court Reporters 1025 Connecticut Avenue, NW, Suite 1014
į.	Washington, D.C. 20036 (202) 842-0034

security, we're re-examining the threshold itself to ensure it's not an issue.

1

2

MS. MADISON: I was just going to mention that. We have -- one of the bullets on here says we will re-evaluate those. We are re-evaluating those thresholds based upon the historical data that the licensees gave us on the 21st of January.

In looking at -- we're considering raising the threshold -- or lowering, actually, the threshold on the security equipment performance index, but we're still going to -- we still identify some outliers, and that's the purpose of the index.

I think it's about seven or eight plants that we think will be identified based upon that, and in talking to our security folks, they're considered true outliers in performance in the industry.

17 It may be because of some design concerns that 18 they have on their security equipment, but their security 19 equipment is considered as an outlier in performance in the 20 industry.

We haven't seen anything in these performance indicators that would say otherwise so far.

23DR. WALLIS: How many PI's are there?24MS. MADISON: There are 19.25DR. WALLIS: Nineteen. So, it's conceivable that

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

the 95 percentile will identify 50 percent of the plants but 1 2 only in one PI. MS. MADISON: We're doing 95 percentile per 3 performance indicator. 4 That's right. So, it could be that DR. WALLIS: 5 this field of green, every plant could have a white on 6 7 something. MS. MADISON: Yes. 8 DR. WALLIS: This isn't 5 percent of plants in 9 10 that regard. MS. MADISON: Per indicator, that's correct. 11 MR. JOHNSON: But there is no denying the point 12 that Dana makes, that the relative rarity of whites makes 13 the pucker factor for when you get a white very high, and 14 that's something we've seen in the pilot program, and I 15 think Alan's right. 16 DR. BONACA: I do believe one of the reasons why 17 you don't see more of these whites that Dana is talking 18 about is because they are not sensitive. 19 I mean they are so high, the thresholds, in my 20 judgement, that the issue of 5 percent of the plants for 21 some indicators -- like, for example, barrier performance. 22 I don't know where you have one of those. 23 I mean 50 percent of your tech spec value on 24 containment leakage, on fuel activity -- I mean you could 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036

(202) 842-0034

have bundles of fuel leaking to get those kind of values.

1

2

3

4

5

6

7

23

24

Again, I think it will go down to the last bullet and it will talk about then the objective shouldn't be that you change a threshold when you have an increasing risk. We already said you're not measuring the risk.

The objective should be that you have a sensitive enough indicator that it will tell you something.

MS. MADISON: There are some exclusions to that, 8 and in the barrier indicators, we did not choose on the 95 9 percentile. We chose based upon tech spec limits, and if 10 you look at the tech spec limits, they are really a very 11 small percentage of the Part 100 limits in the barriers. 12 So, the impact on true risk to the public is very, very 13 small, even at 50 percent of tech spec. 14

If the objective was purely the one DR. BONACA: 15 of looking at increasing risk, but I thought the objective 16 was the one of being able to see, I mean to have a sensitive 17 indicator that will tell you this -- there is a trend. 18

MS. MADISON: And we're looking at those 19 thresholds. We're also looking at those indicators to 20 determine whether or not we keep those indicators, because 21 of that very concern. 22

I think I've talked about that pretty much.

As I mentioned, we are probably making a change to the security equipment performance index. We're looking at 25

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

all the other thresholds in the performance indicators.

1

2

3

4

5

6

23

24

25

As you see on the last bullet, we're talking about the -- at least for the initiating events and mitigating systems cornerstones, the yellow and the red thresholds did have a direct tie to risk, in our estimation, as we developed those thresholds.

7 In those performance indicators that do not -- for 8 example, the safety system functional failures do not show a 9 direct correlation to risk -- we chose not to have a red 10 threshold. We chose just to have the lower thresholds, 11 because the action taken based upon the action matrix would 12 be sufficient to get to the root cause of problems in those 13 areas.

DR. APOSTOLAKIS: If one indicator is yellow, then I have a delta CDF of about 10 to the minus 5. If two of them are yellow, what happens? Two times 10 to the minus 5?

MS. MADISON: It's strictly on one performance indicator at a time, but in the action matrix, we try to then add those issues together to accelerate our action taken to address the problems.

21 At this point, if there's no other clarification 22 questions, I'd like Gareth --

CHAIRMAN POWERS: I have a clarification question. MS. MADISON: Oh, I'm sorry, Dana. CHAIRMAN POWERS: And it's in this last one, and

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

it comes to this red corresponds to about 10 to the -- a delta CDF of 10 to the minus 4th.

1

2

24

25

Maybe we take something that everybody seems to 3 focus on, scrams, and I look at the information used to come 4 up with that, and I guess I don't understand exactly how you 5 got the number you did and why it's pertinent, because I 6 certainly see plants that get about a 10 to the minus 4 with 7 scrams much lower -- that get scrams much lower than your 8 yellow-to-red threshold, and I see others where the number 9 of scrams has to be much higher to get about a 10 to the 10 11 minus 4.

When I try to say, okay, this top 5 percent of those, I don't find that in -- I mean just going through the numbers, I don't get that same number.

MS. MADISON: If the explanation in SECY 99-007 was inadequate, I'll get someone to -- I would ask Gareth if he would add some detail to the discussion on the scrams. Gareth, along with several others, helped develop the thresholds on that performance indicator.

20 MR. PARRY: I'm not really sure I understood your 21 comment there, Dana.

CHAIRMAN POWERS: I guess what I'm asking is really the mechanics of deriving the threshold values.

MR. PARRY: The white/yellow and the yellow/red thresholds.

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

CHAIRMAN POWERS: Any one of them would probably 1 2 help me, but I focused here just because the yellow-to-red has some quantifications with it, so I could go back and 3 4 check. MR. PARRY: Right. 5 Well, the way that was done was to take the 6 parameter in the suite of PRA models that we used and varied :7 it from the base that was in the model until we got a delta 8 CDF of 10 to the minus 5 or 10 to the minus 4, and you'll 9 see that there's a significant variation between plants, but 10 for most of them, the simple reactor trip, which is the 11 parameter we used, is not a major contributor to risk, and 12 that's why you see these rather large numbers associated 13 with the thresholds. 14 CHAIRMAN POWERS: I believe the number you came up 15 with there -- and correct me if I'm wrong -- is about 50. 16 MS. MADISON: No, 25. 17 MR. BARTON: There is a 50, I think, at one time. 18 MR. PARRY: For one of the plants, maybe. 19 CHAIRMAN POWERS: Okay. 20 If I used the criterion, most of the plants --21 then most of the plants in the tables would be 100. 22 MR. PARRY: A lot of them would be, that's true, 23 but that's just a reflection of the fact that simple reactor 24 trips are not major contributors to risk. 25

60

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

61 CHAIRMAN POWERS: Whatever they are, they are a 1 performance indicator, they have a threshold, and I'm 2 interested in how the threshold was found. Someone has 3 asked me what is the technical foundation for these 4 thresholds, and I've got to answer him, because he has a 5 higher pay grade than I do. 6 MR. PARRY: I've just tried to explain how we did 7 it. 8 CHAIRMAN POWERS: And I understand, but when I try 9 to go back and look at the numbers and re-do it myself, I 10 don't come up with that number. 11 MR. PARRY: How can you re-do the numbers without 12 having the --13 CHAIRMAN POWERS: Well, I've got these tables. 14 MR. PARRY: Okay. I see what you're saying. In a 15 sense, what we did, I think, to come up with the final 16 number which we used was -- well, we just said it was 17 greater than 25. It's just large. It's not a very useful 18 threshold in that sense, because it's so large. 19 CHAIRMAN POWERS: I have one particular plant 20 where, in your tabulation, it says, gee, if they have more 21 than seven, they've got a delta CDF of 10 to the minus 4. 22 MR. PARRY: Okay. That's probably a SPAR model, 23 right? 24 CHAIRMAN POWERS: And then all of the others -- I 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

mean they can go up to 100. Here's one with 35. Here's 1 2 another one that says greater than 50. It's not apparent to me how the number was 3 actually arrived at. 4 MR. PARRY: Where is the seven? Which plant is 5 this? 6 CHAIRMAN POWERS: If you look in Appendix H, page 7 H-9, Table 2. Maybe I'm misinterpreting the numbers. 8 MR. PARRY: Okay. These are the risk significance 9 10 scrams that you're talking about. CHAIRMAN POWERS: Yes. 11 MR. PARRY: Okay. 12 That's a different scram. 13 MS. MADISON: MR. PARRY: These are essentially losses of 14 15 feedwater. MS. MADISON: That's a different indicator, 16 though, Dana. 17 CHAIRMAN POWERS: Yes, I understand it's a 18 different indicator. Many of your thresholds are very, very 19 subjective, by your own admission, because you have no 20 quantitative tool to deal with them. A couple of them you 21 have quantitative tools to deal with. 22 I'm just trying to understand how you got the 23 actual numbers in a way that I can go back and reproduce and 24 say, oh, yes, had I accepted all your assumptions, all your 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036

(202) 842-0034

predications, which I'm willing to do, I, too, would have come up with this number.

MR. PARRY: This is over a year ago now. CHAIRMAN POWERS: Well, maybe you can give that

5 some thought.

1

2

3

4

15

16

17

18

19

24

25

There is a discussion of that MR. PARRY: 6 particular plant, which is Palo Verde, and it's a 7 design-specific feature, I think, of that plant, which is 8 the reason why that one comes out a little low, and I think 9 the exception is that we're going to set it at 10 for the 10 white/yellow except for those plants where feed-and-bleed is 11 not an option, which Palo Verde is one of them, I think, and 12 it says that this plant will be treated in a design-specific 13 14way.

CHAIRMAN POWERS: Okay. But you see what my problem is. You set the number at 10. All the other plants -- I mean they get numbers of 46, greater than 100, 34, 21. MR. PARRY: Well, you're mixing two tables there.

CHAIRMAN POWERS: Because I'm just asking a

20 question.

Now, if you want to get specific on one, I'm perfectly willing to do it. It sounds like you don't have a facile answer to my question.

MR. PARRY: I think the simple answer to your question is we looked at the results, we chose the lowest of

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

the set of those results and chose that as the threshold, unless there was a reason for an exception, and in this case, for the risk significance scrams, that was true, because Palo Verde does not have the feed-and-bleed option.

1

2

3

4

5

6

7

13

CHAIRMAN POWERS: Okay. So, I can go back and reproduce your numbers by looking at these tables and come up with exactly that number.

8 MR. PARRY: I think you should be able to 9 understand where the numbers came from. You might come up 10 with a slightly different perspective, because we've 11 probably done some rounding-off here, but yes, you should be 12 able to read Appendix H and come up with those values.

CHAIRMAN POWERS: It will stun me if I do.

MS. MADISON: I'm not laying it all on Gareth's plate either. Gareth worked with several other folks in industry as well as NRC, and their discussions, which he probably can't remember now, after over a year, led to that type of decision.

19 CHAIRMAN POWERS: I guess I think this is bad 20 practice to establish thresholds and not have a good 21 documentation on exactly where those numbers came from, 22 because sooner or later, at some time in the future, perhaps 23 after Dr. Parry has left the agency for greener pastures or 24 more delightful pursuits, somebody's going to want to change 25 those numbers.

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

DR. APOSTOLAKIS: Want to define greener? What's the threshold?

CHAIRMAN POWERS: Well, it's not white. He's got white here today. He doesn't need that anymore.

MR. DEAN: Dr. Powers, you make a good point, and 5 one of the things that we intend to do once we can get out 6 of the developmental phase and get into a more stable 7 implementation phase is to go back and develop what we are 8 going to call a basis document that will help do exactly 9 what you describe, what was the basis for all these 1.0decisions that led to the thresholds, and collect that all 11 in one document so that there is, indeed, not the reliance 12 on more, okay, but there is a documented basis that we have 13 14 in one place.

15 It's in a number of different places, 99-07,
16 07-alpha. There's a lot of places.

17

18

MS. MADISON: Yes, we've taken that on as a task. It's kind of the never-ending-job part of the process.

DR. APOSTOLAKIS: I have another question. Again,
it's clarification.

Let's take two plants. One, as the IP's have found, is from the ones that have a core damage frequency greater than 10 to the minus 4, let's say 5 10 to the minus 4, 19 PWR units were found to have that, and then the other one has a core damage frequency of 3 10 to the minus 5, so

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

big difference.

1

2

3

4

5

6

7

8

12

13

14

15

16

17

18

19

There will be random changes in performance, right? I mean it's not always consistent.

Wouldn't it be easier, due to random causes, for the plant that is already at 5 10 to the minus 4, to have a delta CDF of 10 to the minus 5 or more, easier than the plant that's already down to the 10 to minus 5, because that plant has to double its CDF.

9 So, for the plant that is already at the 5 10 to 10 the minus 4, would I expect it to be in the yellow region a 11 lot of the time, whereas the other one would not?

MR. PARRY: I don't think that's necessarily the case, because you are talking about -- you have to decompose what goes into that 10 to the minus 4, and if the thing that you're changing is in a very low cut-set, the delta might be the same for both plants.

DR. APOSTOLAKIS: Yes, but it seems to me, if I'm already at 5 10 to the minus 4 --

MR. PARRY: But if we're working on deltas --

DR. APOSTOLAKIS: -- changes there on the order of 10 to the minus 5 would not be something that would surprise me.

It would even be sensitive to the way I calculate things, because that's not a first decimal place, where the other one is way down there, something really drastic has to

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

happen for 10 to the minus 5 delta CDF.

1

2

3

4

So, the question is, should they prepare to see more yellows for the high core damage frequency plant, and what does that say about the process? I don't know.

5 MS. MADISON: Well, there's two answers, I think, 6 to that, and Gareth started with one of them. That's not 7 necessarily the case, just because there's a greater risk 8 overall at that plant, that the change will be greater based 9 upon an equipment failure.

The second is, you know, if part of the purpose of the program is to focus our resources more effectively where the risk to the public is greater and if the risk at that plant to the public is greater and they have more problems and they do go into the white or the yellow more often, that's where we should be focusing our resources.

DR. APOSTOLAKIS: But the question is whether getting into the delta CDF of 10 to the minus 5 is something that's sort of expected due to random causes for that plant. So, there is no reason for alarm, whereas for the other plant there should be.

I don't know the answer myself.

MS. MADISON: We'll have to watch that during the implementation phase. That's, again, another question that we'll have to try to answer during initial implementation. MR. DEAN: And one of the other things is that,

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

21

within our program, part of our inspection procedures is an event response element which is defined to allow the agency to react appropriately to issues that cross thresholds but to look at other performance attributes of that that have to be evaluated.

1

2

3

4

5

6 So, in other words, you may have an event that, 7 because of the very nature of the event, has a certain risk 8 significance to it and that we would want to respond with a 9 certain inspection reaction, but that may not, it and of 10 itself, be a relationship to a performance issue. It may be 11 something that's related to the actual risk characteristics 12 of the plant.

MR. GILLESPIE: George, is your fundamental question, if someone's got a plant that's designed with more redundancy in certain functional areas, do they have an advantage? The answer is yes. The answer to that question is yes.

18 DR. APOSTOLAKIS: I guess I was coming from 19 another point of view.

If already the CDF is high, then we anticipate random changes with time around the baseline value, which is an average value.

So, if I'm already high, a delta CDF of 10 to the minus 5 should be something that I should see very often in my plant, because that means small variations with respect

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

to my baseline CDF.

1

2

3

4

5

6

7

8

24

25

MR. GILLESPIE: Yes. Now you're exactly where the staff was in wrestling with thresholds, because up until this point, the criticism was the thresholds are too tight, and this argument could be used for saying the thresholds go the other way, and that was precisely the problem in being risk-informed, by the way, not risk-based, that we needed to wrestle with.

9 Now, what the industry data is showing us -- and 10 the team just got all the industry data in on the PI's --11 they have to step back and look, does that profile look the 12 same as the pilot plants and what was anticipated, and 13 they're still in the process of kind of doing that, but 14 we're not necessarily anticipating, I don't think, a lot of 15 whites by design, if you would.

MS. MADISON: And we have not seen a lot of problems with the historical data submittal that we would necessarily need to change thresholds dramatically, although we're still -- it's under review. We think there are some changes to be made, but we're still looking at it.

Did you want Gareth to talk about the plant-specific issue, because he has some information he'd like to share.

DR. WALLIS: I have a follow-up question to George's question about plants with a large CDF.

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

Now, you get into red by doing something which is
 increasing your CDF by 10 to the minus 4.

Can you get out of it by fixing something else which has something to do with something completely different from what got you into this red, because you already have a large CDF to play with, so you can fiddle something else to get you a negative delta CDF to cancel out the one you've just gotten.

MS. MADISON: It's issue-specific.

9

25

So, if you have a piece of equipment failure -pardon me -- a performance indicator that causes an availability of that piece of equipment, the emergency diesel generator, to be out for that period of time, that is an unavailability number that will cause you to cross a threshold.

16 There's not another piece of equipment, as far as 17 that's concerned, you can throw that back.

DR. WALLIS: You can get back, though, by -- in that specific -- delta CDF of 10 minus 4 -- by getting back part-way, till it's a half 10 to the minus 4, then you go back to yellow, or do you have to fix the whole thing?

I mean you could get out of this state in the same way you got into it, by reversing exactly the same thing that you got into --

MS. MADISON: By reversing performance.

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

For example, the scrams -- once the scram crosses 1 the threshold, that number stays there for a certain period 2 3 of time. DR. WALLIS: You can't cancel that out. 4 MS. MADISON: Well, you can't cancel out 5 unavailability of a piece of equipment either. 6 DR. WALLIS: You're bound to stay red for a long 7 time if you have a lot of scrams, no matter what you do? 8 MS. MADISON: As your critical hours increases, as 9 your denominator increases, that number will go down. 10 That's no different than what MR. BARTON: 11 industry does not. You cross the threshold, it just stays 12 in there for a few years. 13 DR. WALLIS: You could also cross the threshold by 14 making some error which you could fix. 15 You can't. MR. SIEBER: 16 DR. WALLIS: You can't? 17 MS. MADISON: There is an issue in unavailability 18 with fault exposure hours if you find a design problem which 19 you might consider an error that's been around for 20 years. 20 An aggressive program on the part of the licensee, going out 21 to look for design issues, they find this issue, and when 22 looking at it, it says that piece of equipment would have 23 been unavailable because of that design issue. 24 Now, we've tried to accommodate that in the 25 ANN RILEY & ASSOCIATES, LTD.

Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

process by saying that could probably cause you to stay white, yellow, or red for a long period of time.

If that issue is corrected, if we have reviewed 3 and found that issue -- the correction to be adequate and 4 5 we've documented that in a report, after four quarters, we'll remove that fault exposure hours to take that off of 6 the books, number one, to say -- you know, to compensate, 7 you know, it was not necessarily a performance issue on your 8 part, it was something we needed to focus on, we needed to 9 apply some resources, and number two, we don't want to mask 10 any future issues that may crop up, because you have this 11 large number of fault exposure hours due to a design issue. 12

We're looking for that type of issue if it comes up in other performance indicators, and we may need to make similar type of adjustments.

DR. KRESS: Where in the performance indicators do you incorporate this time element? If a performance indicators jumps above the threshold, do you say it has to reside there a certain amount of time before you trigger some sort of action?

21

24

25

1

2

MS. MADISON: No.

DR. KRESS: If you could have a time element, it could take care of George's problem of randomness --

DR. APOSTOLAKIS: Yes.

DR. KRESS: -- because it wouldn't be there long

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

if it was random, and if it were a real performance 1 degradation, it probably stays there a long time. 2 MR. JOHNSON: Well, remember what we do with all 3 of these things in terms of the action matrix -- and all of 4 5 this is driving to get us to a point where we can decide what the regulatory response should be and what the licensee 6 response should be, and in fact, the consequence of, you 7 know, a spike above a threshold, for example, the 8 consequence -- the ultimate consequence for a white is that 9 we go do some additional inspection and do some diagnostic 10 look, and in fact, the result of that inspection could 11 indicate that this was random. 12 DR. KRESS: Okay. That would be another way to 13 deal with it. 14 DR. APOSTOLAKIS: You had how many, six pilots, 15 six pilot plants? 16 MS. MADISON: Nine. 17 DR. APOSTOLAKIS: Are the baseline core damage 18 frequencies for these plants available easily? 19 MS. MADISON: I'm sure they are. 20 DR. APOSTOLAKIS: And the question is really did 21 you check whether there was any correlation between the 22 findings and the baseline CDF? 23 MS. MADISON: Frankly, we didn't have enough 24 findings greater than white to draw any kind of conclusions 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014

Washington, D.C. 20036 (202) 842-0034

in that area. We'll have to look at that closer during 1 2 initial implementation. DR. APOSTOLAKIS: Okay. 3 MS. MADISON: Gareth? 4 5 At this time, I'd like Gareth to address the issue of plant-specific thresholds. 6 MR. PARRY: Let me see if I get this straight. 7 You'd like to see plant-specific thresholds. Is that right, 8 George? 9 10 [Laughter.] 11 MR. PARRY: Okay. DR. APOSTOLAKIS: All this, you know, everything 12 we do depends fundamentally on what the process is designed 13 to achieve, and it seems to me -- so, the first thing is we 14 have to have consistency between the objectives of the 15 process and the way it's implemented, and then we have the 16 second issue, do you agree with the objectives? 17 So, from the discussion today, and other 18 discussions, I get the impression that the process is really 19 designed to maintain or to alert the staff that the level of 20 safety at that plant has changed in the wrong direction, 21 because if it changed in a good direction, we really don't 22 23 care. So, if you start with that premise as an 24 objective, then everything else has to be plant-specific, 25 ANN RILEY & ASSOCIATES, LTD.

74

Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034 and that would be consistent with what we do in other parts of the regulations -- as I mentioned, 50.59.

1

2

3

4

5

6

24

25

I mean we agonized over what is negligible, minimal, whatever other terms we used, but we said we really want to maintain the licensing basis, and a lot of other things.

Now, if you start from that point of view, then you're saying, well, gee, you know, I want a plant-specific set of, say, performance indicators, but then you may decide that the performance indicators really should be the same for all plants because of certain reasons, but you started with the idea that you would try to define it on a plant-specific basis.

Then the thresholds, which is a separate issue, you know -- I may decide that the PI's are generic, but then the thresholds -- and I think that's where my disagreement is -- again, I start with that premise, they have to be plant-specific.

Now, for certain things, I may decide that, you know, the number I'm using for plant X really should be applied to a whole class of plants or maybe all the plants. That's fine, too, but you started again from the fundamental premise that it has to be plant-specific.

If you start with generic, then there are all sorts of problems with inconsistency and so on, and this is

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

really my fundamental problem, the consistency with the objectives of the process and then what are the right objectives of the process.

MR. PARRY: Okay. And I think the staff's on record as saying that, certainly in the ideal world, we would like plant-specific thresholds, and I'm trying to think of the way that you'd set this up.

Now, presumably, if you had a good PRA model for each plant, you could extract from that the appropriate parameter value that would give you what the long-term expected value of the particular PI would be that would -that gives you that level of risk, and you could use that as the current status of the plant, if you like. Okay?

So, you'd have a target, much like the maintenance rule for setting their goals on reliability and availability.

Okay.

1

2

3

4

5

6

7

17

Now, what that represents, though, is a long-term
average about which we're going to have statistical
fluctuations. Let's get to that in a minute.

First of all, we're making an assumption here that that value of the PI is going to be dramatically different from plant to plant -- at least it's going to be different from plant to plant and that the variability has a direct correlation with the level of CDF.

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

I think if you look at the particular parameters 1 that we're dealing with, which are diesel generator 2 unavailability, HPCI unavailability -- if you look at those 3 from plant to plant, from the plant's own assessments and 4 5 also from the AEOD assessments, you're not going to find that that varies tremendously, and perhaps it's more a 6 function of the fact -- and the argument's a little easier 7 to make, I think, for the HPCI pumps, where they tend to be 8 fairly uniform design -- that perhaps what we're seeing is 9 more a fundamental limitation on the way they can be 10 maintained and operated rather than a conscious decision 11 that, in some plants, we have to really look at this 12 carefully to maintain the level of risk, and I think, if you 13 look at that variability, you're not going to see a great 14 variability, which argues, I think, for the fact that, at 15 the level of the indicators that we're talking about, that 16 the generic types of values and thresholds are, in fact, not 17 18 such a bad approximation.

Now, the other thing is, I keep hearing that youthink that the green/white threshold is high.

21 DR. APOSTOLAKIS: I think a lot of people think 22 that.

MR. PARRY: Yes. I'm not just saying you. Wekeep hearing that it is high.

DR. APOSTOLAKIS: Yes.

25

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

MR. PARRY: If you look at the thresholds, in fact, they are not so very high compared to typical unavailabilities that you see in PRAs.

The other thing I would point out, too, is that we 4 did look at this in terms of sensitivity studies, and if you 5 look at the back of Appendix H, you see, for a couple of the 6 plants, what we did was we took all the PRA's for the 7 reactor, for the initiating events and mitigating systems, 8 we bumped them all to the green/white threshold, okay, so 9 they're all at the top, and in putting all of those at that 1.0 value, we still didn't generate a delta CDF that was 10 to 11 the minus 6, and it's because you can't say that there's one 12 plant that contributes at the highest level to each of those 13 indicators, but I think these are plausibility arguments, I 14 think, to suggest that the thresholds we've chosen are 15 adequate for the purpose that we need them for and that they 16 are not -- it's not necessary to have plant-specific 17 18 thresholds.

DR. APOSTOLAKIS: No, but it seems to me -- you see, I think we have an issue of presentation here, because the logic that you followed is exactly the logic I would follow.

Now, the last sentence I disagree with, because if you did all that, then it is plant-specific.

25

1

2

3

Plant-specific does not mean that the number is

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

different for each plant. The numbers may turn out to be very close, and you say, well, I'll pick this number, but this is not what's written here.

1

2

3

4

5

6

7

8

9

The second question -- so, you really follow the logic that I'm advocating, because your argument was that we really looked at plant-specific data, but we concluded that there was not really variability, and instead of producing 103 numbers that are within the noise of each other, we said, well, go with this, which I think makes perfect sense, but that's not what it says here. 10

Second, though, you said that you looked at the 11 data and you didn't see variability. 12

Now, I think that deserves some discussion, 13 because if I look at page H-18 and H-19 and I read in the 14text that the bars that I see here are the highest values 15 per year over five years -- these are not just the actual 16 numbers, these are the highest numbers. 17

I don't know that if I look, say, at Figure H.1 on 18 page H-18, that I can conclude that there is no variability. 19 I mean on what basis are we deciding that this is 20 statistically insignificant? 21

On what basis are we deciding on the next figure 22 for BWR high-pressure injection system unavailability, that 23 for example -- you see if I look at plant 54, it has an 24 unavailability of perhaps .005 or something, or 6, and then 25

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

I have other plants that have, you know, .04 and even
 higher.

3 So, the argument that we looked at the 4 plant-specific data and we didn't observe any significant 5 change, I'm not sure how you can justify that in light of 6 this evidence, because these are the highest numbers. These 7 are not the actual numbers.

MR. PARRY: I don't want to mislead you, George. We didn't look at this to see the plant-to-plant variability. What I'm saying is that I looked at various sources like IP's, the AEOD studies, okay, and in those studies, the long-term average of the unavailabilities that people use for these systems are not that variable. That's what I'm saying.

15 Sure, we expect to see variability because of the 16 statistical variation, because what we're dealing with is 17 relatively infrequent events.

DR. APOSTOLAKIS: But Gareth, if this is the highest over five years, the highest per year over a period of five years --

21 MR. PARRY: It's the highest three-year rolling 22 average over five years, I believe, is the way it is.

23 DR. APOSTOLAKIS: Then that should be a robust 24 indicator.

25

I mean that shouldn't change that much, and if I

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

have these differences that I see in these pictures, it seems to me I should worry about this variability, and maybe that should be an input to the studies that the AEOD has done and so on, but it's not something that immediately convinces me that the generic value would be good enough, because for example, for the high-pressure injection system unavailability, for plants 51, 54, 55, 62, the threshold is way too high, because it was driven by other plants.

1

2

3

4

5

6

:7

8

Now, again, should you, within the time
constraints you had, have developed plant-specific values
for all these? Probably not. But in the maintenance rule,
you ask the licensees to do it for you. Why don't you do
the same thing here? Spread the work.

There are several issues here -- the conceptual issues, the practical issues. You know, I do appreciate that you're under tremendous time pressure, but --

DR. BONACA: I think you have a problem, also, with the fact that thresholds are being set at a value where safety is not degraded.

So, there is a presumption of risk information, and we are talking about whether it's legitimate, but I thought the more important issue we discussed at the beginning of the meeting was that you should be able to trend performance from what it was last month or last quarter and see trends.

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

I mean the importance of the indicators is trending, it seems to me, and again, I do believe that, by using the criterion of safety is not being degraded, you're making these indicators too insensitive to changes, and I still think there is a confusion between what objectives you have --

1

2

3

4

5

6

7

8

9

10

I think the safety degraded issue is MS. MADISON: a measurement sense of how degraded is it. Any error, any industrial error that's made out at the plant could be construed to be a reduction in safety or an increase in risk. 11

We're saying that, at the green/white threshold, 12 it is a very small increase -- it's a small increase in the 13 risk. 14

I understand that, but let me just DR. BONACA: 15 tell you why I have just a very practical concern. I want 16 to get away from -- the practical concern is, if I get all 17 greens -- assume we get all greens -- and that's probably 18 going to be true for many plants -- then the indicators are 19 irrelevant. 20

I am going back to everything else you've got in 21 the inspection program, the baseline program, being the 22 fundamental element that you're looking at. 23

However, you still have a statement of all green, 24 and it may be an impediment or a reduced ability on your 25

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

part to rely on --

1

2

3

4

MS. MADISON: What it means, being all green, is that we will do the baseline inspection program, and the baseline inspection program can still identify problems.

5 DR. BONACA: I understand that, but I'm saying 6 that if, in fact, it doesn't give you an ability to 7 discriminate and it's generally green, why do you have it at 8 all? Just throw it away.

MS. MADISON: Because that's one of the basic premises of the program, that there is a level of performance at the licensee below which we don't need to get more involved other than the baseline inspection program.

That is the basic premise of the program, that says if they are green in those indicators or if they are green in their performance, that the maximum level of involvement we need to have at that point is the baseline inspection program, and if that's true for all plants, then that's true.

MR. DEAN: And remember -- I mean our inspection
process is a sampling process.

I mean you very well know that we don't look at every aspect of every plant operation or activity we sample, and that's one of the reasons why we have a continuous inspection program and why we go back and do the same inspections, looking at the same things, because maybe this

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

1	84
1	one time we don't find that performance issue but maybe
2	another time we will, and then we can pull that thread and
3	maybe uncover
4	DR. APOSTOLAKIS: Is plant 54 on two different
5	figures the same plant?
.6	MR. PARRY: I think it is, yes.
. 7	DR. APOSTOLAKIS: Okay.
8	So, if I look at Figure H-2, 54 is a very good
9	performer, page 19, H-19.
10	The BWR HP injection system unavailability is very
11	small.
12	Then I go on to the next figure, which is
13	emergency AC power system unavailability; 54 is again among
14	the best performers.
15	Then I go to the next figure, BWR RHR system
16	unavailability 54 is doing very well.
17	Three indicators and 54 is one of the best plants.
18	So, the threshold is higher than the performance of this
19	plant in all three indicators.
20	So, this plant now would be allowed to deteriorate
21	its performance on three key indicators and it would still
22	be in green, because the threshold is determined by the
23	performance of other plants, and is that something that an
24	oversight process ought to allow?
25	MS. MADISON: On an individual basis that's a
	ANN RILEY & ASSOCIATES, LTD.

Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

question that we're going to have to answer for the program sometime after initial implementation.

1

2

One of the processes that Bill was going to get 3 into at the end was we need to develop a oversight process 4 for the oversight process -- in other words, a quality 5 assurance process for this where we look back at the 6 program, at industry as a whole, in the macro sense, and say 7 have we maintained safety in the industry, or because of 8 what you're talking about, George, has safety in an 9 industry-wide sense decreased, and that's a question we're 10 going to have to answer, and we've committed to answer that 11 question in June of 2001 based upon our review of initial 12 implementation. 13

Now, that's going to be a process that's going to look at some industry-wide indicators that we may already have, some yet to be developed, and it's also going to look at, programmatically, how it's been implemented and some of the lessons we've learned out of the program, but that is a question we're going to have to answer.

DR. APOSTOLAKIS: Now I think it's clear what my fundamental problem is, that there is this plant 54 that is doing very well, and now you're setting the threshold so high that this plant, on three key indicators, can -- not that they will try to do it, but if its performance deteriorates on all three, the agency will do nothing.

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

MR. GILLESPIE: Inherent in that is they're still in compliance with their license.

86

CHAIRMAN POWERS: Suppose that it is true that this plant is doing very well because of heroic efforts on its part.

It has concentrated resources, it has focused its engineering department, it has focused its training program. It does very well on these things, at the expense of substantial investment on its part.

10 Why shouldn't it be acceptable for this plant to 11 relax on that because it is going -- it's over-devoting 12 resources in those areas and should be devoting in the areas 13 such as fire protection or emergency preparedness, where 14 maybe it doesn't do so well?

I mean why isn't that one of the objectives of having a risk-informed regulation, that we want resources to go to the areas where they're needed, as opposed to areas that are thought to be important?

DR. APOSTOLAKIS: Well, that argument, by itself, could have some merit, although we would have to look more carefully.

CHAIRMAN POWERS: You can understand why sometimes our planning and procedures meetings go long, with this kind of support from my Vice-Chairman.

[Laughter.]

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

1

25

1

DR. APOSTOLAKIS: But it would be absurd for the same plant, if they want to change some minor thing, to have to argue that they are within the requirements of 50.59. Either we change all the regulations, then, to say, you know, go ahead and change things and we'll look only at what's important or try to be consistent.

1

2

3

4

5

6

25

MS. MADISON: A lot of those are consistent in 7 that they utilize Req. Guide 1.174 as kind of a basis for 8 deciding whether or not to make that change, and we've tried 9 to rely on Reg. Guide 1.174 to also help us define what is 10 the significance, and 1 times 10 the minus 6th or 1 times 10 11 to the minus 5th fits into Reg. Guide 1.174 and the backfit 12 rule as far as what is considered a significant enough issue 13 that we need to get involved or we need to review that 14 15 closely.

MR. BARTON: I think the bottom line here -- and you can change indicators -- and George's concern is, well, this plant can now be allowed to slip, and Dana's saying, well, why not, because they're focused on other areas. Fine.

But isn't the real key here how is the new process going to allow you to identify problem plants in a more timely basis than the old process, which was a criticism of the old process?

MS. MADISON: Exactly.

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

MR. BARTON: Now, how are you going to be able to do that with all these fluctuations and this, well, it's got a little bit of risk, but it's still in the licensing basis, and there's this new process to allow you to identify the problem plants on a more timely basis.

1

2

3

4

5

21

22

23

24

25

6 MR. DEAN: The combination of having a more 7 frequent submittal of information that reflects on plant 8 performance, that we're looking at this information on a 9 quarterly basis, that we have in place a predictable process 10 by which we can react to performance issues, that we will, 11 as performance degrades, apply a greater amount of resources 12 and focus on those plants to better understand the issues.

I think just the very fact that we have a periodic 13 updating, a public display of what the overall performance 14 assessment is of the plant is, in and of itself, a 15 substantial driver of trying to enhance consistent safe 16 performance of the plants, because there's going to be a lot 17 more public pressure, as you will, to maintain indicators 18 within appropriate bands of performance, so that the NRC is 19 not engaging --20

MS. MADISON: I think there's two ways.

Number one, by the significance determination process and the indicators, helping us identify those areas that aren't as risk-significant, we can stop looking at those areas and spending resources there, freeing up those

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

resources to look at more risk-significant areas, where we can identify problems, will help us identify problem plants in a more timely manner, and as Bill mentioned, the more frequent information coming up, but frankly, it's the idea that we put out a system that establishes -- that says, if we have these inputs, this is what we're going to do. We're no longer a black box.

1

2

3

4

5

6

7

20

21

24

You know, the Arthur Anderson study -- one of the 8 things -- in '96 -- one of the things they said is we're an 9 agency that had more information available to us than any 10 other regulatory agency they had seen. It wasn't that we 11 lacked information at the facilities. It's just we may have 12 reacted slowly to it. 13

What this process does is it puts out in front and 14advertises this is what we're going to do if we get this 15 information, and to react differently, we're going to have 16 to justify that. That's new. That's something we haven't 17 had in the past, and I think, frankly, it will force us to 18 react in a timely manner. 19

DR. APOSTOLAKIS: I have a second thought.

DR. KRESS: I do, too.

CHAIRMAN POWERS: Let's let Dr. Kress introduce 22 his perspective. 23

DR. KRESS: As you said, how you implement this system should start from your fundamental objective. Ιt 25

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

looks to me like the fundamental objective is to keep the performance below an acceptable level -- I mean above an acceptable level.

1

2

3

21

24

25

4 CHAIRMAN POWERS: Up and down is going to be a 5 problem.

DR. KRESS: But if you viewed that as the objective, then all this makes sense. The acceptable levels are the thresholds, and it doesn't matter how far below you are, as long as you're below it.

DR. APOSTOLAKIS: I would answer you the same way IN I would answer Dana, that this is a noble objective, rearranging resources and so on, but I don't think it's the job of this particular regulation to do that. That's why we have 1.174.

15 If the licensee feels they can spend the resources 16 in a better way, they can always come to us and argue to 17 change -- you know, to request a change in their licensing 18 basis, and we have other regulations that deal with that. 19 The job of the oversight process is to make sure that what 20 we approved remains the way we approved it.

MS. MADISON: We would disagree.

DR. APOSTOLAKIS: It's not the job of this regulation to allow changes.

> CHAIRMAN POWERS: I think we've got to move along. MS. MADISON: I guess we want to ask you at this

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

	91
1	point where do you want us to go? Because I think we've
2	reached our 10:30
-3	MR. BARTON: Well, NEI does not have a 15-minute
4	presentation. As I understand, they just want to make some
5	comments.
6	Is that true? Is NEI here?
7	MR. HOUGHTON: Tom Houghton, NEI.
8	We didn't have a prepared presentation. I think
9	we laid out our issues at the last meeting.
10	Industry has presented their data to NRC. We're
11	satisfied with the program as it is right now and ready to
12	move ahead, and we believe that there are a number of issues
13	that require looking at the thresholds, and that will
14	continue in the public venue.
15	Preliminary look at the data that's been
16	submitted, although it hasn't all been verified yet, would
17	show that there are a number of plants which have exceeded
18	the threshold, and so, it is not a program that will result
19	in all greens for everybody.
20	CHAIRMAN POWERS: Well, can you speak to the issue
21	of someone exceeding the green-to-white threshold, for
22	example, not because of any poor performance on their part
23	but, rather, because the way the threshold was chosen is not
24	consistent with the kind of design they have.
25	I mean they are forced into exceeding this
н - С С С С С С С С.	ANN RILEY & ASSOCIATES, LTD. Court Reporters

Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

threshold by design, even though the plant has, throughout the licensing process, been found certainly safe enough, maybe even exemplarily safe.

1

2

3

4

5

7

18

25

MR. HOUGHTON: There were a number of plants that thought that the thresholds would unfairly treat them. Those issues are being looked at. However, the preliminary 6 data shows that it hasn't disadvantaged them.

8 The plants with the whites that we see so far --9 their data shows that they've had unavailabilities which would show up in the data and for which they want to make 10 correction. 11

CHAIRMAN POWERS: And that's kind of the same 12 answer that you had found, but again, we go from pilots to 13 more extensive, we need to be alert to that, and we'll have 14 to figure out some way to handle it, because I think it does 15 not serve any of us well to have a plant highlighted for no 16 17 reason.

> MS. MADISON: No.

MR. DEAN: I will share one of the things that we 19 would have gotten to if we had continued the presentation --20 I think you need to continue to make 21 MR. BARTON: the points you want to make on PI's and then jump into the 22 SDP, because we haven't even talked about that yet. 23 MS. MADISON: Do you want us to continue on, then? 24

MR. BARTON: Yes, I think so.

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

MS. MADISON: Really, the only point I wanted to make on the next slide, really focus on, was kind of respond to your question you had on the SSA, why it was not used, although there are some other issues as far as how we developed these performance indicators.

1

2

3

4

5

I just want to remind you there was a rigorous process that -- we thought a fairly rigorous process -- to go through and select performance indicators and drive down through what we called the football diagrams to look for important attributes, important areas to measure, and see if there was a performance indicator available.

Now, I'll refer you to SECY 99-007 on page I-11, and we responded to this question over a year ago about the SSA, and our answer was the SSA indicator proposed by NEI did not differentiate between plants or add any new information.

Only one plant, a declining trend plant, was in the white band, and it was also in the white band for transients.

Lowering the threshold by one would capture two average plants and three watch list plants, all of which were identified by other PI's.

In addition, the SSA indicator did not show a strong correlation to the discussion plants in the Arthur Anderson analysis. For these reasons, we did not include

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

the SSA.

1

2

3

4

5

25

And I guess the two points there I want to highlight are, you know, the information was provided -that the SSA provides is also provided by other indicators. So, we have bounded the SSA.

6 There's no new information provided by the SSA, 7 and we felt the other indicators actually were better 8 indicators.

9 MR. BARTON: I think that was part of a larger 10 question which said are you satisfied that you've got enough 11 indicators to be able to assess performance?

MS. MADISON: In connection with the baseline inspection program, again, you know, being aware that it's not just a performance indicator program. It's an oversight program that includes performance indicators and inspection.

MR. DEAN: Could we have better indicators or
indicators that would give us a more comprehensive view of
plant performance? Absolutely.

MS. MADISON: Yes. And we're looking at those, and that's the next slide, the ongoing work.

21 You had some questions about the other long-term 22 issues that were out there.

We're continuing to look at the consistency of PIdefinitions.

We feel we're consistent right now, agency-wide,

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

with the availability definition, and that includes the maintenance rule folks, because we worked with them to help develop this definition.

1

2

3

4

5

6

22

Industry, NEI has agreed that this definition is correct. INPO has agreed that the definition is correct. They're trying to work with WANO to get them on board.

7 We finally found an agency that's slower to react8 than we are.

DR. APOSTOLAKIS: Would you add the two issues that we raised today to the ongoing work, please? The definition of the objectives for the program and the issue of plant-specific information. Or is that something that you will do in the future?

MS. MADISON: We'll take those questions back and look at them again. I'm not sure we'll add them to our workload. We'll have to look at those two questions, though, George. I've noted them in my notes.

DR. APOSTOLAKIS: With the industry and WANO, since the fundamental objection here seems to be that the thresholds are too high, it's not really surprising that the industry supports this, is it?

MR. BARTON: Not to me.

DR. APOSTOLAKIS: So, that doesn't really mean much. You are giving them more than they have now, so why should they object?

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

1MS. MADISON: We're also satisfied. We feel that2the level --

DR. APOSTOLAKIS: I understand that.

3

25

MS. MADISON: -- noted by the performance indicators allow us enough opportunity to get involved and to do our inspection activities and identify our concerns before there is unsafe performance at a plant.

8 MR. BARTON: George, what I'm hearing loud and 9 clear today -- maybe we didn't focus on it or absorb it in 10 the past -- is I keep hearing the inspection program really 11 is what they're relying on, since the PI's have got, you 12 know, these concerns that we've been talking about. I think 13 the key here is how good is the inspection program and the 14 SDP process.

DR. APOSTOLAKIS: And it's plant-specific, so I'm happy.

MS. MADISON: Do you have any other questions on 17 what we have -- the last two bullets up here are really kind 18 of what I had mentioned earlier as far as developing an 19 oversight program for the oversight program, looking at 20 those long-term, a self-assessment program, looking at 21 industry-wide performance, and we're developing -- as we 22 said, we're continuing to look at additional indicators, 23 better indicators. 24

The research has an effort right now ongoing for

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

us to look at risk-based indicators, and we're going to consider those in the future.

1

2

24

25

3 DR. BONACA: One last comment I'll make is that I 4 still have a problem in answering the question about the 5 technical adequacy of the performance indicators, and the 6 reason is, anytime I raise an objection to them, or to the 7 threshold set for those, I get statement that says but we 8 have the baseline inspections and we have the significance 9 determinations.

I mean -- and it leads me into limbo about, you know, the significance of those indicators. That's a problem I'm having.

And I understand the program. Actually, you know, 13 I'm more impressed today because I heard that you're going 14 to have some kind of gradation you are going to make, also, 15 on your baseline inspections, so therefore you have some 16 ways of balancing the full green from the indicators or 17 something else, but still, I've got a problem in addressing 18 the question regarding technical adequacy, because anytime I 19 find some problem with it, I get an answer that says but 20 there is something else. 21

MS. MADISON: That's one of the problems we had in developing the program.

The first proposal by NEI was a program that relied entirely on performance indicators, and when we

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

looked at the performance indicators that were available, that we had, industry had, or that we could devise quickly, we couldn't find any that we could just rely strictly or solely on performance indicators.

1

2

3

4

5

6

We had to devise a program that was supplemented and complemented by inspection.

We're going to continue to look at the performance 7 indicators and try to come up with better ones, and more 8 technically adequate, but remember, again, they're not : 9 measures, they're just indicators, and even if -- and Arthur 10 Anderson said this -- if you add enough numbers together and 11 you can show a correlation to performance, by looking 12 backwards, then you probably have an indicator of some 13 worth, and we've proven that with the safety system 14 functional failure indicator. 15

DR. BONACA: And yet, they will be questioned and judged independently as a set. Independent of all the considerations we are making here, there is also the baseline inspection, because that's the way -- how things happen.

21 You have a matrix there, and people are going to 22 ask questions specifically about those.

23 MR. DEAN: You're absolutely right, and we've 24 struggled with that in every meeting, whatever venue we 25 have, that there tends to be a focus on the performance

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

indicators as being a complete, comprehensive set of information, and they're not.

MS. MADISON: I want to move on now to the significance determination process, kind of focus a little bit on the basics of this, and I understand Mr. Bonaca has 5 not read SECY 99-007A that describes -- one of the appendices to that describes the basis for the significance 7 determination process. 8

99

What we wanted to do and devise was a simple tool 9 for inspectors to use to characterize inspection findings, 10 and what we wanted to do was make sure that the output of 11 the significance determination process correlated closely to 12 the output of the performance indicator process, colors with 13 the same relative risk significance. 14

It's an approximation within an order of 15 magnitude, hopefully a conservative approximation, but it's 16 17 an approximation.

We're not trying to draw any bright lines between performance. We have numbers associated with the thresholds, but they're approximate numbers.

So, in determining the characterization of the 21 significance of an inspection finding, there's no 22 difference, in our minds, between .8 and 1.1. They're the 23 It's a fuzzy line, in other words. 24 same.

The SDP process goes through -- I'm just going to

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

1

2

3

4

6

18

19

20

quickly describe it.

1

12

13

14

15

16

17

18

19

25

First of all, the input to the significance determination process is the output of one of our documents, the manual chapter 0610, which says that the basement of issues or the threshold of issues to be discussed in the inspection report is right about the minor violation threshold, and that's true for issues that aren't necessarily violations.

9 They have the same relative risk significance 10 characterization of issues that are not violations that you 11 would discuss in an inspection report.

That's where we define what we call a finding.

Those issues, then, can be put into a significance determination process, and it's not just one significant -the significance determination process, there's multiple processes.

We have one for the reactor side of the house, but it doesn't have, right now, the issues of containment or shutdown involved in it. We're still developing those.

There are other processes for the non-reactor side, for EP, safeguards, and there's actually a couple of processes in the health physics area, but they're tools. Again, they're simple tools for inspectors to identify the relative risk significance.

The phase one part of the process is a screening

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

process that, on a conservative nature, says does this inspection finding have any likelihood of being greater than green, and if it doesn't pass that screen, it is a green finding, it should be turned over to the licensee for evaluation and correction.

6 If it has any likelihood of being greater than 7 green, it goes to phase two.

1

2

3

4

5

24

25

Phase two involves, then, the site-specific 8 work-sheets that have -- we've gone back and looked at 9 initially the IPE's, the information that we had available 10 on the docket from the licensees, developed the 11 site-specific work-sheets, and then went out to the sites 12 and looked at, site-specifically, what issues, what changes 13 to the sequences should be made, what changes to the event 14 frequencies should be made, and what other mitigating 15 systems should be considered within that phase two 16 screening. 17

18 That phase two screening is, again, more 19 site-specific, more involved, but it, again, is a 20 conservative screen, and it's an approximation screen in 21 orders of magnitude.

That is an initial determination of the relative risk significance of the inspection finding.

The phase three review -- what that phase two review, then, does is say this is definitely greater than

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

green, this inspection finding is definitely greater than green, and it should be considered by a -- in a more rigorous manner, and we throw this into the SRA's, the Senior Risk Analysis in the region, as well as in 4 headquarters, who then look at this issue more closely and 5 determine its actual risk significance. 6

So, the phase three is more detailed and would use 7 more discriminating tools, more definite risk models than 8 the significance determination process, to come to a final 9 determination. 10

11

1

2

3

I see some questions.

I guess that the phase three is CHAIRMAN POWERS: 12 a problematic area in your first attempts to do it? I qet 13 the impression that phase three may be a time-consuming 14 activity done largely outside the realm of public scrutiny? 15

MS. MADISON: That's a definite perception. 16 There's a couple of reasons for that, we think, that we have 17 tried to address. 18

The first phase three review that was attempted to 19 be done was we had not awoken to the fact that site-specific 20 phase two documents, work-sheets were necessary. We were 21 still under the misconception that we could do this 22 generically, and that happened at the -- Prairie Island 23 raised an issue that definitely needed site-specific 24 information on, and because of that new knowledge, it took 25

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

us an inordinate amount of time to come to conclusion on that inspection finding.

1

2

25

The phase three review that was done at the Sequoyah issue was more of a -- involving how much is enough due process allowed to the licensee, how much information should we be gathering from the licensee, how much input do we need to have from the licensee before we come to a final determination.

We discussed this at the lessons learned workshop, 9 and one of the conclusions that we came to is that, in 10 agreement with industry, because of the public perception 11 issue, when we make the initial determination that this is a 12 risk-significant issue, that is has potential for being 13 white or greater, we should document that in a report; the 14 public needs to have notification of that immediately, and 15 that's what the new process should have. 16

So, when the initial phase two review has had some screening by management, some oversight, that will be documented in an inspection report.

Now, after that point, we do need to allow -- we may need more additional information from the licensee, more technical information from them to complete our review, and we do need to allow them some sort of appeal process, but that will be further structured within the process.

MR. JOHNSON: It's a good question. It's not a

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

1 new issue. It's, in fact, an issue that we've dealt with 2 for a long time in the enforcement program, as you're well 3 aware. Escalated enforcement actions have taken time to 4 resolve.

5 We've got some challenges. We need to be open to 6 the public, and we're sensitive to that.

7 We also need to have a process that allows the 8 licensees to respond to us.

And so, it's working out how we're going to do that with this new process that we've run into some challenges and we're putting in place some fixes.

12

13

14

MR. DEAN: Yes, but I think it's important to emphasize, just like our current process, if there's an operability issue, that's dealt with in an immediate nature.

So, there's no change in the fact that, if we've got a concern about operability of a piece of safety equipment, that's going to be dealt with in an immediate fashion.

MS. MADISON: But the other part of your question, Dana, is the -- there is more time required to review the issue, once it's raised to the level of significance, there is more demand for technical knowledge in the area of risk, there's more demand on the senior risk analysis with this process, the analysts, than in the past. We recognize that that may be an impact on our resources that we're going to

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

have to address.

1

2	CHAIRMAN POWERS: I think we're quickly running
3	out of time in an area that still is fertile for discussion.
4	I personally have quite a few questions on the significance
5	determination process, not so much in those that are clearly
6	treatable with risk analysis tools or those that are clearly
7	un-treatable by risk analysis tools but those that lie in
8	they should be able to treat with risk analysis tools, and I
9	can see you're still struggling with some of those, and I
10	also think this phase three needs to be looked at in a lot
11	more detail as we gain some experience.
12	MR. BARTON: We've got a Commission paper on this
13	subject the middle of February. We'll have these people
14	before us again in the March meeting, and our letter to the
15	Commission is due in March.
16	Would it be appropriate to get into further
17	discussion on the SDP in the March meeting, or is that not
18	timely enough for you?
19	CHAIRMAN POWERS: I guess we're going to have to
20	discuss that. I don't know what we'd do given our
21	constraints of schedule and whatnot, because I think the SDP
22	discussion is protracted. I think we have a number of them
23	that we need to walk through to understand why it is not
24	capricious and arbitrary.
25	MR. BARTON: Right. I understand that.

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

DR. APOSTOLAKIS: Are you -- we have already mentioned problems with the third bullet, you know, the 2 availability of PRA's and the IP's, the problems they have, 3 but even if one had a good PRA, a lot of the inspections 4 deal with issues that are details, the noise of the PRA, so 5 you would have to be a little creative to see how this 6 finding affects the PRA. 7

1

But in light of all these issues, are you prepared 8 to tell the Commission that there is a need for research in 9 this area, that this process will not work very well until 10 we have reasonably good PRA's that can be used in phase 11 three, and possibly in other phrases, to determine the 12 significance of issues? 13

MR. DEAN: I don't think so. I think that, once 14 again, what we've tried to develop is a risk-informed and 15 not a risk-based process, and one of the challenges that we 16 have as a staff is trying to make sure that the significance 17 determination process is as Alan described, that it's a 18 usable and relatively simple tool that an inspector can use 19 to provide some risk characterization to his inspection 20 finding that can be easily communicated to the public and to 21 his management as to why we believe this issue is important 22 and needs to be dealt with, and we have to be very careful 23 that we don't fall onto the side of trying risk-base our 24 process where now we find ourselves into this realm of PRA's 25

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

with a lot of uncertainties, and I think that's all recognized, that risk analysis is still an uncertain proposition in a lot of respects and that the assumptions that are made, you know, have to be considered.

1

2

3

4

MS. MADISON: It's really lessons learned out of 5 6 the Sequoyah issue. One of the reasons why it took so long is the licensee kept trying to provide additional 7 information to have us cross this -- what in their minds was 8 a line that we had to cross to get them below green or below 9 white, but we told them that, because of the uncertainties, 10 there is no fine line and we didn't consider the information 11 was enough to cause us to change our opinion of what the 12 characterization of that issue was. 13

DR. APOSTOLAKIS: I think, although I appreciate your point, there is an unintended consequence which is not insignificant for this agency.

Because the staff is reluctant to say when they 17 are dealing with specific problems and to tell the 18 Commission that there is a need for research in certain 19 areas, the Office of Research is viewed as almost 20 unnecessary, and some Commissioners, in public speeches, 21 have expressed doubts about the need for any further 22 research, and it's understandable, because the staff never 23 comes back to them to say, gee, we really can't do this very 24 well unless certain issues are resolved which are properly 25

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

1

2

3

4

5

6

within the domain of the Office of Research.

So, I don't know how we can face this, because you know, how can you do bullet number three there if you have an IPE which had a different objective, you know, looking for vulnerabilities and so on, and the Commissioners are not aware of it?

7 If we don't tell them that, for some cases, the
8 tools are not there, why should they know? They're not
9 going to go a conference and read the papers.

10So, it seems to me there are conflicting interests11here.

On the one hand, of course, you don't want to say, gee, we can't do this because we don't have perfect tools, but on the other hand, it seems to me that that attitude, for a long time, has created the impression on the decision-makers that the Office of Research is not needed.

MS. MADISON: We think with this process, number one, as far as the SDP process of phase two, we do not need a perfect tool.

20 DR. APOSTOLAKIS: It doesn't have to be perfect, 21 Alan.

MS. MADISON: We're looking for something that is close enough, that gives us a characterization of the finding within a band, and there are uncertainties to it, but there are uncertainties to the models, to the SPAR

109 models, to the other models that we have. There are 1 uncertainties there, as well. 2 DR. BONACA: I would like to ask a question 3 4 regarding the -- this assessment program. 5 The question is this: You have an event -- for example, a misalignment, 6 which may be significant, and you have a process now by 7 which you're going to determine the significance of that, 8 and I could go right through it, and you can come up and say 9 that it was not safety significant, and that's the 10 conclusion of that. 11 What if you have a situation where there are 12 multiple misalignments taking place in a given period of 13 time, okay? Is the significance process going to be applied 14 to that condition, and how would it be treated? 15 I didn't understand by reading that document how 16 that would come through. 17 For example, you may get lucky and you may have 10 18 misalignments, and none of them is safety significant, yet 19 the fact itself that you are having these multiple repeats 20 21 _ _ MR. BARTON: It's a programmatic problem. 22 MR. DEAN: What you're getting, Mario, is 23 something that's been at the core of a lot of concerns on 24 the part of our inspectors, is that what do I do with that 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014

Washington, D.C. 20036 (202) 842-0034

situation where I have green issues -- here's a green issue, 1 2 here's another green issue -- I never tripped that significance threshold, but I'm seeing a pattern and a trend 3 that I believe is indicative of a potential programmatic 4 problem, and the Commission, if you back to the SRM that the 5 Commission gave the staff, after we briefed them on the 6 pilot program preparations, is that they told us they did 7 not want us aggregating green issues to try and come up with 8 a different risk significance number, but on the same hand, 9 they told us to make sure that this program was robust 10 enough to detect programmatic breakdowns. So, that puts us 11 in a tough situation. 12

I think what you've seen -- and I discussed earlier about cross-cutting issues. I think where we see that type of performance having an impact is in cross-cutting areas.

A number of human performance issues occur over a 17 period of time, problems in not identifying problems or 18 recurrence of problems that you thought you resolved, and 19 so, one of the things that we have included into the program 20 that will be part of the ongoing structure is to allow our 21 inspectors to be able to weigh in on those situations where 22 the issue, in and of itself, may not have caused a SDP 23 threshold to be crossed but that they have seen over a 24 period of time a collection of these issues and that we want 25

to make sure that we raise the forward in the inspection report and in the assessment process to make the licensee aware of the fact that we've seen this pattern or trend, you ought to pay attention.

1

2

3

4

DR. BONACA: Just a comment about the process. In fact, I would have liked to see a question, this is event and there are these boxes that throw you to a green or send you further in the process.

What would be important to us is the question, are similar events occurring? Are events with similar characteristics and so on and so forth -- I mean I think some improvements can be made in the determination process. I understand where the Commission is going, but that's an important issue.

MS. MADISON: Well, as far as concurrent issues,
if you're talking about concurrent failures --

DR. BONACA: No, not concurrent, just saying, hey, is something else happening of a similar type that tells me there is a programmatic breakdown?

That thinking process doesn't address the specific significance of the event, but it tells me, in fact, if I had a programmatic breakdown or at least I should be looking into it, and I think that that would be an important part of the -- because otherwise, to say the safety determination -it's almost like a hand waver at times in other plants to

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

say, oh, but that wasn't safety significant, you know, so that's no problem, no issue.

1

2

3

4

Well, there are issues which are important just because they happen on a certain frequency.

5 DR. APOSTOLAKIS: I think we should wrap up now, 6 because there are many important issues.

7 DR. BONACA: I understand, but I think this is a 8 very important one.

9 MR. BARTON: I think we need to continue this 10 discussion the next time we meet with the staff.

11DR. APOSTOLAKIS: So, if you had one minute, how12would you wrap up the presentation? No more transparencies.

I would wrap up the presentation by MR. DEAN: 13 leaving the message that we think that the process that we 14have designed, the revised reactor oversight process, is, on 15 a broad number of measures and given the direction given to 16 us by the Commission, is a substantial improvement in terms 17 of its structure and its framework as to how we go about the 18 business of overseeing nuclear power plant activities and 19 operations. 20

I think the pilot program has given us a substantial set of information and lessons learned that we have made revisions to and are working on, making refinements to this process to prepare us for implementation of this program at all sites.

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

M

1

MR. BARTON: Initial implementation.

Initial implementation at all sites, so MR. DEAN: 2 that we can utilize the increased scope and breadth of 3 information and experiences to really fully flesh out the 4 process and be able to address some of the underlying 5 concerns that not only our internal inspectors have but a 6 number of external stakeholders about we just aren't 7 convinced, we're not sure that the pilot program has told us 8 enough, and we agree with that, and we think that we need to 9 expand the process to be able to hopefully build the 10 confidence in our inspectors and in our public stakeholders 11 that, indeed, we have established a good framework and a 12 good process for a reasonable assurance of plant safety. 13 DR. APOSTOLAKIS: John, anything else? 14 MR. BARTON: I don't have anything else. 15 DR. APOSTOLAKIS: Okay. 16 We'll recess until 10 minutes after 11. 17 [Recess.] 18 19 DR. APOSTOLAKIS: The next subject is proposed final amendment to 10 CFR 50.72 and 50.73. 20 Dr. Bonaca is the cognizant member. 21 DR. BONACA: The staff plans to present a proposed 22 final amendment to 10 CFR 50.72 and 50.73. 23 The objectives of the proposed amendment, just to 24 remind, include to better align reporting requirements to 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014

Washington, D.C. 20036 (202) 842-0034

the NRC's reporting needs, to reduce the reporting burden consistent with the NRC's reporting needs, and to clarify the reporting requirements where needed.

1

2

3

4

5

6

The staff has met with the industry and other stakeholders during several workshops and meetings to discuss the proposed amendments.

We, the ACRS, reviewed the proposed amendment in March 1999 and issued a letter which included a number of conclusions and recommendations that I will read here, restate.

11 One, issue the proposed amendment for public 12 comment.

Two, eliminate the requirement for reporting late surveillance tests by amending the rule and not by revising the associated regulatory guide.

16 Three, the staff should comprehensively examine 17 the NRC reporting requirements to assure no duplication or 18 inconsistencies.

And four, plant-specific lists of risk-significant systems should be developed, and they should not be included in the rule.

NEI is concerned with the addition of the requirement for reporting components. It believes that the requirement lacks clarity, is ambiguous, and does not warrant backfit, and they are here to, I believe, provide us

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

with a presentation of that.

1

2

3

4

5

6

7

8

13

15

20

We would like the staff, during its presentation, to specifically address their recommendations concerning plant-specific lists of risk-significant systems and NEI's concern with added requirements.

I would like just to add one question, which is, over the past month, I have received two drafts of this proposed amendment with significant changes.

In fact, the last one I received was last Monday 9 and had significant changes from the December 30th, and I 10 just really wonder if we are ready to have a final amendment 11 because of that. 12

I would like you to explain how these issues, which are not unimportant -- like, for example, the systems 14 which are listed in the rule, which were taken out in December and now are put back in -- you know, if we have now 16 a final position on that. 17

18 With that, I'll let the staff go to its 19 presentation.

> MS. MALLOY: Thank you.

I am Melinda Malloy. I am the Section Chief in 21 the Rulemaking Group within NRR. The branch that we reside 22 in is the Generic Issues, Environmental, Financial, and 23 Rulemaking Branch, in the Division of Regulatory Improvement 24 Programs. 25

We are, I believe, prepared to address your concerns that you've raised, to answer the questions that you would like us to address, and we'll get to them throughout the presentation.

As you know, the proposed rule was published for public comment back in July of '99. We received 27 letters of public comment, mostly coming from the industry, and they were critical of the couple of the areas that you've mentioned.

The staff has worked very hard over the last few months to take the public comments to heart and to develop revisions at the rulemaking that we feel are responsive to the public comments but, at the same time, preserving the staff's need for information.

We have undergone extensive internal reviews over 15 the last two months, and that's probably the main reason for 16 the revisions that you've seen, but I think we can say with 17 great confidence that we are at a point in time where the 18 staff -- and we are talking not just NRR staff, but we have 19 coordinated extensively with IRO, as well as Research and 20 other interested parties, to come up with workable 21 requirements for the rule, and so, with that, I would like 22 to introduce the other folks that are here to support this 23 briefing. 24

25

1

2

3

4

To my immediate left is our Deputy Division

Director, Scott Newberry, who I think you've seen from time to time, and to his left is Denny Allison, who is the Task Leader for this particular rulemaking, and Denny will be giving a presentation for us.

We also have in the audience some key members of our internal stakeholders that are here to help support us during this briefing.

So, go ahead, Denny.

1

2

3

4

5

6

7

8

25

9 MR. ALLISON: Dr. Bonaca, thank you for the 10 introduction.

As far as -- I'll deal explicitly with the ACRS's recommendation about the list of systems in the presentation, as well as with NEI's concern about which -their biggest concern, of course, is with the proposed new criterion that was in the proposed rule.

With regard to whether we're ready, I think we have a position that will be the staff's position. I think it's final.

19 I'm waiting yet for Brian Sheron's side of NRR to 20 wade in formally, but we've met twice with all the division 21 directors in NRR, and the first time we agreed on what to 22 say, in general, and then the second meeting, with all these 23 same guys, was about how to -- specifically how to say it, 24 because we had some problems with the words.

So, I think that the Federal Register notice that

I've provided to you is the staff's position. I hope so.

1

2

3

4

5

21

22

25

MR. NEWBERRY: Well, let me clarify, Mr. Chairman. We're at the point where what you'll see here today is the proposed position. We're at the point of filling in aspects of the Federal Register notice and perhaps some examples in the NUREG. 6

So, I would request that, you know, what you see 7 here we work with and that being the proposal in front of 8 the committee. 9

MR. ALLISON: Now, the objectives of this 10 rulemaking I think most people subscribe to. That's to 11 clarify the requirements, where that's needed, to reduce 12 unnecessary burden, not to reduce worthwhile burden but 13 unnecessary burden, and use risk-informed thinking. 14

You know, I wouldn't call the whole rule 15 risk-informed, but we've got some risk-informed thinking in 16 the changes we're making, and to be consistent with the 17 NRC's new programs, and particularly the new oversight 18 programs, and in a nutshell, that means don't get rid of 19 things we need for that program. 20

> DR. WALLIS: Immediate?

MR. ALLISON: I'm sorry?

DR. WALLIS: Immediate means in the blink of an 23 eye or what? 24

MR. ALLISON: Where does "immediate" --

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

DR. WALLIS: "Immediate" is key in the first two 1 2 Oh. Yes, sir. That's the title of MR. ALLISON: 3 50.72, and all of the requirements in 50.72 are stated that 4 way. Declaration of an emergency class is to be reported 5 immediately after the state is called. 6 Well, I was sort of intrigued by the .7 DR. WALLIS: term "immediate NRC action." How fast can the NRC do : 8 anything? 9 MR. ALLISON: Well --10 This means within a day or something? 11 DR. WALLIS: MR. ALLISON: No. Immediate --12 DR. WALLIS: Fifteen minutes? So, it's less than 13 14 an hour, anyway. Yes, sir, although there are 15 MR. ALLISON: four-hour and eight-hour reporting requirements, but those 16 are also stated as as soon as practical and in all cases 17 18 within four hours. The principle changes that we're making are we're 19 deleting outside the design basis of the plant, and you'll 20 see another slide in a minute as to how we're doing that and 21 what will stand in its stead to ensure that we don't miss 22 events that we need to know about; the system actuations, 23 which I'll get into, and that was a specific ACRS comment, 24 but we're proposing a list that will make things more 25 ANN RILEY & ASSOCIATES, LTD.

119

Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034 consistent and, on balance, a small reduction in the number of reports.

1

2

9

11

21

22

23

24

25

Invalid actuations -- most commenters object to 3 any report -- any reporting of invalid actuations, because 4 invalid actuations involve conditions -- pardon me -- do not 5 involve conditions -- plant conditions that require the 6 actuation, like low reactor coolant system pressure or 7 something which would turn on the ECCS system. 8

So, they're for some other reason, usually a dropped jumper or something, and so, we're going to reduce ľ0 the burden of those reports by a good bit by turning them into telephone calls rather than LERs, but there is a 12 reason, and when we get there, I'll explain it, why we still 13 need those. 14

The required initial reporting times are being 15 relaxed to greater or less degree depending on the reporting 16 requirement. 17

The reporting of emergency conditions is, of 18 course, not being relaxed. That's still immediately after 19 20 calling the state.

One of the things -- and it's not the principle comment that the ACRS had, but I remember Dr. Powers wanting us to go back and look at these times again.

We were going with a rather simple approach of everything's in one hour or eight hours or 60 days, and we

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

have done that, and we've put in a few more shades of gray based on experience and the perceived need.

1

2

22

23

24

25

The reporting of historical problems -- we're excluding reports of things that happened more than three years ago and no longer exist, that haven't existed for the past three years, and that's not a big problem, but it just eliminates some unnecessary work in searching old logs and things like that.

9 Finally, the late surveillance test is the biggest 10 example of a reduction in reporting burden. It's going to 11 get rid of about 200 LERs per year, and those are simply 12 cases where a surveillance test was performed late but the 13 system passed anyway, and of course, that doesn't have much 14 significance, because the system was working all along, and 15 so, we're getting rid of those LERs.

So, with regard to outside the design basis, in the proposed rule we have proposed to eliminate that requirement, and we described how events that we need to know about, events that are significant, would -- are still captured by these criteria, including this proposed new one, and that is the one where we got a lot of comment.

Basically, the intent was just to try to make sure we didn't throw out the baby with the bath-water, but the commenters essentially were saying that we missed the boat and this would be vague and it would require a lot of

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

additional reporting. So, we've changed it substantially now.

1

2

3

4

5

6

7

8

24

25

In the draft final rule, we're still removing the requirement to report a condition outside the design basis of the plant, because that requirement is vague or unclear in its application, and the other side of the same coin to that is that it requires reporting of events that are not very significant, depending on how you read the requirement.

9 So, the new criterion we've modified, and what it 10 requires now is reporting any event or condition that 11 requires corrective action for a single cause or condition 12 in order to ensure the availability of multiple trains or 13 channels to perform the required safety function.

14 This is -- the idea here that we're trying to capture is this would be an event -- it may not qualify as a 15 common cause failure -- that is, it may not make independent 16 trains inoperable at the same time, but it's getting close 17 to it, and it's things like you've discovered gummed-up 18 solenoid valves due to some common cause and you have to go 19 and replace a bunch of them and clean out the air system, 20 that sort of thing, and that sort of thing is the kind of 21 thing that the NRC needs to consider taking some action to 22 make sure it's addressed. 23

> DR. BONACA: I have two questions. One, you changed the definition of the new

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

criterion from December to this, and I don't understand what the intent of the change was.

1

2

13

14

15

16

17

And the second question I have -- some of the examples provided -- to me, they would be reportable under Part 21 -- for example, the, you know, stem of an MOV that is made of the wrong material and therefore is subject to certain cracking -- or to other reporting requirements anyway.

9 So, the question I'm asking is are you sure you're 10 fulfilling the objective of assuring that what is being 11 reported under some other means of reporting is not 12 duplicated here?

MR. ALLISON: Yes, sir.

As to the Part 21, that stem might be reportable, maybe, by a vendor, if it was discovered by the vendor, but it's -- certainly, it wouldn't be reportable by a reactor licensee.

The threshold in Part 21 is very high. It's a major reduction in the level of safety of the plant. That's what a substantial safety hazard is, and it corresponds more or less with -- you pretty much have to have an abnormal occurrence.

DR. BONACA: But if I found a stem that is cracking and that's because the material is old or stems in MOVs in other applications, that's a substantial safety

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

hazard in my mind.

1

4

17

20

21

2.4

25

2 MR. ALLISON: I don't believe that would be 3 reported under Part 21 as a rule.

DR. BONACA: Okay.

5 MR. ALLISON: I do remember a case, just to give 6 you a quick example, when we ran this through the Part 21 7 process and found that it was not reportable.

It happened at McGuire, I think, a test of a spare scram breaker, and it didn't work, because a plastic part was cracking, opened up the other scram breakers at McGuire, several of them were cracking, but they hadn't failed, went over to Catawba, same kind of breakers, cracking, some of them maybe didn't work, not reportable under Part 21. That's the kind of a threshold that Part 21 has.

Now, maybe that should have been, but -- and it was reported, of course, under 50.72 and 73.

DR. BONACA: Okay.

So far as the two definitions, could you explain what the logic was in changing the definition?

MR. ALLISON: Yes, sir.

The December package --

DR. BONACA: You have that at the bottom of page three of your presentation.

MR. ALLISON: Okay.

Well, the commenters -- we have some problems with

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

this criterion.

1

I would say the first one is a vague point where we say "could reasonably be expected to apply to other similar components in the plant."

5 Now, the objective is the same here, of course, is 6 to get something that has some significant generic 7 implications, but the commenters said that, as soon as 8 something fails, you know, in many, many cases, they're 9 going to end up in an argument with the inspectors, then, 10 about whether that same failure mechanism could reasonably 11 be expected to apply to everything else.

The other one is, of course, there was -- the word "significant" is in there, "significantly degraded," and by that, we meant on the verge of failure, not failed. So, we're talking about substantially -- or greatly reduced margins, but that's hard to define objectively.

DR. BONACA: So, you went to this new criteria which you have now at page four.

MR. ALLISON: Yes, sir, and I think this can be objective, because it -- it can be a lot more objective, certainly, because it's going to have to be a change -first the licensee has to determine corrective action is necessary, so we're not arguing about someone's perception, it's a determination that will be made, and it's got to be necessary for that reason, not for instance, to meet the EQ

rule, but to make the system perform its safety function, and so -- and you don't have to review every failure, you only have to look at your corrective actions programs, and the next slide, under the guidance, you see time is allowed there.

Licensees are given time to decide whether the corrective action is needed and what it's needed for.

8 DR. WALLIS: It seems to me there's some 9 vagueness.

1

2

3

4

5

6

7

25

I mean if I have a valve which is supposed to open fully and let in some emergency coolant or something and it turns out that valve travel in some way is not 100 percent, so it opens 90 percent of the way, it's just sort of iffy about whether this is significant or not.

MR. ALLISON: Well, the term of art that's in here is the ability to perform the specified safety function, and that really means operable, and that's a determination the licensee is going to have to make.

Operability is a determination the licensee has to make one way or the other, and the NRC knows what this determination is. If we disagree with it, we can raise it with the licensee. The inspectors look at these things. But that's the definition of operability, able to perform its specified safety function.

Now, something could be operable today but getting

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

worse, and you have to take corrective action. That would be reportable. But if something is just operable for the -will remain so indefinitely, that would not be under this criterion.

5 MR. NEWBERRY: Dennis, while we're on that point, 6 thinking back to Dr. Bonaca's opening remark, there's many 7 comments on that proposed criteria, as you can well imagine, 8 and it wasn't until recently that the staff came to this 9 proposal and let, you know, the different things that the 10 committee may oversee.

I think, in looking at it within the last few days, this is going to be the first time that many people see this new criterion, but we're approaching the final, you know, draft rule point.

So, our thought is -- and I think you're going to 15 hear about this later today -- that we really think it's in 16 17 everyone's best interest to have a public meeting, announce a public meeting on, certainly, this part of the rule, I 18 19 don't imagine others, but the intent of the meeting would 20 not be to negotiate a position -- I mean we're in a rulemaking process here, but certainly for the staff to 21 explain to anyone who would be interested the rationale for 22 the position, answer questions of clarification on the 23 position. 24

25

1

2

3

4

I think that would be reasonable to do before we

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

1 go up to the Commission.

2

3

4

MR. ALLISON: These are just some of the additional guidance that you find in that Federal Register notice that I've sent you.

The principle one is that it is -- you screen what your corrective action program comes up with instead of every failure, you screen the corrective actions, and you have the time to do that. The reporting clock doesn't start until you've made that decision.

DR. WALLIS: So, you can dilly-dally in making up your mind? There ought to be some incentive to determine this, whether a corrective action is needed or not, pretty quickly.

MR. ALLISON: Well, there is. We have guidance in Generic Letter 91-18 that requires licensees to make operability determinations on a time scale that's commensurate with the risk importance, the safety significance of the issue, and so on, and so, they will make that determination pretty quickly.

20

25

Yes, sir.

21 MR. SIEBER: I think the other aspect of that is 22 tech specs, typically, for systems important to safety, will 23 force you to correct a non-conforming or inoperable 24 condition within a certain amount of time.

So, that forces the clock to start on LER

issuance, correct? 1 That's right. But you can't MR. ALLISON: Yes. 2 really tell whether something is truly reportable under this 3 criterion until you decide what the corrective action is. 4 5 MR. SIEBER: That's correct. MR. ALLISON: That was my presentation on this 6 criterion. 7 The next one is of lesser importance, but it was 8 the number two issue, I guess. 9 DR. BONACA: And we will hear the industry's 10 perspective later, right? 11 MR. ALLISON: Yes, sir. 12 The number two is system actuation, and in the 13 proposed rule, we proposed a list of systems and so on. 14 The ACRS, among others -- well, the industry 15 opposed the list of systems. They wanted to use the list 16 that's in their FSAR, which varies from plant to plant. The 17 ACRS commented that this list shouldn't be in the rule but 18 should be developed. 19 In the final rule, what we're saying is to go 20 ahead and impose the list. 21 Now, the list has been changed in response to 2.2 specific comments. 23 So, we've gotten rid of some things that the 24 industry pointed out didn't really need to be on the list or 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

weren't appropriate, but this will be, on balance, a small net reduction in reporting, it will be consistent, and one of the things with regard to the ACRS recommendation -- the industry commenters said I don't think we're really to the point where we have good criteria developed that we can develop a plant-specific list of systems.

Now, that's supposed to come in the future, in the
risk-informing of Part 50, but it's not here right now, so
why don't we do it then? That was their idea, and we
basically agreed with it.

11 So, rather than try to solve the problem of how to 12 define risk significance in terms of systems in the context 13 of this rule, we're putting it off, but the things that are 14 on that list, I would say, are always risk significant. We 15 don't have things on that list that are going to be 16 insignificant at any plants.

DR. UHRIG: I have a question on that, however. Is there inconsistency in some FSAR's between the list that you have in this rule and what they call --

20

25

1

2

3

4

5

6

MR. ALLISON: -- ESF's.

DR. UHRIG: There is inconsistency in the FSAR's. One of the issues was that some of the FSAR's would not recognize, for example, auxiliary feedwater or emergency power as one of the systems.

MR. ALLISON: That's correct, yes.

DR. UHRIG: And you were trying to resolve that 1 2 issue. MR. ALLISON: Some plants don't classify auxiliary 3 feedwater, for instance, as an ESF. So, they wouldn't be 4 bound to report it as long as they're using the list in 5 their FSAR. 6 DR. UHRIG: But with this change in this rule, 7 they would be bound to report it. 8 MR. ALLISON: Yes, they would, and so, that would 9 lead to a few more reports here and there, but the list also 10 eliminates some reports, about twice as many as it adds, but 11 both of them are small numbers. 12 DR. UHRIG: Does it represent, this change, a 13 backfit in the licensing basis? 14 MR. ALLISON: I'm sorry. 15 DR. UHRIG: Does it represent some change also in 16 their licensing basis? 17 MR. ALLISON: No, it doesn't, because we're not --18 this change does not say these systems are ESF's. 19 20 DR. UHRIG: Okay. MR. ALLISON: It says report the actuation of the 21 following, and the numbers are small. I think we would 2.2 require about eight reports a year that wouldn't be made 23 under the current regimen, but we'll eliminate about 16. 24 In The next point is invalid system actuations. 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036

(202) 842-0034

the proposed rule, we recognized that there was no need to pick up the phone and call us in four hours or eight hours about these, because the plant conditions that require actuation aren't there in this case.

1

2

3

4

5

6

7

Licensees objected to any reporting, but we -- and this was an issue that had been gone through at the advanced notice of proposed rulemaking stage, as well.

8 We need those for reliability estimates and things 9 like that to help us to move towards risk-informed 10 regulation, and in fact, we had some years ago proposed a 11 data rule to get that information, and the industry proposed 12 a voluntary alternative, and we accepted it, and one of the 13 bases for accepting the voluntary alternative was having 14 these reports.

So, in the final rule, what we've done is we're keeping the reports, but we're changing them to a 60-day phone call under 50.73, and in the guidance, we specify just what needs to be in the call. It's not a lot of information, but we have to specify it.

This reduces the burden drastically for those events that are only spurious actuations, and those are not going to be considered LER's. The guidance will state this is not considered an LER, but it's like a factor of 50 reduction in burden for a given event, and this is maybe 60 events a year.

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

DR. WALLIS: Are there no spurious actuations which actually compromise the system's operation later on?

1

2

3

4

5

6

7

15

25

MR. ALLISON: I can't think of any. I mean you could have a spurious actuation where the system fails to work, that reveals a failure of some kind, but I can't think of spurious actuations that really create problems other than possible failures.

DR. WALLIS: Unless it put a plant through a 8 9 transient that did some damage.

MR. ALLISON: Well, that will certainly be 10 reportable, though. If you get a transient, you'll have 11 valid actuations occurring. 12

The next thing was required initial reporting 13 times, and rather than the one-hour, eight-hour, and 60-day 14 approach that was in the proposed rule, in the final rule we're saying one hour and four hours some events that are of 16 a little more urgency. 17

One of them is press releases, because -- and the 18 reason for that report is not the urgency of taking action 19 but it's in responding to public concern. 20

The other one is unplanned transients, like valid 21 ECCS injections, shutdowns required by the technical 22 specifications, and so on, and then eight-hour reporting for 23 other events under 50.72. 24

We're also deleting three redundant criteria from

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

50.72. Those are actual threats and radiation releases, and 1 the reason is that those are captured -- under 72, they're 2 captured by other criteria. 3 DR. WALLIS: What is the concern about reporting 4 to other government agencies? 5 MR. ALLISON: Well, the -- that's to respond --6 again, going back to the objectives -- respond to heightened 7 public concern. 8 If the state gets a report and if they're :9 concerned about it and they want to call the NRC, we want to 10 11 know about the event. It could really be generalized to a DR. WALLIS: 12 plant notification of any other party. 13 MR. ALLISON: It could be, but it's -- there is a 14 difference. That is, if they notify a consultant or their 15 board of directors, that's not required under the rule. 16 It's only another government agency or a press release. 17 Nobody's complained that we need to generalize it 18 further. 19 Historical problems -- in the proposed rule, we 20 recommended limiting these reports for just two specific 21 types of events. 22 In the draft final rule, we're expanding it to all 23 events reportable under 50.72 and 50.73. That was actually 24 -- I guess that suggestion really came from the 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036

(202) 842-0034

Commissioners in the SRM on the proposed rule, and we asked for comments specifically, and everybody supported expanding it to all kinds.

The final change in my list of principle changes is late surveillance tests, and I discussed that with the first slide. These events don't involve an impact on the ability to perform a safety function, and therefore, they're not very important to us.

My last slide is the schedule, and we're going to 9 brief the CRGR next week, and we're due to provide this 10 package to the Commissioners on the 10th of March, which 11 means to the EDO a week before that, and so on. 12

So, we're getting close to the date, and we're going to have to hold the meeting that Scott mentioned a 14 minute ago sometime within the next month. 15

16

13

1

2

3

4

5

6

7

8

Yes, sir.

MR. SIEBER: I guess -- and I want to pick on a 17 18 specific phrase that you used, but I've heard it over and over again when we talk about risk-informed regulation and 19 enforcement and so forth. The phrase is, well, this is not 20 21 very important.

To me, that has a bad connotation to people who 22 work in power plants, and maybe the plant manager, the vice 23 president, or SRO's can make that differentiation, but 24 everybody else says, well, this isn't very important and so 25

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

my attention need not be as high at performing surveillance tests on time or doing any other thing on time, since it's not very important, and it would be better if we could use another phrase than that, because I think it puts a negative motivation into power plants and workers.

MR. ALLISON: I agree.

1

2

3

4

5

6

7

8

MR. SIEBER: All right.

MR. ALLISON: It was a bad term to use.

DR. SEALE: There's, if you will, almost an 9 industry that's grown up within the Commission and within 10 other groups that are concerned with the operation of power 11 plants, and that is that group of people who essentially 12 mine such reports to extract from them useful data on 13 causes, consequences, remedial interventions, and so on, the 14 kind of thing that AEOD did in the old days, the kind of 15 things that the people in INPO and WANO do in their 16 independent realms on events. 17

In modifying these reporting requirements, have you checked with those people to be sure that you haven't reduced the usefulness of these data for the people who are using it with the greatest effectiveness?

22 MR. ALLISON: Well, we've coordinated with the NRC 23 staff organizations, and our assertion is that we're not 24 eliminating any reports that we need, and we asked the 25 public specifically in the Federal Register notice, if you

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

can identify an example of something that's needed that 1 would be eliminated, please tell us, and of course, none 2 were, and so, I think, yes, we've coordinated with 3 4 everybody. DR. SEALE: Perhaps I'll want to ask the person 5 from NEI later whether or not they've inquired in a similar 6 vein with the people at INPO. 7 8 DR. BONACA: Any other questions. 9 [No response.] 10 DR. BONACA: I think we'd like to thank you for 11 the presentation. MR. ALLISON: Thank you. 12 DR. BONACA: We'd like to hear from NEI. 13 14 MR. DAVIS: Good morning. Jim Davis, Director of Operations at Nuclear Energy Institute. 15 Looks like I have the unenviable position of being 16 between you and lunch. 17 I've got a number of slides here, but I've only 18 19 got two points to make. DR. BONACA: Take your time. I really want to 20 hear about this. 21 MR. DAVIS: One, when we briefed you last year, in 22 23 March, one of the things we said, we thought the rulemaking process embarked on in this area was very good. We got the 24 ANPR that laid it out in some detail. 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

We got an opportunity to interact in that arena, and throughout the process, there were a number of interactions between the staff, the regional examiners and inspectors that have to enforce this, and the operators that have to make it work at the plant, and through a bunch of workshops, tabletop exercises and so forth, there was a lot of effort put on solving this problem that we've gone through for the last eight years, so everybody understood exactly what the requirements were and what the rule said.

1

2

3

4

5

6

7

8

9

In many cases, we found that the intent was clear. We all knew what we wanted to do, but the perspective from the three visions didn't quite fit, and there was a lot of time and attention put on that particular aspect of it, and we told you last year that we were very satisfied with the process.

Then I come to the point that I will tell you -and in that process -- I'm sorry, I moved my slides around -- operability is a key aspect of it.

At every meeting, operability, operability At every meeting, operability, operability determinations, and how we do those are the things that we all understand, and as you see, we move very quickly to a process of how do you figure out whether a report is required?

24 Operability is a key issue. We do the operability 25 determination. It's a very clear process. It's an

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

expectable processing. It does involve some risk insights, where it's appropriate. That's a key to the entire business.

1

2

3

My second point: The draft rule comes out, and as 4 65 far as the industry is concerned, the rule should not have gone forward. We could not support the rule as written. It 6 didn't meet the three criteria that the staff had put out, :7 it was not clear, it did not reduce any burden, and the 8 industry was ready to go to the Commission to say don't put 9 this rule, we'll solve the problem in harmonizing Part 50. 10 You already know what the problem is. It's 11 50.73(a)(2)(ii)(C), the reporting of degraded components. 12 It's related to my first point. 13

This showed up for the first time in the final Federal Register notice that came out for public comment. It did not go through the process that all the other elements in this rule went through.

I have no comments on the list of what systems will be reported on. We went through the process. We made our comments. We gave the staff our best input, and they've got to make a decision, because that's what rulemaking does. This particular element didn't go through the process.

To address your issue, sir, we don't think that this is a data collection rule. We've been through the data collection rule. We've been through the discussion. There

are opportunities for the staff to get the data they need from other arenas.

1

2

23

24

25

INPO's database has been made available to the 3 staff and they're working in that area, and we are really 4 5 concerned that, in one case, we say we no longer require the reporting of design basis events and turn right around in 6 the Federal Register notice, we point out design basis --7 ໍ8 the purpose of this particular section, this data collection element, was to ensure we continue to collect design basis 9 information, so we clearly didn't meet the requirements. 10

I will tell you -- I'll skip a slide. The examples in NUREG 1022 made no sense. It was a very important part of the process that we bring the implementing NUREG along at the same time we were developing the rule.

So, we had the rule, we had the NUREG, we could 15 16 look at them both simultaneously, and when this came out and we looked at the examples, we could make no sense of the 17 examples in the NUREG, and the further we've gotten into it 18 since the workshop we had last year and the closure of the 19 public comment, the more confused we've gotten, and we put 20 forth a big effort to make absolutely sure the staff 21 understood where we were in that particular arena. 22

> DR. WALLIS: Did this get resolved? MR. DAVIS: I'll get to that in just a second. DR. WALLIS: Okay.

MR. DAVIS: If you removed -- I want to make sure I make this point.

1

2

3

4

5

6

7

8

25

If you remove that one small section on reporting degraded components, we feel that the draft rule does improve the clarity of reporting in all other areas, does provide a clear focus and a nexus to safety, and I think that's one of the things that we were trying to achieve using the operability determination process.

We have one we can understand, one the inspectors can understand, and we think one that provides the headquarters and the people upstairs and the operations center the information they need to make timely decisions, would eliminate the unnecessary reports that don't help anybody, and would be a great conclusion to eight years' worth of effort.

16 Coming into the exercise, what were our 17 recommendations?

If you want to go forward to the rule, eliminate the degraded component reporting or separate it out and do the backfit analysis that we think would be required to support that level of reporting, or if we can't come to agreement in that area, just let's stop the whole process and let's harmonize this rule as we go through the Part 50 process.

Looking at what was proposed in the briefing

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

1

2

3

4

5

6

7

8

today, it obviously moves in the right direction.

It gets us back to a discussion of operability and what's in that area, and our intent is to reinforce what we just heard, as we will provide a request to the staff that they, one, give us the language and the examples for NUREG 1022 in advance and that we have a workshop and follow the same process that we followed on the other pieces of it for this narrow thing.

You know, I don't want to open the whole rule 9 again, or we'll spend eons arguing, but we've had a 10 11 significant enough change and this is an important enough issue that we need to get it right, and I think we need to 12 have an opportunity for the industry, other stakeholders, 13 and the regional people to look at it, discuss it, and make 14 absolutely sure we understand what the words mean, get the 15 right words in there in that particular area, and also 16 ensure that we've got the right examples in NUREG 1022 as we 17 go forward on this, and presuming that's about to occur, I 18 think we'll have achieved our purpose, but the nexus is 19 20 process.

21 We had a good process, and the one piece of the 22 rule that becomes the major contention is the one that 23 didn't follow the -- didn't run through that process. So, I 24 emphasize that, because it's sort of a more global issue 25 there.

DR. KRESS: Your objection to that part of the rule, I gather, is more than just it didn't go through the process.

MR. DAVIS: That's absolutely correct.

DR. KRESS: You say it would increase burden significantly.

4

5

6

25

One plant looked at it over a MR. DAVIS: Yes. 7 period of nine months, and it would have required them to 8 evaluate a significant number of items in their plant. 9 It didn't generate a report for every one of those, but every 10 time you have a component with an abnormality, you suddenly 11 have to go through this evaluation of if and whether 12 reasonable could, significantly, and all these other vague 13 words to try to come up with a engineering determination of 14 whether it fits in that category. 15

16 DR. SEALE: In other words, this is reporting of 17 degraded but operable components.

DR. BONACA: You seem to have made a distinction there, at the beginning, in your second overhead, or third, regarding operability.

21 So, are you saying that the operability 22 determination process is sufficient to deal with the 23 significant issues on degraded components without the 24 necessity of reporting? Are you saying that?

MR. DAVIS: Let me answer it this way. We found

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

that operability determinations that are required in the rest of this revised rule work. The words that I look at appear to tie this to the same operability to process for It is in the the component that we're looking at. operability. It impacts the operability of the system we're 5 talking about. 6

1

2

3

4

15

If that is truly what we're saying, I suspect that 7 will go a long way to solve the problem. That's why we'd 8 like to make sure -- you know, have the discussion to make 9 sure that's what we really mean in this process. 10

The question I have for the staff is, 11 DR. BONACA: is this an event or condition of a single cause? Is this a 12 component which is operable but degraded? I would like to 13 14 understand --

MR. ALLISON: It could be.

DR. BONACA: -- how the issue of operability 16 addresses this or doesn't address this. 17

18 MR. ALLISON: It could be, but it would have to be something that pointed out to the licensee that he has to 19 take corrective action on multiple trains to ensure that 20 21 they remain operable. So, that would be -- so, it could be degraded but operable, but it has to fulfill those other 22 conditions. 23

DR. BONACA: It seems to me that there hasn't been 24 sufficient communication of this issue, and you're talking 25

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

about, in fact, a public workshop or something, maybe, under which that could be --

1

2

3 MR. ALLISON: Yes. Mr. Davis is in a bad position 4 as far as commenting on this criterion, since he's just 5 seeing it, but as he said, it goes a ways towards resolving 6 the comments, and we will schedule a meeting between now and 7 when we send this paper to the Commission.

MR. NEWBERRY: I'd like to offer another comment. This is a good discussion a very difficult issue. I can think of a number of comments.

I guess it should be no surprise on the inconsistent views given the term "design basis," which we're working on to clarify in another area we've talked about with the committee, but one of the points here I'd like to emphasize is the inclusion of the term -- the notion of corrective action.

When I talked to folks in industry or where they came up to me at every opportunity in the last few months on this issue, said, you know, we have a process, an Appendix B process, we have a corrective action program at the facility to handle these issues.

If a degraded condition is identified, we put it into our process, we evaluate it for operability, we evaluate it also for the need to take corrective action under Appendix B, and so, it was that line of commenting and

thought that led us to this criterion, to say, well, we inspect that program, we oversee that program, do we need a report for all the data that goes into the program?

1

2

3

4

5

6

7

8

24

25

We concluded no, but when the evaluation is completed and the utility determines that action is necessary at that plant that could also occur at another plant, we said, okay -- we looked at the objectives of the rule. We said, okay, we should have a report for those.

Now, maybe there are some areas there we would
need to explore further and get some dialogue going with,
you know, the industry, but that was the thought process,
was to try to credit further, as we are in other areas, the
programs at the plant.

DR. BONACA: Thank you. Now I understand why it got in there. All right. I didn't understand it before. I understand it.

MR. SIEBER: On the other hand, the staff has been aware of NEI's position on this, I presume?

MR. DAVIS: Yes. I mean we were -- the comments were very clear and very detailed on this. There's no question that the staff understood exactly where the industry stood and why we had difficulties with the wording that was in there the first time around.

MR. NEWBERRY: Yes. It was clear we needed to rethink totally what we had proposed, and that's why it's no

longer being proposed. We came up with the new criteria which Mr. Davis is saying he thinks is headed in the right direction but we need to talk about further.

1

2

3

4

5

6

11

24

25

DR. BONACA: My feeling is that we are not ready to write a letter on this. I mean clearly this is an open issue, in my mind.

Even if the staff has resolved that they want to
proceed with this to the degree to which you're going to
have a public meeting in which there is going to be exchange
of information, things may change.

I would like to have your comments on that, Jack.

MR. SIEBER: Well, I just want to agree with you that, until the staff resolves this one way or another and takes a position, I don't think there's anything that we can do to endorse or not endorse where the staff is at this point in time.

DR. BONACA: It is going to be, you know, a burden. Clearly, you know how much time is being spent on operability determinations. I mean it's very time-consuming, and this is going to add.

21 So, there has to be a real buying-in from the 22 stakeholders that this is a necessary thing to do, and 23 communication is important.

MR. DAVIS: I must also admit that we would like to see the rule change completed in a timely manner. There

are other parts of it that have some benefit to the
 industry.

3 So, if we can -- you know, if closure on this one 4 issue can be achieved quickly, we would support moving 5 forward with the rest of it.

Even though I haven't seen the rest of it, you know, I got some insights into it. You've got to have some faith in the process and the opportunity to share information, that that information will be used, and so, we're really focused -- I mean this is really a very narrow focus.

I don't want to open the whole rule and go through the whole process again. I'm just narrowly focused on this one issue that I think needs some additional thought on our part.

MR. NEWBERRY: Mr. Chairman, I would propose that, 16 you know, consistent with Mr. Davis' comment on the need for 17 18 dialogue, we talk with them and then talk to your staff about a process that we could use to satisfy the objective 19 of timely implementation of the rule but also get the 20 committee the information that they would need to inform 21 them so that you could write a letter on a timeframe to 22 support the rulemaking. 23

24 So, we'll take that as an action and get back to 25 you.

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

	149
1	DR. BONACA: We will support you promptly, but I
2	think that, at this stage, with this issue open, that's a
-3	major comment that we need to address, and we really can't
4	right now.
5	Any thoughts?
6	DR. SEALE: That's a reasonable position, yes.
7	DR. BONACA: With that, I thank you for the
: 8	presentation.
9	MR. DAVIS: Thank you very much for the
10	opportunity.
11	DR. BONACA: Mr. Chairman?
12	DR. APOSTOLAKIS: Thank you, Mario.
13	Recess until 10 after one.
14	[Whereupon, at 12:10 p.m., the meeting was
15	recessed, to reconvene at 1:10 p.m., this same day.]
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
-	ANN RILEY & ASSOCIATES, LTD.
	Court Reporters 1025 Connecticut Avenue, NW, Suite 1014
	Washington, D.C. 20036 (202) 842-0034

AFTERNOON SESSION 1 [1:13 p.m.] 2 CHAIRMAN POWERS: Let's come back into session. Ι 3 think we are going to discuss a new and different topic that 4 we are relatively unfamiliar with --5 6 [Laughter.] 7 CHAIRMAN POWERS: -- and so I expect all members to pay close and keen attention as I ask -- Jack, you are 8 going to help us explore this untrammeled territory? 9 MR. SIEBER: Yes, sir. 10 CHAIRMAN POWERS: Okay. 11 The purpose of this afternoon's 12 MR. SIEBER: session is to hear a briefing by the NRC Staff and the 13 14 Nuclear Energy Institute and hold discussions with them regarding the status of a proposed Regulatory Guide which, 15 if it is issued, will endorse the guidance of NEI 96-07, 16 associated with the implementation of the revised 10 CFR 17 50.59 process -- 10 CFR 50.59 is a keystone regulation 18 probably used more extensively by licensees than any other, 19 and it allows under certain controlled circumstances changes 20 in the plant and also tests and experiments. 21 The current version 50.59, in force, has been in 22 force for about 30 years. During this last summer there was 23 a new rule issues which changes the three criteria in the 24 old 50.59 to eight criteria, clarifies a number of aspects 25

of the process and was issued as a final rule.

1

2

3

4

5

6

7

8

9

24

25

The implementation of the final rule occurs 90 days after the associated Regulatory Guide is issued and that has not been issued. It was contemplated by the Staff that the Regulatory Guide would endorse NEI 96-07 and all of us have received a copy of that and I am sure reviewed it. At the time I reviewed it there were, it seemed to me, 24 outstanding items based on the matrix that was sent along with it.

I understand also and have received a copy of a final draft of 96-07, which I got this morning and the Staff got Monday in spite of the snow and it seems to me that the Regulatory Process is such that a final determination as to the acceptability of the changes and the resolution the remaining open items couldn't be done between last Monday and today.

So what we will hear about today is a status report on the issues of the Regulatory Guide and NEI 97-07. It would be good if we could talk a little bit about the outstanding items and those which remain outstanding which, by my count, should be six, unless others have developed in the meantime -- if we could hear a little bit about that and what the problems are.

In addition to that presentation, I expect the representatives from NEI to avail themselves of time during

this session.

1

2

3

4

5

6

7

8

9

What I would like to do now is introduce Eileen McKenna, who is responsible for this presentation. Eileen?

MS. McKENNA: Okay, thank you very much, members of the committee. I might also mention Scott Newberry, our Deputy Division Director, is here at the table for any questions, and I was going to suggest if the committee had no objection that Mr. Bell sit at the table here, so we can discuss this. I think it may be helpful to turn it over at a certain point and then turn back over, to kind of give an 10 idea of what the discussions have been between us. 11

I think in terms of my first slide, your 12 13 introduction pretty much covered the information I have there that indicated the rule was issued in October, the 14 90-day timeframe after the approval of the guidance for 15 implementation of the rule, and that we are looking to try 16 to endorse an industry document through a Req Guide as the 17 18 regulatory guidance for the rulemaking.

I want to make a couple comments about why this is 19 a status briefing rather than coming to you with the draft 20 Req Guide. I think our original plan and schedule would 21 have called for us to be ready to give you a draft Reg Guide 22 to present at this meeting and get a letter, but because of 23 24 some of the open issues that you alluded to, we are not 25 quite to that point in time and I will come back to the

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

question of where we are on schedule and some of the reasons therefore in a little while, but that is why it is status report to discuss the distance we have come but some of the issues that are still remaining, and then where we expect to be going to.

6 CHAIRMAN POWERS: I am curious. Is there some 7 absolute need that you need a letter from us?

1

2

3

4

5

MS. McKENNA: Well, I think there are some options for the committee. You know, we are going out for a draft Reg Guide and then we will have a public comment period, to be followed by a final Reg Guide. This is an item of high Commission interest, so we do have Commission due dates and attention and we are working with that.

I think our view at this point is that we would 14 not be ready to come to the committee in March, because 15 since that is only a month away, we would have to have our 16 final, have our Reg Guide put together in about two weeks, 17 and I don't see that happening, so obviously the next window 18 after that is April, which is perhaps a little later than we 19 had hoped to publish in order to meet some of our other 20 21 objections on the schedule but we are trying to work with 22 that.

23 CHAIRMAN POWERS: Well, let me ask you this. If 24 you have got outstanding items with NEI do you think the 25 ACRS can help resolve those issues? I mean I am not asking

you to overestimate or underestimate. I am asking for a prognostication on your part about your abilities. Do you think you'll get it all sorted out and be happy with it?

1

2

3

MS. McKENNA: Well, I think we are going to come to a resolution. Obviously we may or may not be able to agree with what they propose and they may not agree with where we come out on some of these things, and if that is the case then what we may have to do is have a Reg Guide that at least at the draft stage has some clarifications or exceptions, if that is where it comes out.

Some of the issues I think the committee may be able to help us on. There are a few that we are wrestling with that are perhaps more in the "how do they fit with the regulations and the process" and the committee may feel less comfortable providing their input in that area, but we will try to cover what the different ones are.

I think we need to think CHAIRMAN POWERS: 17 carefully about the value added at this late stage of the 18 process where we are really working on implementation, I am 19 wondering if it is really not necessary to have them get a 20 blessing, because that is all we would be doing is just 21 passing judgment over something that we have seen many times 22 and they are down into the implementation stage and I am not 23 sure -- I think we may need to use our judgment about 24 whether we -- we all know and love Eileen, but she is free 25

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

to visit us without 50.59.

1

2

3

4

5

7

24

25

MS. McKENNA: I hope so.

[Laughter.]

MS. McKENNA: And as I said, this is the draft stage and we would have a final stage and there would be another opportunity at that point for the committee to 6 revisit and after we have the benefit of comments. I think that is an option that the committee may want to consider. 8

MR. SIEBER: Yes. Actually, the SRM that controls 9 your due dates says May, 2000. 10

MS. McKENNA: Yes, we have approached the 11 12 Commission about an extension on that, because obviously if we are here in February and don't have a draft Reg Guide, we 13 are not going to be at the Commission in May with a final, 14 15 and we have made an approach to move that date out a few 16 months in recognition of those facts, yes, but I think anything the committee can do to help us with the schedule 17 18 we would appreciate.

MR. SIEBER: I think that we can certainly try but 19 20 I don't think there is value added in rushing through 21 something and perhaps missing it because once the final 22 document is issues it stays there for a long time before anybody has an opportunity to change it. 23

MS. McKENNA: Yes.

MR. SIEBER: So we ought to get it right the first

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

time.

1

2

3

4

5

6

7

8

MS. MCKENNA: Okay. I thought at this point might be a good opportunity to ask Mr. Bell to talk a little bit about the development of 96-07, since what we are trying to do is endorse that document, so I felt this might be a good opportunity to let me make some presentation and then I will come back and talk about where we see the status on some of these issues.

9 MR. SIEBER: Did you want to do these first? 10 MS. McKENNA: Well, I suspect we have some overlap 11 in our slides since we really didn't try to coordinate in 12 any detail. I think I have covered some of these bullets. 13 We have had some draft interactions and I can go into this 14 in more detail.

The document that you mentioned, presented on 15 January 18th for our consideration, we are in the process, 16 there are some questions and issues we have, and we are in 17 the process of getting a letter back out that we hope to get 18 out this week, but it is not yet out of what some of those 19 remaining issues that we are still working on. We have 20 scheduled a meeting next week to talk about what those 21 22 issues are and what we are going to do about them, and, as you may be aware, there is a Commission briefing scheduled 23 on February 29th on this subject and we will be probably 24 covering very similar territory with the Commission, as you 25

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

will be hearing.

1

2

3

4

5

6

· 7

16

20

It's rather than where we hope to be, perhaps, in terms of February. At this point we are looking at perhaps a two month -- it might be a little shorter if we don't come back for a letter on the Reg Guide. We may be able to shorten that by a couple of weeks, but it is that kind of timeframe we see at this point for publishing the Reg Guide.

8 MS. McKENNA: I'll move over to the other side, 9 how's that?

MR. BELL: Thank you and good afternoon. I am 10 Russell Bell, with the Nuclear Energy Institute. I am the 11 Project Manager on the 50.59 issue. I had a nice cover 12 I think everybody has my copy of these. Ι 13 slide. appreciate somebody -- Dr. Seale, was it you? -- who likes 14 "what's past is prologue"? 15

DR. SEALE: Yes.

MR. BELL: I had a draft slide that just said Background" up there and I thought that this might be an audience that might appreciate something else.

DR. SEALE: Quicker than most.

MR. BELL: There's certainly an overlap with some of the things Eileen just said, but just suffice to say this has been a story in the making for some time, probably the seed were laid for where we are today back in 1989, when the industry produced the first guideline document on 50.59, and

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

the consciously or unconsciously a decision was made not to go the extra mile and get a Reg Guide, you know, NRC endorsement of the thing.

1

2

3

4

5

6

The rest of these events here that are kind of captured are almost predictable based on that early direction chosen, so here we are today.

The most recent thrust/assault at this issue began 7 I guess three years ago now, say, and we wrote this 8 objective and I thought I would trot it back out because I :9 think it still holds, so this was an observed, very 10 extensively used regulation where there is misunderstanding 11 about its requirements and expectations, there is regulatory 12 instability, and we certainly experienced that, so we set 13 out to resolve that. 14

Indeed, the rulemaking, which was completed last 15 summer but is not yet effective, went a long way towards 16 resolving the regulatory instability. It removed the 17 18 so-called "zero standard" that was reflected in the original It established key definitions where there were 19 rule. really no commonly understood definitions before. The 20 margin of safety criterion was somewhat problematic and that 21 has been replaced, we think improved. So these kinds of 22 things were accomplished, have been accomplished already in 23 the rule, and what is left to us, and it is not necessarily 24 the easy part, is to then translate that into implementation 25

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

guidance.

1

CHAIRMAN POWERS: Well, you have done a lot in 2 that direction, but I can't help but think a little bit 3 about our initial discussions of what to do with 50.59 that 4 came about, I think, because our ability to quantify some of 5 the questions in the original 50.59 has just improved so 6 * **7** much over the years that what in the past was indistinguishable from zero suddenly became distinguishable : 8 from zero. 9

We talked about, gee, let's think about doing a risk-informed or maybe even a risk-based 50.59, but in the interim we have to do something and get this out of the way quickly and the operative phrase was "quickly" but now I want to turn to the risk-informed.

Having gone through this, do you and your fellows within the nuclear industry see advantages to now launching forth on a risk-informed 50.59?

MR. BELL: The Staff may be able to update 18 farther, but my understanding is that we are proposing 19 certain things as a part of another issue that I think the 20 committee will hear about in this meeting, the 21 risk-informing of Part 50; 50.59 is certainly a part of 22 that, so I think the answer is yes, we still see a benefit. 23 DR. WALLIS: I noticed a lack of enthusiasm. Ι 24 was expecting you to come back and say "Yes!" 25

[Laughter.] 1 DR. APOSTOLAKIS: Russ doesn't do things like 2 3 that. CHAIRMAN POWERS: You are looking at 4 5 battle-scarred veterans here. [Laughter.] 6 7 DR. APOSTOLAKIS: Well, I think though we have to make clear what we mean by risk-informing 50.59, because I 8 think a lot of people think that the objectives would be the 9 same. You would just be using risk information, and at 10 11 least some of us are thinking about it in a different way. Perhaps the benefits of risk-informing 50.59 or the process 12 of allowing changes without review are not very clear to a 13 lot of the industry. 14 If I told you right now that I was advocating a 15 50.59-like process that would have as a sole criterion that 16 the core damage frequency doesn't go about 10 to the minus 17 four, would you say yes, the way Dr. Wallis wants it? 18 I would allow you to do anything you want except 19 exceed 10 to the minus four core damage frequency. 20 That is an extreme, of course, but, you know, the 21 22 benefits of a new process have not been articulated very well. 23 MR. BELL: The other way to come at that is to 24 somehow risk inform the scope of matters that 50.59 would be 25 ANN RILEY & ASSOCIATES, LTD.

Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

ļ	161
·1	applied to. I believe they are looking at both approaches
2	in terms of out to improve things.
³ 3	DR. APOSTOLAKIS: But coming back to the issue of
4	quick fix that Dr. Powers mentioned, is this quick?
÷5	[Laughter.]
6	MR. BELL: I have seen things quicker and things
7	take longer.
- 8	DR. APOSTOLAKIS: This is pretty good?
.9	DR. BONACA: No.
10	DR. APOSTOLAKIS: Are we going to go into details
11	of this?
12	DR. SEALE: A blink of El Nino's eye.
13	DR. APOSTOLAKIS: Because I have two questions I
14	want to ask.
15	MR. BELL: Well, I might identify I guess my
16	purpose is to, in the middle of Eileen's status report, just
17	to provide you some context by going through providing an
18	outline of the document and some of its key aspects. I
19	would try to do that as quickly as possible, although we
20	have a day and a half workshop devoted to this document
21	planned in April and so it is quite a challenge to cover
22	that material in just a few minutes, so I am willing to try
23	though to again provide some context.
24	DR. APOSTOLAKIS: Can I ask my questions now? I
25	like plant-specific, document-specific questions.
	ANN RILEY & ASSOCIATES, LTD.
.÷	Court Reporters 1025 Connecticut Avenue, NW, Suite 1014
-	Washington, D.C. 20036 (202) 842-0034

:	162
1	I noticed that in 96-07 there is actually a
2	quantitative criterion for the increase in frequency of
3	occurrence of an accident which is not the way I understand
4	the document to be used only when one chooses to use a PRA.
5	This is on page 39 of the document. It says
6	MR. BELL: Section 4.3.1
[:] 7	DR. APOSTOLAKIS: It's in the book.
8	MR. BELL: That is the old one.
9	DR. APOSTOLAKIS: What I have is the old?
10	MR. BELL: Yes.
11	MS. McKENNA: I don't think that page changed very
12	much, so it should be about the same place.
13	MR. SIEBER: It might not be the right page.
14	MS. McKENNA: That's possible.
15	DR. SEALE: What is the section number?
16	MS. McKENNA: The section is 4.3.1.
17	DR. APOSTOLAKIS: You have a different one?
18	MR. BELL: Yes, this is the latest and greatest.
19	DR. APOSTOLAKIS: Well, I am going with what we
20	have in the book. So it is 4.3.1 so it says, "If the
21	proposed activity affects the overall system performance in
22	a manner that could cause an accident previously evaluated
23	to shift to the higher frequency category or result in a
24	calculated frequency increase to be 10 percent or greater,
25	then the proposed activity would be more than minimally
м. М	ANN RILEY & ASSOCIATES, LTD.

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034 increased."

- 1

24

25

Now "or result in a calculated frequency" -- now I can choose not to calculate the frequency, the change in the frequency?

MS. MCKENNA: Yes. I think you phrased it a -5 little differently than I might have phrased it in terms of 6 the usage of this criteria, that the criteria is trying to 7 cover both the cases where a licensee chooses to do a 8 qualitative assessment of a particular change against this 9 criterion, and also the cases where a licensee chooses to do 10 some kind of quantitative assessment, whether that is PRA or 11 it is some other way of approaching it but with some kind of 12 quantification involved, and that this part of the guidance 13 would apply where that kind of quantification, numerical 14 usage, comes into play. 15

DR. APOSTOLAKIS: The distinction is made much more clear later on on the next section, 4.3.2, where you talk about the equipment malfunction, where there is a list of eight levels of performance, and then with boldface letters it says, "Number 8. For use where the change in likelihood of a malfunction is calculated."

The distinction is much clearer here, whereas there it is buried in that "or" --

> MR. BELL: Clearer that it is optional. DR. APOSTOLAKIS: Yes, clearer that it is optional

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

that you don't have to do it. 1 MR. BELL: Sounds like a --2 3 DR. APOSTOLAKIS: I think it is --MR. BELL: -- fair comment. 4 5 DR. APOSTOLAKIS: -- in the frequency as well, but here, now, I have a problem with this paragraph. 6 7 Essentially if you read it --- 8 MR. BELL: Which paragraph? DR. APOSTOLAKIS: Eight. - 9 10 MR. BELL: Okay. DR. APOSTOLAKIS: Number 8, C-8. 11 12 MR. BELL: I think before you -- I think we In fact, that paragraph has 13 addressed that problem. basically gone away. We call that an elegant solution, when 14 15 you just eliminate things. 16 [Laughter.] DR. APOSTOLAKIS: The intent of this, though --17 MR. BELL: Yes --18 DR. APOSTOLAKIS: -- was really use this criterion 19 20 only if you are sure that you will be below a factor of two, because if you are above, it is inconclusive. You can still 21 22 use qualitative arguments to argue, which seems to me like a cyclical argument because in order for me to conclude that 23 24 the change in the probability is greater by more than a 25 factor of two -- that the change in the likelihood of an

164

occurrence of malfunction is increased by more than a factor 1 2 of two I will have to use qualitative arguments and engineering judgment, so how then after I conclude it is 3 three I can use qualitative arguments and engineering 4 5 judgment to knock it down? MR. BELL: In fact, the Staff identified that to 6 [:]7 us. DR. APOSTOLAKIS: That is why it is eliminated. 8 MR. BELL: On further thought, that whole thought 9 has been eliminated. What you have there I think is a 10 December revision. 11 DR. APOSTOLAKIS: December 20th. 12 MR. BELL: The latest one is January 18th. 13 DR. APOSTOLAKIS: So there is no paragraph like 14 that? Absolutely nothing? A factor of two? 15 MS. McKENNA: It just has -- there is a CH that 16 says "increasing the likelihood of a malfunction" -- excuse 17 18 me, "of occurrence of malfunction by more than a factor of two." 19 MR. BELL: And then the note equivalent to the 20 21 bold --22 MR. BARTON: There is a footnote, George. DR. APOSTOLAKIS: I see the footnote. Okay. So 23 the self-consistency of this paragraph then goes away. 24 Now is there any way we can avoid presenting this 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036

(202) 842-0034

kind of criterion or analysis as an additional analysis? In other words, it looks like, if you read it now, that one would still have to satisfy one through seven and then as an addition to eight, because perhaps it is easier to show that it doesn't increase by more than two, but if one goes through the expense and effort of quantifying these probabilities, shouldn't that person get some relief from the other requirements?

1

2

3

4

5

6

7

8

9 MR. BELL: In fact, this list of A, B, C, and then 10 there are subconsiderations under each, are a list of 11 considerations, and in fact the intent would not be that you 12 have to check all those off.

In fact, many may not apply to a particular activity that you are trying to evaluate, but it does represent a list of things that you ought to consider to the extent they are applicable, and that goes for the last one as well, the one you are talking about, in the case where you are practically able to or able as a practical matter to calculate.

DR. APOSTOLAKIS: I guess my -- not objection, really, but something that does not excite me too much is this idea that Number 8 is in addition, that if someone really spends money to do a PRA, then, you know, still have to do the other stuff. Reducing system redundancy, diversity or independence -- I mean I can argue

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

qualitatively now that there is a minimal change or I can go ahead and quantify and then get into trouble.

1

2

3

:4

5

6

23

24

25

Now this factor of two or greater refers to the mean value of the frequency of failure? Because there is a distribution there. I have a PRA, I get a distribution. I don't get a number, so it refers to which number, the mean?

MR. BELL: Do you recall if that was a mean number from -- we took that number from --

9 MS. McKENNA: I don't think it was specified in 10 the other document.

DR. APOSTOLAKIS: Because doubling the mean is not 11 12 really a minimal change. Most likely what you are going to see is a distortion of the shape of the epistemic 13 distribution of the failure rate, but the mean will not jump 14 up by a factor of two. That would have to be a significant 15 change, so maybe you can eliminate the sentence that 16 survived under 8 and don't say anything, because I don't 17 think that sufficient thinking has gone into this, what it 18 19 means -- unless you want to do that.

20 See, if I have a distribution, to move the mean up 21 by a factor of two is not -- you have to do something 22 significant on the high side.

You were thinking probably in terms of point estimates, which are not well defined anyway.

MR. BELL: I think you are probably right.

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

Well, I think that is a point well taken.

You know, by the way, comments such as that or others the ACES has -- that subject came up earlier -- to the extent they are known at the same time that the public comment period is taking place, I would think that would be the timely way to capture some of that. 6

1

2

3

4

5

24

25

DR. APOSTOLAKIS: Let me put the question a 7 different way. I realize that a lot of these changes are 8 difficult to evaluate quantitatively, because either the 9 equipment does not appear in the PRA at all, which is very 10 common, or the change is of such a nature that you say, my 11 god, how does that affect anything? 12

Would it be useful to make a distinction between 13 components that are in the PRA and components that are not 14 and reserve all this qualitative discussion for the ones 15 that are not, but for the ones that are in the PRA you must 16 look at the distribution of the failure rate. It is not an 17 18 option -- because you are going to get that question anyway. It's similar to this thing that you will have a two-tier 19 regulatory system, one risk-informed and one, the 20 traditional system, which I think is an illusion, because 21 you are going to get the question of what happens to the 22 core damage frequency anyway. 23

So if it is in the PRA, please provide arguments. The arguments can be qualitative, but look at the

distribution and tell me what you think happened. That would make it cleaner. There will be no ambiguity, at least in the guide. The guy who is doing it, of course, is going to have a problem, because you can't really say I am doing something that may affect, you know, the function of a major pump, of a safety system and then say, "Well, qualitatively I conclude."

1

2

3

4

5

6

7

25

I mean the question what happened to the distribution that everybody else is using will come up. They may still argue that it doesn't change much.

11 MR. BELL: The longstanding, I guess, posture on 12 this is that these are qualitative guidelines and --

DR. APOSTOLAKIS: They will be qualitative. MR. BELL: -- and the intent with this document was to stick with that, and not in any case really compel folks to do a quantitative or probabilistic --

DR. APOSTOLAKIS: But what I am saying is that as a practical matter, if there is -- if these components are used routinely in the PRA and there are distributions for the failure rate, I can't imagine that the reviewer would not go and say, gee, this is the number, what do you think?

MR. BELL: I agree with you. I would be very surprise if they had that tool and didn't avail themselves of it.

DR. APOSTOLAKIS: The argument will have to be

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

qualitative, but at least the issue will be addressed. Maybe we should recognize that. Just a thought.

1

2

3

4

5

6

7

8

11

12

13

14

15

16

25

DR. BONACA: I would like to ask one question. As you move through the presentations today, I would appreciate if you could, you know, emphasize the changes that you made since we met previously when we reviewed this in detail, first, and second, how you addressed the comments of the ACES.

9 We had a number of detailed comments. I think it would worthwhile for us to know how they were addressed. 10

MR. BELL: We might be able to do that.

DR. BONACA: I don't mean to disrupt your presentation, just simply, you know, I looked at it and a lot of this seems to be some review of things we already reviewed before and I would like to know what changes took place between the industry and the NRC since that time.

I sure hope that is the case, because 17 MR. BELL: this is an implementation document that really implements a 18 final rule, and as you say, we have been through --19

MS. McKENNA: Maybe it would helpful if I went 20 back just briefly on one of my slides, which was kind of 21 22 what changed in the rule, just in case -- it's been several months for some of you and some may be new members who 23 aren't familiar with all the changes that were made. 24 There were some organizational changes. A major

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

change was adding definitions in terms of what "change" 1 2 means, what facility is described, what are procedures. In 3 terms of the way those definitions are applied, it allows some degree of screening as to whether something is a change 4 5 for the facility as described, and I think a number of changes on the evaluation criteria that were alluded to, the 6 7 concept of the minimal increases in the likelihoods of failure and in consequences, not much change with respect to 8 the criteria of new or different accidents and new or 9 10 different malfunction, and removing the old margin of safety and using two other criteria, one on design basis limits, 11 fission product barriers, and one on methods of evaluation. 12

13 Those were the things that were in rule and in the 14 statement of considerations, which was what the committee 15 had reviewed.

Now at that time of course, 96-07 had been drafted more along the lines of what the existing rule reflected, and therefore there were a number of changes that were necessary, and I think you saw they showed up first in the September version of the document that was provided to the Staff.

Then, as was mentioned, the Staff provided some comments, and then in December NEI responded with I think the matrix that you mentioned of how they responded to the questions we had asked at that time.

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

The December version we had another meeting and we had some additional discussions and there were some ' relatively small -- I guess I would characterize them as changes -- in the January versions, and as I mentioned, there still are some issues that we are wrestling with, trying to get to agreement among all the parties within the Staff, and we are trying to put those down on paper to let NEI know what those are and where we have perhaps some hard spots with the guidance that is there now.

1

2

3

4

5

6

. 7

: 8

9

22

23

24

25

One comment I think in terms of what is different. 10 I think it is recognized that a lot of the stuff that we saw 11 in September was kind of carrying forward from what was in 12 I look at it as the rule and putting that down on paper. 13 there were some additional additions or extensions or 14 however you want to characterize it of taking the thoughts a 15 little further that were offered in December, and I think it 16 is primarily in those areas where material is a little bit 17 new to us that we are having these discussions, not so much 18 on minimal increases in consequences and things like that, 19 where I think we are pretty much on the same page, but when 20 we get to some of the open issues. 21

As one example, we have had a lot of discussion about the question of methods, criteria and methods and when is a licensee changing a method sufficiently that an NRC review would be appropriate, and one of the areas where we

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

have had a lot of discussion is the extent to which a method 1 that was approved on a plant-specific, individual basis can 2 be then used by another licensee as a rationale that that 3 methodology is acceptable to NRC without further review, and 4 that is an area where there is some additional information 5 in the guidance that we have been discussing and we are 6 making progress but we are not totally in agreement with at **7** this point a couple of other ones that are kind of in that `8 new bin as well, so I think that is -- some of the old 9 issues about what was in 96-07 may not really fit on the 10 11 table anymore.

You know, we are into these areas where things were changed and then they perhaps, to conform with the rule, and whether that has all been taken care of and then perhaps in these areas get pushed a little further.

16 So that is where I see it in terms of where the 17 changes are arising.

18 DR. WALLIS: Are we going to talk about some of 19 these, like minimal?

MR. BELL: Yes, a little bit.

20

24

25

DR. WALLIS: I don't know quite where to interject a question, because I don't want to interrupt but I do have a question about that at some time.

MR. BELL: Let's try and move on. That was --Eileen highlighted a number of the key changes to the rule

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

itself, okay, and that part of the process is done and we're quite satisfied with the way that turned out, but it is bigger than a bread box to take it the rest of the way and translate that into clear guidance.

1

2

3

4

5 That is where we are now. The clarity of the guidance is one of our objectives, comprehensive in the 6 ÷7 sense that we have been looking back at past generic 8 communications, notices, letters and so forth that have 9 touched on 50.59 and tried to be sure that the quidance that we are preparing now deals with those issues and if need be 10 11 clarifies those kinds of things, so we are trying to have a one-stop shop for folks on 50.59 implementation. 12

We think that the result will be more consistent and effective implementation, owing largely to following through and getting the NRC endorsement of it, and I feel that we are on track with that.

The status is, as Eileen mentioned, there was an iteration in here that I have left off my slide, the December version, but we are now at the point where we have what we consider to be a pretty good draft subject to a few remaining issues that Eileen has identified.

So how do you implement this process? At a certain level it boils down to this -- does the rule apply or is some other process more geared towards governing changes, like in the area of EP, emergency planning,

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

security. There are change processes set for that. Tech spec changes, that's another process.

1

2

20

It might surprise you to know that some utilities in the past have done 50.59s for all of those, duplicate kinds of evaluations and reportings and so forth. One of the important things this rule clarifies is that's not necessary. Just do the evaluation where it makes most sense and follow that set of guidance and you don't have to do it more than once, so that's important.

10 Secondly, and it probably should say "must" --11 must the activity you are proposing to do be subject to the 12 eight questions? Somebody mentioned earlier that we went 13 from three to eight questions, or three criteria to eight 14 criteria, and this middle step we call the screening 15 process, and I'll have a little more to say about that.

Finally and more to the point, once you get to the evaluation criteria, there is NRC approval.

18 DR. APOSTOLAKIS: Isn't that question the same as 19 the first?

MR. BELL: This one --

DR. APOSTOLAKIS: The first and third bullets, aren't they the same thing?

23 MR. BELL: Well, 50.59 -- does it apply would mean 24 do I even need to do this screening step, or because it is 25 an emergency planning program change I have a separate

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

criterion for that, in 50.54(q) or -- maybe it is -- so that is what this question means. This is the screening step and the evaluation step and some of that might be a little clearer.

1

2

3

4

5

6

7

Now if you skip a page in your package, I think you will find a copy of this diagram.

MS. McKENNA: It is in the 96-07.

8 MR. BELL: That is Figure 1 from our document. 9 This is basically the applicability question, the step we 10 just talked about. This is the screening step, the 11 evaluation and then implementation.

Over here I listed a number of the other 12 13 regulatory processes that might be more appropriate or are more appropriate for certain changes. I mentioned EP, 14 security. There are Part 20 kinds of changes on effluents 15 and things like that. One of the more interesting ones is 16 the maintenance rule, one of the areas, maintenance rule 17 quidance related to the new (a) (4) provision on the risk 18 impact assessments. Well, that, it would seem to me, it 19 would seem to us if you did a maintenance rule assessment 20 under (a) (4) that you wouldn't also need to do a 50.59 21 evaluation that duplicates that assessment, and so 22 fortunately both quidance documents were in play at the same 23 timeframe, and with the NRC we have been trying to get the 24 quidance to dovetail, again to avoid the duplicate or 25

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

overlapping, I should say, requirements.

1

2

3

4

24

25

So that is one of the things that didn't settle down until I guess the December version and there may be more clarification of that that is needed.

5 MR. SIEBER: Maybe I can jump in and ask a 6 question here. One of the exemptions under the maintenance 7 portion of this guidance is the hanging of lead from pipes, 8 and it says you don't have to do a 50.59 to hang lead.

I remember always doing that because you don't necessarily hang lead on the system that is out of service for maintenance. You may hang it on an active system. You need to know about whether you are increasing stress in the pipe or stressing a hangar, bending something, so maybe you can clarify to me exactly what it is you are doing when you are talking about hanging lead.

MR. BELL: As I say, we are trying to make the two 16 quidelines dovetail. One of the things that the (a)(4) will 17 say is that, hey, if you do something like that under the 18 maintenance -- for ostensibly maintenance purposes you need 19 20 to consider the effects of those kinds of activities on other plant systems and if that is a new addition to the 21 22 most recent revision of that (a) (4) guidance, it is intended to get exactly at that kind of question. 23

MS. McKENNA: This is one of those that I mentioned we are kind of in this -- it is somewhat technical

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

and also somewhat process questions that we are wrestling 1 with, because the kind of thing you are talking about you 2 could look at and say, yes, this is a change because it is 3 changing the piping or whatever I am hanging it on. The 4 5 purpose I am doing it may be because I want to do maintenance on something, and what are the right kinds of . 6 assessments and processes that should be looking at those 7 8 changes, and can you truly be under one or the other or are 9 there overlaps, and that is still something I think we are dealing with is it is not always easy to tell that it is 10 just maintenance because it is only working on the thing 11 that you are doing maintenance on, or it is 50.59 because 12 you are hanging the lead on something else or you are moving 13 the equipment by something else, or there are other 14 configurations you can be in. 15 You're setting up scaffolding --16 MR. SIEBER: there are all kinds of things --17 18 MS. McKENNA: Absolutely. 19 MR. SIEBER: MR. SIEBER: -- having an impact on other systems 20 and hopefully the maintenance activity, the assessment that 21 occurs because of that covers all these other systems, as 22 opposed to somebody putting blinders on and saying the box I 23 am working in is the piece of equipment that I am working on 24 25 and what I do around it, which might have a seismic impact,

a fire impact, change the loading on a system, is somehow or other not included in that assessment -- just so that's clear.

MR. BELL: That's first an issue for the guidance and then it is really a training and follow-through issue and we have a maintenance rule workshop scheduled in March, 50.59 in April, and more after that in terms of getting this kind of awareness --

MR. SIEBER: Part of that is organizational, because typically 50.59s are done by the Engineering Department or the Safety Department, whereas maintenance assessments are done by maintenance engineers --

MR. BELL: True.

1

2

3

13

14

23

24

25

MR. SIEBER: -- who ordinarily don't do 50.59s.

MS. McKENNA: I think because both of these, the 15 (a) (4) is in the process, it is kind of similar to 50.59 in 16 a way in that it has this when the guidance is ready then it 17 18 becomes effective, and that hasn't kicked in yet, that we don't really know exactly how it is going to work yet, and 19 therefore trying to -- we have two moving targets, so to try 20 21 to nail down one and then see how it impacts the other is something we are having some difficulty with. 22

MR. SIEBER:

MR. SIEBER: Well, I would like to see them dovetail in a way that there are no open holes between the

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

two.

1

19

MS. McKENNA: That is what we are trying to look at. I think NEI is trying to make a proposal that they are separate and -- some of the parts may be separate, parts may overlap and we try to see where that overlap is, and, as you say, make sure that if we think it is over there that it really is over there and that it is just not there.

MR. SIEBER: My picture of the process is that it is interlocking, that it has to be comprehensive enough and everything has to be covered someplace, otherwise you are going to have some unanalyzed safety condition out there, which I think is unacceptable.

MR. BELL: In each case where there is perhaps more appropriate or more specific regulatory process to evaluate the change the guidance makes the point that, hey, there may be aspects of that activity that affect both your emergency planning -- maybe it is a change to your, what do they call it? -- facility --

MR. SIEBER: The EOF?

MR. BELL: Yes, the EOF, that affects one of the SSCs credited in the safety analyses or designs so we are very careful I think to identify that in the guidance and then there will be a training and awareness issue in terms of the follow-through, so you could have to do both, but where it is a purely -- clearly maintenance, clearly

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

emergency planning, then there are better rules than in the general change rules to apply. The point is well taken.

Just a little more on the screening process --

DR. WALLIS: I guess I have a question. I'm sorry. This big diagram that you showed us, really you need another set of diagrams. "Perform 10 CFR 50.59 Evaluation" is just one blob on this. That involves a lot of steps and I think you need to provide a framework for how you do that.

MR. BELL: We certainly could --

DR. WALLIS: Not just words, but some sort of a diagram -- do this, then this, this, ask these questions.

MR. BELL: That clearly alludes to that section of the document. It's a lot of words. There are some further documents that are going to generically implement this on a plant-specific basis -- generically on a plant-specific basis?

17

1

2

3

4

5

6

7

8

9

[Laughter.]

MR. BELL: Generic procedures, forms and so forth, for implementing this thing are -- we are working with some utilities to develop those. That might be a place for additional pictures.

MR. SIEBER: Well, I agree with Dr. Wallis that it would be very helpful in this document. It's the process under Section 4.1.4.2.4.3 -- it is difficult to follow unless you almost make a checklist.

DR. WALLIS: You have to make your own diagram.

MR. SIEBER: Yes, you have to make the diagram, whether you do it or NEI does or somebody does it in order to understand it.

1

2

3

4

5

6

7

8

9

10

11

12

DR. SEALE: The hard part is knowing when to quit. When we started on this, Dr. Powers mentioned the fact that it was in fact the ability to quantify risk and to come up with numerical values for changes that are purported to result from some particular action that to our dismay, I guess, quantified zero, and made us accept the fact that zero was no longer a neighborhood but was in fact a point on the line, but there is another aspect to that.

We have mentioned it before here. That is, sometimes when you make a change and the immediate impact of that change is perhaps a slight increase in the risk, there are attendant modifications which reduce the risk and so on balance the effect of -- and I will hesitate to use the word "everything" -- is a negative.

The question is how far do you go before you declare that you have got everything, because, you know, clearly it is the old question of completeness that we face in any kind of evaluation like this. It is still out there with this. Presumably what you are doing here is coming up with this list of the regulations you want to look at and so forth and somehow that tells you when you have done

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

everything in the context of the regulatory process to 1 evaluate all the changes, but it is still kind of an open 2 issue, isn't it? 3 In the context of 50.59, the guidance 4 MR. BELL: is that you really need to take every change and look at it 5 6 unto itself. Now you can link certain other things if they are a direct result or a necessity of the primary change. 7 DR. SEALE: Or a direct consequence of the change, 8 9 yes. MR. BELL: But there is essentially a prohibition 10 11 against drawing that envelope wider and wider until we -- we find, lo, we really did improve our risk profile. 12 DR. SEALE: Yes. 13 14 MR. BELL: That doesn't sound risk-informed. That sounds like we may be doing perhaps more than we need, 15 nonetheless, that has been the state of affairs and this 16 17 document maintains that. MS. McKENNA: I think that is the way the process 18 19 is structured, that you are looking at the individual changes and you try to keep each of those minimal as opposed 20 to perhaps a different framework that was put all the 21 changes together and as long as you net has not gone more 22 than whatever the number or is a net change of zero, but the 23 difficulty you have is how you put them together in those 24 kinds of approaches. 25

DR. SEALE: So the process known as bundling 1 2 doesn't apply to 50.59? MS. McKENNA: That's correct. 3 DR. SEALE: That is an interesting point. 4 MR. BELL: It is intuitive. 5 CHAIRMAN POWERS: To create a risk-informed 10 CFR , 6 50.59, wouldn't bundling ipso facto be used? 7 MS. McKENNA: Yes, that's my personal -- because . 8 you are looking at things in a different way -- but you need . 9 some method of looking at them together and if you are doing 10 these individual changes to different things, saying this 11 one is a little bit here, this one's a little bit there, 12 that is kind of what the process does now. 13 You would have to have some different tool to do 14 it in an across-the-board type of sense. 15 CHAIRMAN POWERS: I'll be honest with you. I am 16 using this briefing more to think about going to a 17 risk-informed 50.59 than I am about the details, because I 18 have a feeling that you can worry about them enough for both 19 of us, to be quite honest with you. 20 21 [Laughter.] MS. McKENNA: Yes, I think sometimes down in -- I 22 was going to say the nitty-gritty but to a certain degree of 23 actually certain things crack through the system. 24 CHAIRMAN POWERS: I don't look at it just as being 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014

> Washington, D.C. 20036 (202) 842-0034

down in the nitty-gritty. I just think it takes more knowledge about the length and the breadth of it than I am able to assimilate.

1

2

3

4

5

6

7

MS. McKENNA: Yes, I think that is fair.

CHAIRMAN POWERS: You have been living with it, and I haven't -- although I sometimes feel like I have been. MS. McKENNA: Yes.

CHAIRMAN POWERS: But I do think it deserves to 8 pull out of this exercise that you are going through lessons 9 that might be applicable to going to risk informing, because 10 I have a feeling that people who are thinking about that may 11 not have been living that either, and they may not be down 12 in the details of knowing what constrains you and what 13 constraints you want to carry forward and what you would 14 like a risk-informed 50.59 to get rid of. 15

I am sure you have run across constraints and said, yes, it exists. It's because of the way people put the words together in the past, and if we had to do it all over again we would never have written the words that way.

I think the risk-informed is essentially a chanceto rewrite the words.

DR. BONACA: Although of course this is, what I want to point out is a tremendous benefit to the industry that finally there is a convergence of agreement. This is like, you know, this game has been played in the field for

40 years and the referees have used rules which are different from ones of the players. That is the fundamental problem, so the players believe that they can do something. They make some motion there and they get bolted for it. They get penalties -- and this is the first time there is an agreement among referees and players on what rules to play, so in and of itself it is tremendous progress, the fact that finally they can speak the same language.

1

2

3

4

5

6

7

8

The reason why I am bringing this up, mostly to know when is this going to be done? When is it going to be finished? I am sure that the industry is pretty anxious to see it done.

13 MS. McKENNA: I'm sure they are. We certainly are 14 too. As I think I indicated, we are working to get these 15 issues that I mentioned that we are still discussing settled 16 in some fashion to be able to put the draft Reg Guide on the 17 street. We're looking I'll say in the April timeframe to do 18 that and have a public comment process, then we resolve and 19 consider the comments and then kind of take it back through, 20 as a final Req Guide, to the Commission for their approval, 21 which would then start the 90-day clock on the rule, so I 22 think we are kind of looking realistically, if we go out, 23 say, in April and public comment ends some time in June, get a package back together, it's probably towards the end of 24 25 the summer before it is back with the Commission and then

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

187 1 however long it takes from that point in time. In the year 2000? DR. BONACA: 2 MS. McKENNA: It will probably be end of the year 3 2000 or early 2001 at our current estimate, yes. 4 5 DR. WALLIS: Are you going to move to the next 6 slide? 7 MR. SIEBER: I'm pretty sure that we have all had an opportunity and have read 96-07. Maybe we could just 8 move through that quickly. 9 DR. WALLIS: I would like to go to the next slide, 10 11 because I a very specific question about the next viewgraph. 12 MR. BELL: I was going to suggest that, you know, 13 some of this does smack as implementation detail of key 14 issues that have been --15 DR. WALLIS: I have a fundamental question, which is not just implementation. 16 17 MS. McKENNA: Let's have your question. MR. SIEBER: We'll put the next slide up and then 18 19 we can --20 DR. WALLIS: Next slide and page 37. This is a question of determining whether or not there is a minimal 21 increase -- the next one -- whether or not there -- minimal 22 23 permeates this whole document. MR. BELL: Yes, that's right. 24 DR. WALLIS: And when I look on page 37, this is 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

how you determine whether or not you have a minimal increase in frequency of occurrence, it says, "Normally the determination of a frequency increase is based upon a qualitative assessment using engineering evaluations, however the plant-specific frequency in PRA may be used."

Now this seems to me to be going the wrong way altogether. It ought to --

DR. SEALE: Backwards.

1

2

3

4

5

6

7

8

20

9 DR. WALLIS: It ought to say normally PRA is the 10 best method of determining whether or not the frequency has 11 been increased within allowable limits. Occasionally it may 12 be possible to make a qualitative assessment which is 13 acceptable.

But to put qualitative assessment as the norm seems to me very strange. You can waffle about it -- that is the norm, the easy way -- who is going to ever want to do the proper assessment involving a PRA?

18 It's backwards. Does the Staff really approve19 this approach?

MS. McKENNA: I'm sorry, go ahead.

DR. SEALE: As a matter of fact, if I were asked to characterize the relationship, I would say that a quantitative document like a PRA to the extent that it is would be associated with frequency. A qualitative assessment would be related to likelihood.

1 DR. WALLIS: It's the same thing. Well, except likelihood is lesser DR. SEALE: 2 3 degree of precision. DR. WALLIS: Qualitative is associated more with •4 5 estimate or quesstimates. DR. SEALE: Yes, right. 6 7 DR. WALLIS: And likelihood has a real meaning, 8 like probability. I am really concerned with putting this 9 back to the sort of wishy-washy language as the primary approach. Qualitatively is sort of to be preferred and 10 surely, if possible, you should use a quantitative method. 11 MR. BELL: Well, you are not misreading the 12 13 intent. The intent is to keep with longstanding practice 14 and the utilities feel this way, too, because they are very comfortable with the way they have done this in the past, to 15 use PRA in a support mode, not as the primary so there are a 16 17 number of considerations of a gualitative nature. DR. WALLIS: Then how do you accept -- I don't 18 19 understand that acceptance criteria for a qualitative 20 assessment. We're very specific here about PRAs and a change of 10 percent and -- I understand those, but 21 qualitative seems to leave it all up to argument and 22 23 personality and persuasiveness. MR. SIEBER: I think it is even worse than that, 24 Dr. Wallis, because the whole idea of going through this was 25

189

to take the zero sum game out of it and to be able to use a quantitative measure so that you could have some leeway above zero change, because the old rule with the three criteria really said no change.

1

2

3

4

5

24

25

MS. McKENNA: Right, may be increased.

MR. SIEBER: You had to get better or zero. You could not tolerate any change, no matter how minimal it was, so this change in the rule was to get us beyond that and we ought to be using that tool.

CHAIRMAN POWERS: Remember, I'm thinking about the 10 old rule, when they said zero they meant really 11 12 indistinguishable from zero and at the time when the resolution was by decades, what happened is we perhaps had 13 fooled ourselves or perhaps because of improved technology, 14 now we don't think that three times 10 to the minus four is 15 16 the same as 10 to the minus five because we have much higher resolution in risk and suddenly what before were so small as 17 18 to be essentially zero change now became pretty substantial changes, actually. 19

They are no longer indistinguishable from zero and the difficulty a lot of people had was that zero to them did mean indistinguishable from zero and these numbers that we have now weren't.

DR. WALLIS: If this were risk-informed then PRA would be the way to go, and then there might be another way,

which would be qualitative. The language sort of puts down PRA, makes it more difficult, favors the qualitative approach and so you are moving away from risk-informed.

MR. BELL: I think -- again, I think that is the intent. I think it is recognized that if we want to make that lead to the more effective tool that the time to do that would be when this rule is risk-informed, as we talked earlier.

9 This is not the risk-informing of 50.59 and so the 10 emphasis on qualitative assessment you still see here.

DR. WALLIS: So why would a utility ever use anything other than qualitative assessment?

DR. APOSTOLAKIS: That has been my problem too. If I were a manager, I would never touch a PRA, especially if they have a comment that Dr. Bonaca brought to my attention, Section 4.3.1 -- "It should be emphasized that PRAs are just one of the tools for evaluating the impact of proposed activities and their use is not required."

19 It used to be just a tool. Now it is just one of 20 the tools. It is a level lower.

[Laughter.]

1

2

3

4

5

6

7

8

21

22 MR. SIEBER: It's equal to intuition. 23 DR. APOSTOLAKIS: I come back to my earlier --24 CHAIRMAN POWERS: Haven't we crossed this debate 25 once before?

MS. McKENNA: I think we have in terms of --CHAIRMAN POWERS: When we said that if we try to go risk-informed now we simply delay a process, that it really is quite important --

> MS. MCKENNA: Yes.

1

2

3

4

5

6

7

8

9

10

11

21

24

CHAIRMAN POWERS: -- urgent I would say, to get some stability in the field on this and although we cannot achieve perhaps the quintessence of perfection, we can get something that is functional, was functional, and will be functional in the future.

This has not been an area of abuse by anyone.

MS. McKENNA: Right, and I think the other point 12 13 is that we have to consider the wide spectrum of changes that a licensee may be making, and some of them are going to 14 be more amenable to a quantitative assessment than others, 15 16 and so I think that there's a lot of those kinds of procedural things or I am doing something --17

18 DR. WALLIS: But then you should say -- excuse me -- if it is amenable to qualitative assessment then it is 19 encouraged that they use it, you know? 20

MS. McKENNA: That may be a fair comment.

DR. WALLIS: There may be some cases where 22 23 qualitative is more appropriate.

DR. APOSTOLAKIS: Which is related to my comment earlier. I mean if there is a frequency for the failure 25

rate in the common PRAs, it seems to me it should be a requirement to look at it. Yes, you can argue qualitatively that it doesn't affect it much, but I just don't see how a reviewer can ignore that. It can't be an option. That makes the document much cleaner than it is now. It is the same thing power uprate. The licensee

1

2

3

4

5

18

25

It is the same thing power uprate. The licensee did not choose to go the risk-informed approach. Five seconds into the presentation Dr. Kress -- "What did that do to the CDF?" The licensee, "We'll tell you what it did. We did it." They had the answer because they knew the question was coming and it will be the same thing here.

12 I mean you can't ignore reality that there are13 PRAs out there.

DR. KRESS: Unless, George, the qualitative assessments have already been looked at and said we know that if we meet those if we look at a typical PRA it's not qoing to affect it much.

MS. McKENNA: Right.

19DR. KRESS: But I don't know that that has been20done but I think in essence that was in the thinking.21DR. APOSTOLAKIS: But it is not in the document.22DR. KRESS: It's not. It's not explicit, that's23right.24DR. APOSTOLAKIS: When I say look at the PRA, that

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

is what I expect 99 percent of the arguments are going to be

1

2

3

5

6

12

15

23

of that nature.

DR. KRESS: Yes.

DR. APOSTOLAKIS: I don't expect that one would do calculations because I know these changes are not really the 4 kinds of changes that you quantify.

MR. BELL: Right.

7 DR. APOSTOLAKIS: But you may argue a little bit, 8 you know, and look at the distribution if there is a distribution. 9

10 CHAIRMAN POWERS: How many PRAs do you know that have distributions? 11

[Laughter.]

DR. APOSTOLAKIS: Well, you see, that's another 13 14 thing.

> CHAIRMAN POWERS: I didn't expect an answer.

16 DR. BONACA: One comment we made in our review, 17 which relates to this point is that so many of the decision 18 points on probabilities are hard-wired on defense-in-depth 19 concepts.

20 For example, if you change something which affects 21 the diversity, it's by definition an increase in probability of a malfunction. 22

MS. McKENNA: Right.

24 Therefore, you have that process DR. BONACA: that, you know, almost pushes by definition the use of 25

judgment rather than PRA and it is all over the place.

1

2

3

4

5

6

7

I mean in my experience, and I have seen literally thousands of safety evaluations -- literally -- most of these judgments are based on that kind of cause, and most of them are hard-wired to criteria that you have in the general design criteria or somewhere else that tells you, yes, this is an increasing probability whether it is or not.

8 The other thing is I think the founding fathers 9 when they wrote 50.59 were thinking really about the fact 10 that you put accidents into four different categories, and I 11 believe still today that all they were worried about was 12 that an increasing probability that shifted an accident from 13 one category to the next, because you have different 14 expectations for that.

Then with time we have taken probability to mean any increase in probability and that is how we go into this bind, but again, I mean, you know, the engineering judgment, it is so entrenched into the use of 50.59 that it will be a big shift to go to a frequency category -- PRA.

DR. WALLIS: You mentioned the term frequency category? What is a frequency category? I don't understand that.

CHAIRMAN POWERS: Page 46.
MS. MCKENNA: There you go.
CHAIRMAN POWERS: At the time of the original

50.59 there was a categorization of accidents in which they 1 did talk about risk. They did talk about accident 2 frequencies, but the frequencies were basically, if my 3 memory serves me, expected at a facility every year, 4 5 expected in the lifetime of the facility, unlikely to occur, in the lifetime of the facility, and extremely unlikely to 6 occur -- and they basically corresponded to something 7 between a frequency of one in 100, between 10 to the three 8 and 10 to the four, and between 10 to the five and 10 to the 9 sixth. 10

DR. BONACA: And then for each of them you had different acceptance criteria.

MS. McKENNA: Correct, yes.

13

25

DR. BONACA: You could not have fuel failures if 14 there were highly probable or expected during the life, or 15 you could have some fuel damage if they were infrequent and 16 you could have specifically, you know, for LOCA you could 17 have some amount of fuel damage, so they were important for 18 a reason. You didn't want to shift because you had 19 different expectations of the frequencies, but again the 20 judgment was so vaque that judgment was sufficient for that 21 22 perspective.

23 MR. SIEBER: Let me ask a question just to make 24 sure I understand.

When the rulemaking for 50.59 was initiated, was

it intended to make the new 50.59 risk-informed? 1 MR. BARTON: No. 2 3 DR. APOSTOLAKIS: It was explicitly stated no. MR. SIEBER: Okay, and therefore the guidance 4 5 probably shouldn't be risk-informed either, right? 6 MS. MCKENNA: I think the quidance can't be more 7 risk-informed than the rule is is the way I would characterize it.e 8 9 MR. SIEBER: The question is when you set about to 10 risk-inform Part 50, all of the Part 50, will 50.59 be included in that? 11 MS. McKENNA: It is one of the rules that is under 12 consideration. I don't know -- I wasn't that involved in 13 14 the specifics of how it might be done. 15 MR. SIEBER: So today the issue of whether this is risk-informed or not risk-informed or tends toward 16 deterministic and qualitative as opposed to quantitative is 17 consistent with the intention that the rule was formulated 18 19 in the first place? 20 DR. WALLIS: I find that entirely incongruous 21 though, that at a time when we are trying to move toward 22 risk-informed regulation and this is the propaganda, that 23 there is a conscious effort to go away from it in this 24 particular change. 25 DR. APOSTOLAKIS: The rule has been approved ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036

(202) 842-0034

though.

1

2

3

4

23

DR. WALLIS: I know, it's all right.

DR. APOSTOLAKIS: This is just the Regulatory Guide.

5 CHAIRMAN POWERS: I mean the decision was made 6 consciously that there was such a step going to have to be 7 made to go to a risk-informed 50.59 and not the least was 8 the concern that a standardization of PRA techniques would 9 have to be in place, that it would cause an unwarranted 10 delay in the process and so this is viewed as an interim 11 measure, and I think that was not a bad decision.

I think we did not anticipate it would take this much to get where we are now, but that is probably because we did not recognize how pervasive the use of the 50.59 process is, even though we all said it was pervasive, nor did we understand how intertwined the language is with itself in the process and so you have to be very careful about things.

DR. APOSTOLAKIS: In many respects though -- first of all, this is not risk-informed. The fact that you are just referring to frequencies of malfunctions doesn't make it risk-informed.

MS. McKENNA: Right.

24 DR. APOSTOLAKIS: Okay. We are not using any risk 25 insights, but I think the use of this is very similar, the

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

issue that is being raised is very similar to this two-tier 1 system that I mentioned earlier. 2 The fact that there is a PRA out there forces you 3 to do certain things regardless of the regulatory system. 4 In this particular instance the fact that there 5 6 are distributions for the failure rates for certain 7 equipment is a fact of life and you can't -- what if the reviewer says I would like -- it's boring -- for this pump I 8 - 9 have --CHAIRMAN POWERS: George, let's make very clear 10 who the reviewer is in this case. 11 DR. APOSTOLAKIS: Whoever goes to inspect the 12 records. 13 CHAIRMAN POWERS: This is something that occurs on 14 15 a perhaps annual basis. DR. APOSTOLAKIS: So the probability of having 16 this is low, you are saying? 17 CHAIRMAN POWERS: It happens once in awhile. 18 Ι 19 mean it does happen once in awhile. 20 MS. McKENNA: You are talking about the inspection? 21 CHAIRMAN POWERS: I mean a 50.59 determination is 22 not trotted in to the NRC Staff and they say here is what we 23 did, did we do it right? That is not done. A review is 24 done at the plant. 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036

(202) 842-0034

200 MR. BARTON: An annual review of safety 1 2 evaluations might pick one of these things up. DR. APOSTOLAKIS: So the PSA group at the plant 3 may not raise this question, you don't think? 4 MR. SIEBER: You probably will do three or four or 5 five of these a day. I mean you do them. That's the way of 6 7 life. DR. BONACA: You probably have 1000 or hundred per 8 plant and they have maybe three, four thousand issues they 9 10 are screened for. 11 CHAIRMAN POWERS: That's right. 12 MR. GILLESPIE: Right. That is not to say they do not 13 CHAIRMAN POWERS: 14 get reviewed. When you do one, it gets reviewed at the 15 plant. MR. SIEBER: It is at the plant that it gets 16 17 reviewed. 18 DR. WALLIS: It's a management decision when the 19 PSA group comes up and says actually we have an increase which is more than 10 percent, and yet the qualitative 20 21 determination people say it's fine. DR. APOSTOLAKIS: And I will tell you something 22 In Section 4.3.1, the sentence I read before, it 23 else. really should be deleted because PRA is not a tool for 24 evaluating the impact of proposed activities. We just 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036

(202) 842-0034

agreed that this is not risk-informed. It's a gratuitous statement.

1

2

3

4

5

6

7

8

9

10

MS. MCKENNA: The point was that when you are looking at, the licensee is looking at the change and trying to decide whether that is a good change to make or what are the ramifications of the change that it may be helpful to them to understand exactly what you were talking about and does it change their PRA in any sense, but that is I think the intent.

DR. APOSTOLAKIS: It doesn't make sense --

DR. BONACA: Well, let me just say, it allows at 11 12 least for it to be considered. We get to the point where we used to use PRA to make, disclose a probability, and every 13 time we did, we got in trouble, because if you make a 14 qualitative call there's no problem. No one questions it. 15 If you have a quantitative evaluation, everybody questions 16 it and then there is very much insight -- are you affecting 17 a defense-in-depth issue? 18

DR. APOSTOLAKIS: But I am not allowed to argue on the basis of risk insights. If I go to the criteria later, it says deleting or modifying system protection features or equipment protection features. Can I come back and say, yes, I deleted these protection features, but look, this component has a risk importance of 10 to the minus 100? I am not allowed to say that.

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

1 What I have to do is argue that the probability of malfunction of this component regardless of how important it 2 is negligible -- is minimal, so there is no PRA at all. 3 Just because you use a failure rate, you can't say -- so it 4 seems to me that PRAs are not in fact invited to participate 5 6 in this, so why -- I mean that's a fact. All the criteria 7 you have later have nothing to do with risk insight. 8 CHAIRMAN POWERS: I think the discussion has gone to the minutiae here. Can we progress ahead? 9 10 MR. BELL: And I suggest I give it back to Eileen. 11 MS. McKENNA: Yes, we are running short on time. Yes, go ahead. 12 I have one specific question 13 DR. BONACA: 14 regarding something we communicated to the Staff and it has been misinterpreted. 15 16 MS. McKENNA: Okay. 17 DR. BONACA: And that is on the second slide from 18 NEI regarding fission product barriers exceeded or altered 19 and I believe that the ACRS for the specific case made an 20 example that you have a design change. The design limit hasn't been changed. 21 22 MS. McKENNA: Right. 23 DR. BONACA: What you have done, you have 24 diminished the capability of the barrier because you have 25 put ruptured disk right above the design limit, and so you ANN RILEY & ASSOCIATES, LTD.

Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034 can -- in fact, it can alter the capability of the barrier without affecting its design limit from inside pressure, and here the guideline uses the word "altered" in a different sense. It doesn't address that and I just wanted to point that out. It has defined a new definition, which is interesting -- because we wrote it down and the word was taken and it was altered. The word "altered" was altered.

[Laughter.]

1

2

3

4

5

6

7

8

9 DR. BONACA: I don't think it is a major issue, 10 just simply that a point that we made we think has some 11 merit because at the design level you must still have a clad 12 that you design to have a certain capability of withstanding 13 internal pressures, but you may decide to have it do certain 14 things and you are essentially reducing the margin that you 15 have in the barrier.

I mean all I am talking about is the margin. I don't think that the margin should be reduced in any way or form without NRC review.

MR. SIEBER: Well, you know the example that it gave, which is corrosion of a containment liner, you know the 50.59 screening would say that has to be reviewed by the Commission, okay, because now you have basically lowered the design strength and the capability and we know about cladding. They change cladding from one form of zircaloy to another throughout the years and every one of those you had

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

to go back and get a license amendment for it, so neither one of those -- all those cases would screen through 50.59, either the old rule or the new rule, to go to the Commission and get a license amendment.

5 DR. BONACA: And the word "alter" really meant to 6 control that capability of barriers, realizing that for 7 example in containment we are counting on 130 psi rate 8 because although it is not in the design basis, we have by 9 now taken credit for it in severe accident and we like to 10 have that margin, and so, you know, this in the guideline 11 has really misinterpreted what we meant.

MS. McKENNA: Okay.

1

2

3

4

12

MR. SIEBER: What I would like to do, we are past our normal time, but I would like to get an opportunity to look at what are the outstanding items right now.

16 MS. McKENNA: Okay. I did have it in the packet 17 and I think we have touched on a number of these through the 18 discussion.

The first one, in a way it is similar to some of the discussion on maintenance, where the question of changes to fire protection programs, which are programs that are in the FSAR or referenced in the FSAR, and the proposal was that most plants have this license condition and the proposal is evaluate against the license condition, not against 50.59.

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

This is again one of these where the question of whether there is truly complete overlap versus there is a partial overlap is what we are looking at. I think our view is that it is not a complete overlap between what the license condition provides and 50.59, but that is one of those kind of regulatory process questions as well.

MR. SIEBER: Okay. You are worried more about the records and the bases upon which you would do it rather than 8 9 the fact that it is being reviewed properly or not, right?

10 MS. McKENNA: Well, I mean, yes, kind of what is 11 the -- because the license condition says you can make 12 changes as long as you don't adversely affect the capability of safe shutdown. 13

14 MR. SIEBER: So there is no record of it other 15 than the change itself.

16 MS. McKENNA: Right. There is no requirement for 17 that record and I think 50.59 would say if you are making a 18 change to the FSAR, keep records and explain why it is okay 19 and keep the records and all that kind of stuff, so there 20 are issues with that.

21

1

2

3

4

5

6

7

MR. SIEBER: Okay.

22 MS. McKENNA: I think I have mentioned already the 23 question on methods. The second one is kind of the 24 plant-specific versus the generic. The first one is just in terms of how if you are looking at changes to pieces of the 25

1 method and one of the other things is that as long as your 2 answers come out about the same, you haven't really changed 3 anything, but again just kind of one of the things we are 4 looking at is it's not necessarily did your peak number come 5 out the same, but that you have kind of the same shape and 6 response, and that is one of the clarifications I think we 7 are looking to make with the guidance.

One of the issues that we are looking at is whether for instance for fuel one of the things that is in there, typically we look at something like a DNBR as to how you would judge your performance of the fuel and what was proposed in there as the design basis limit was basically the 95/95 confidence level.

14 I think the Staff's view is that it should be the 15 particular value for that fuel that is the limit, not the confidence level. We didn't really get into the screening 16 17 question. You may have seen in the document some discussion 18 about screening with respect to whether you are affecting 19 functions. We are looking at this and part of that, there 20 is some quidance definition, if you will, of what is meant 21 by design functions, and we are looking at that as to 22 whether is sufficiently comprehensive at the screening level 23 to make sure that changes move forward for evaluation.

MR. SIEBER: Could we go back to the third bullet there?

24

25

MS. McKENNA: Yes. 1 2 MR. SIEBER: Why isn't the Staff comfortable with the 95/95 DNB? 3 MS. McKENNA: I think I would have to call on one 4 5 of our reactor systems staff who I think we have in the audience to -- Chris, do you feel comfortable answering 6 that? Would you come to the mike? 7 MR. SIEBER: Go to the microphone, please. 8 MR. JACKSON: I am a little bit uncomfortable 9 10 here. The limit for fission product departure from 11 nucleate boiling is the ratio at which you would lose 12 13 confidence so that you might experience a department from nucleate boiling. The 95/95 is the acceptance criteria. 14 That is just 95 percent probability with 95 percent 15 confidence, so we would see that as the confidence bounds of 16 17 the acceptance criteria for whatever limit you came up with, 18 so that is the only --So you are satisfied with that or 19 MR. SIEBER: 20 not? You want a specific number? 21 MR. JACKSON: I want the value, the ratio. 22 MR. SIEBER: That would just give you more information -- how confident you are that that number is a 23 24 qood number? 25 MR. JACKSON: The value that they come up with ! ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

1

2

19

20

21

22

23

would be NRC reviewed and approved.

MR. SIEBER: Right.

MR. JACKSON: And they would demonstrate through analysis that they have achieved the 95/95, but the limit is the ratio -- is the critical heat flux. I mean that is the value that they would use to calculate at the plant.

MS. McKENNA: That is Chris Jackson, Reactor8 Systems Branch.

9 We have just one more slide, just a couple more, 10 actually I think the other slide, we talked the numerical 11 values. I think in general we are comfortable, with some 12 clarifications we were interested in. I think the committee 13 indicated some clarifications that we might want to consider 14 with respect to the numerical values that we see in there.

The last one was this maintenance rule assessment If I think that we have already talked about, so those are the areas where we still have some questions and we will be sending that letter in the very near future.

MR. SIEBER: Okay. Let me ask a final question.

Does either the Staff or NEI feel that any one of these issues is unresolvable in a reasonable amount of time? MS. McKENNA: No.

MR. BELL: No.

MS. McKENNA: As I said, I think the nature of the resolution may vary. NEI may agree to make some

adjustments. We may agree that we are just going to 1 disagree and we'll take exception to certain things but I 2 think we can resolve them. It's just what kind of 3 resolution we come to on the particular issues we are 4 5 dealing with. MR. SIEBER: Thank you. Does anybody else have 6 any questions that they would like to ask at this time? 7 DR. SEALE: When is this industry workshop that 8 you are going to have? 9 10 MR. BELL: April 10th and 11th, the Clearwater Beach Hilton, Florida, good place. 11 12 MR. SIEBER: Any other questions? 13 [No response.] If there are no other questions, Mr. 14 MR. SIEBER: 15 Chairman, I return the meeting to you. Thank you, John. I think we 16 CHAIRMAN POWERS: need to struggle internally to come up with a strategy on 17 this, to minimize any impediments the Staff has in moving 18 19 I will articulate my own feelings here that we forward. have a low level of value added at this point of getting to 20 21 the implementation. 22 I think our time might be better spent on discussing the generation going to risk-inform 50.59 rather 23 than rehashing old issues, but I certainly think we need to 24 25 discuss it with the committee and get information back to ANN RILEY & ASSOCIATES, LTD.

Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

210 the Staff as quickly as possible, so they can set their own 1 2 schedules in this regard. With that, Chairman's privilege, I will recess us 3 till five of. 4 [Recess.] 5 CHAIRMAN POWERS: Let's come back to into session. 6 7 Our final presentation today deals with a topic that can't possibly have any controversy associated with it. 8 9 [Laughter.] 10 CHAIRMAN POWERS: And I am sure the presentation 11 will go very smoothly since there will probably not be a 12 single question. Most of the questions we find have 13 procreated dramatically. 14 Dr. Kress, I think you are going to lead us 15 through this discussion? 16 DR. KRESS: I don't know if that is the proper 17 words or not. 18 CHAIRMAN POWERS: Maybe introduce it. 19 Introduce it maybe -- yes. DR. KRESS: This is 20 the session on proposed and potential revisions to the Commission's Safety Goal Policy Statement. 21 22 As you know, we have had meetings on this before 23 and the Staff has told us, at least identified the issues 24 they are looking at that might be part of a revised policy 25 statement. At this point I think we are going to get a kind ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014

> Washington, D.C. 20036 (202) 842-0034

of status report on where they stand on, what sort of position they are going to take on these various -- I think there was about eight -- issues that they are looking at and we commented before we thought these were a comprehensive set of issues and the right things to look at and see whether or not they ought to be in the policy statement.

1

2

3

4

5

6

7 I think today we are going to hear what the Staff
8 about each of these and with that, George, you have anything
9 you want to say before we get started?

I would like you guys to listen carefully on the Staff's positions on each of these issues, and then see what you think because we will be writing a letter, probably not this time, but at least at the next meeting, the March meeting, so with that I will turn the floor over to I guess Joe Murphy or -- Joe? Okay.

MR. MURPHY: Thank you, Mr. Chairman. As you said, we have discussed this subject with the committee on several occasions over the last several years. I would like to back up in the history a little bit more than is indicated on the slide and just remind you that the policy statement itself was issued by the Commission in 1986.

There was a very important Staff Requirements Memorandum that was issued June 15, 1990, which I will reference, that I think explains the policy statement significantly, and one of the things we are doing is trying

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

to incorporate some of the messages from that SRM into the policy statement.

1

2

25

Finally, I want to point out that the Commission 3 4 in its initial SRM that authorizes us to go forward with 5 considering this in the SRM on SECY 98-101 stated that the 6 safety goal should remain a high level document describing 7 the principles consistent with the Commission's views on how safe is safe enough, and then told us the Staff should be 8 mindful not to include too many quantitative guidelines 9 10 which would make it overly prescriptive. I think that quidance is important. 11

12 With that, I will go to what I have up here. In 13 SECY 99-191 we informed the Commission of the progress in 14 developing recommendations and we made a recommendation for a study of the feasibility of overarching safety principles. 15 16 As you are aware the related SRM told us to proceed with the 17 recommendation to modify the policy statement but 18 disapproved the study of the feasibility of the overarching 19 safety principles and of course that is reflected in this 20 presentation.

I know that time is short, but I would like to run through just briefly the relationship between the safety goals and the regulations so you can see where this fits in the whole picture.

Basically the regulations establish the

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

requirements that enable us to do our job. The policy statements provide a high level expression of the safety philosophy of the Commission and the expectations of the Agency.

1

2

3

4

5

6

DR. KRESS: How does that influence what you do in the --

7 MR. MURPHY: Well, I'll give you an example. 8 After the Safety Goal Policy Statement was issued in '86 or as it was being issued, being developed, we issued the 9 regulatory analysis guidelines, the thoughts in terms of 10 11 what is acceptable and what isn't in terms of limits on core damage frequency and large early release and this sort of 12 thing, translated into the regulatory analysis guidelines 13 14 which gave us an indication of how far we should go in looking for regulations. 15

DR. KRESS: Do you think now -- that was one area where it did influence it, and I'll agree, it was a big influence. Do you think now in -- I'll call it the era of risk-informed regulation the Safety Goal Policy Statement would influence the direction that would go in?

MR. MURPHY: I think if we -- yes and no, and the reason it's such an answer is right now a lot of what is going on in risk-informing Part 50 draws on the principle of Reg Guide 1.174. One of the things I am talking about is taking much of what is in that document, which is addressed

towards changes in licensing design basis, and is in the form of a Regulatory Guide, and putting it up into a Commission policy statement.

1

2

3

24

25

Once that information is in the policy statement, yes, then the policy statement will affect what is going on. Right now this is going on in parallel. We are bringing the Safety Goal Policy Statement up to the current practice at the same time we are going forward in other areas.

DR. KRESS: Would you proceed to risk inform the regulations in the same way, even whether or not the policy on safety goal policy was changed or not? Is it necessary to have a policy statement?

MR. MURPHY: It's not necessary to have a policy
statement. The policy statement does provide better
guidance to the Staff in terms of high level philosophical
guidance.

DR. KRESS: The reason I am asking those questions, I have some very distinct opinions on things that are needed, that are policy-like things to properly risk inform the regulations. I just don't know whether they need to be in the policy statement or not or whether you could proceed with them, as long as they are not too inconsistent with the statement as it now exists.

MR. MURPHY: I think the policy statement should remain a high level document, so it covers basic philosophy,

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

if you will, of safety, as opposed to getting into great specifics.

1

2

3

4

5

6

7

8

9

A lot of the things that take the guidance the Commission has given in the statement and put it into regulation, there has to be a lot of flexibility in doing that, and I think that is what the Commission meant when they gave us the warning that we had --

> DR. KRESS: About not being too quantitative? MR. MURPHY: Yes.

DR. WALLIS: Well, Joe, the policy statement could serve the role of sort of a constitution to which you appeal when you have to make a decision and it is difficult to decide which way to go on some regulatory matters and you go back and appeal to certain items in the policy statement in order to make a rational decision based upon some larger principle or assertion.

I haven't seen that happen. The Safety Goal Policy Statement seems to be out here somewhere, where we are always down in the details and very rarely does anyone say we can resolve our controversy by appealing to the policy statement.

22DR. KRESS: Tom has a point, Tom King from the23Staff.

24 MR. KING: That is not totally true. When we put 25 together 1.174 we went back to the policy statement to find

the words that were in there about assessing total risk, about using mean values, about defense-in-depth, treatment of uncertainties. We went back and used the policy statement and I think as we go forward in risk-informing Part 50 we may come back there again and see what does it say about certain issues, so it has been useful.

7 DR. WALLIS: 1.174 is often cited as being a successful story and I am glad to see it's done that here, 9 but it doesn't seem to happen in other contexts very much.

MR. HOLAHAN: This is Gary Holahan of the Staff.

11 I would use a little bit different analogy. It 12 seems to me the safety goals are more like the Declaration 13 of Independence, which is an expression of desires and 14 expectations but in fact has no legal status at all, and I 15 think that is what the safety goal is. It is not the Atomic 16 Energy Act. It is not the regulations. But it gives you 17 some idea about what you are trying to achieve.

18 DR. WALLIS: Well, the Declaration of Independence 19 was an excuse for performing an illegal act at the time. 20 [Laughter.]

21 MR. HOLAHAN: I believe that matter has been 22 settled.

[Laughter.]

1

¹2

3

4

5

6

18

10

23

24 DR. SEALE: Somehow I knew that was going to come 25 up.

MR. MURPHY: The point I wanted to make, I think, Gary said very well, and that was the safety goal is not a legal requirement but they are guidance for the Staff as to ÷3 how to develop regulations. 4

1

2

As to the Safety Goal Policy Statement being used 5 6 in all our regulations, it would clearly not because many of 7 them, most of them were developed before the policy 8 statement.

Has it influenced those that have been developed 9 10 since the policy statement was issued? It has through the 11 regulatory analysis guidelines primarily. One of the reasons for putting everything in one place is to have this 12 high level guidance for when we go forward with 13 14 risk-informing the rest of the regulations and have it in a place that expresses Commission policy, perhaps in a more 15 logical way or more visible way than buried in a Regulatory 16 17 Guide, but we have the Regulatory Guide. We are going forward. 18

19 This is not stopping our progress in going 20 forward, so it is both.

21 In terms of the changes to reflect current policy, 22 I have already talked about some of these. The five principles in Reg Guide 1.174 give us the principles for 23 integrated risk-informed decision-making. We think they 24 25 should be generalized, and I will show you those in a

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

218 minute, to reflect the broader usage, rather than just for 1 2 design basis changes. And put into the implementation of the policy 3 4 statement --DR. WALLIS: Let me ask you something: Are these :5 goals being met today? Is there a measure of how well the 6 7 safety goals are met today? MR. MURPHY: We have been -- the policy statement, 8 as it applies right now, applies to the industry as a whole, 9 10 rather than individual plants. We have results of all the IPEs, which we can 11 12 compare against at least the subsidiary on core damage frequency. Some meet it; some are a little bit above it, 13 based on the analyses that were done some time ago. 14 DR. WALLIS: But understand --15 MR. MURPHY: But understand that the purpose of 16 the goal -- and it is an important message out of the 1990 17 18 SRM -- that is, the goal is something you strive to meet. Yes, but then --19 DR. WALLIS: MR. MURPHY: In striving to meet it, you use 20 21 cost/benefit analysis. DR. WALLIS: But it is the primary statement about 22 how safe is safe enough. Then you ought to have an 23 unequivocal answer as to how well are we doing on this 24 25 measure. ANN RILEY & ASSOCIATES, LTD.

Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034 MR. KING: This is Tom King again. After the safety goal implementing guidance came out in the early 90s, there was a request from the Commission for the staff to go assess how well plants stack up against the safety goals.

1

2

3

4

5 To do that right required not only risk assessment 6 at full power, but at shutdown and external events, maybe 7 not for every plant, but certainly representative of the 8 types of plants that are out there.

9 And we put together the price tag of doing that.
10 It never made it through the budget process to really get
11 funded.

12 So the best we have now is, we took the IPE 13 results. As Joe said, there is a section in the IPE 14 insights report on -- I forget the official title, but it is 15 basically a comparison against safety goals.

And it takes the CDF measures that were reported in all the IPEs, and it tries to, based upon NUREG 1150 results, extrapolate those to what they mean in terms of the QHOS.

And it says basically that given that information, most of the plants meet the safety goals. There are probably a dozen or so that you could argue are questionable, but we didn't carry it any further to do any specific calculations to say definitely yes or no for that dozen or so.

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

	220
1	And that's about as far as we've gone so far.
2	DR. KRESS: Clearly, the NUREG 1150 plants meet
3	it.
4	MR. KING: Yes.
5	DR. KRESS: But they're not
6	MR. KING: Again, that NUREG 1150 analysis is
7	limited, too. It's not a shutdown risk.
^{.:} 8	DR. SHACK: Again, though, if this is a statement
9	of how safe is safe enough, how does this jibe with the
10	expectation you have for the new reactors, where, for
11	example, the core damage frequency would be a factor much,
12	much lower?
13	DR. KRESS: Ten lower, a factor of ten lower.
14	DR. SHACK: Well, I guess that was the
15	expectation. I'm not even sure that if you walked in with a
16	10 ⁽⁻⁵⁾ that you would have been told to go back and look at
17	that again.
18	MR. KING: That question was put before the
19	Commission back in 1990 when we proposed implementing
20	guidance for the safety goals.
21 S	And the question was, should future plants have a
22	10 ⁽⁻⁵⁾ th CDF versus current plants' 10 ⁽⁻⁴⁾ th. The Commission
23	said no; 10 ⁽⁻⁴⁾ th for everybody.
24	And even though advanced plant designers are
25	coming in, EPRI, through their utility requirements
2	ANN RILEY & ASSOCIATES, LTD.
	Court Reporters 1025 Connecticut Avenue, NW, Suite 1014
	Washington, D.C. 20036 (202) 842-0034

Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

document, the ALWRs having their own goals that exceed what 1 the safety goals put forth, that's not a requirement. 2 Isn't there an expectation statement, 3 DR. SHACK: though? 4 5 MR. KING: Yes, there is an advanced reactor 6 policy statement that was issued back in '86 also that said 7 we, the Commission, expects future plants to do better. 8 But they didn't say what "do better" means. They 9 just said, we expect you to do better. 10 DR. SHACK: So, although they're safe enough, you expect them to be a factor of ten safety? 11 12 MR. KING: They didn't say a factor of ten; they 13 said, you know, consider passive safety features, and, you 14 know, others. Less reliance on human actions and other things that would improve safety, but they didn't say a 15 factor of ten. 16 MR. HOLAHAN: But I think in implementing that 17 18 later on in the process, a factor of ten was, in fact, used 19 as a way of judging whether those expectations were being 20 met. 21 DR. WALLIS: I have a problem as a member of the 22 public, understanding why safety enough is something you 23 strive for. I would think that safe enough is the minimal standard, and more safe than safe enough --24 DR. KRESS: Well, safe enough has Joe's qualifying 25

221

phrase on the end of it; safe enough in the sense that to 1 get there, you have to use cost/benefit. 2 3 MR. MURPHY: Yes. That's a qualifier. DR. KRESS: 4 MR. MURPHY: Perhaps in terms of this, later on in 5 6 the discussion, there is a discussion of the structure of 7 the safety goals that derives from comments that the Committee made. 8 They deal with the question of a three-region 9 approach that has an area where you -- the risk is too high 10 11 and you must do something; an area where you employ 12 cost/benefit to decide whether you do something; and then an area where you have reached the level low enough where the 13 14 risk is low enough, and you would not enforce any more requirements. 15 I'll get to that in a minute. 16 17 DR. APOSTOLAKIS: But let me understand this, We apply now, cost/benefit analysis, even to plants 18 though. 19 that have a core damage frequency and LERF below the goal; 20 is that true? MR. MURPHY: We apply cost/benefit analysis most 21 times in terms of the more generic things, in terms of doing 22 rulemaking. In terms of plant-specific backfits, I have to 23 24 ask Gary, but I don't believe we've had many in the last few 25 years that have been justified on the basis of the backfit ANN RILEY & ASSOCIATES, LTD.

222

Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

223 1 rule and the cost/benefit analysis. MR. HOLAHAN: Well, we have not had many, and I 2 think that the judgment about how to do it wouldn't be based 3 on whether they were above or below $10^{(-4)}$. 4 DR. APOSTOLAKIS: My point then is that it's 5 6 really -- I mean, when you say it's safe enough, that means 7 something specific here. It's not safe enough so that the 8 regulatory agency does not concern itself with this plant .9 anymore. 10 MR. HOLAHAN: No. 11 DR. APOSTOLAKIS: Because in the three-region 12 approach, the way the British have published it, it's show 13 the bottom region -- my understanding is they would not even 14 consider cost/benefit analysis. It's so low that we would 15 just leave it alone. Cost/benefit is between -- in the middle region. 16 17 So if something is safe enough, why would you do 18 cost/benefit analysis? 19 DR. SHACK: I don't think you would here. 20 MR. MURPHY: No, you wouldn't. Let me --21 remember, these things are structured more --22 DR. APOSTOLAKIS: Even generically, though. This always comes back to the issue of plant-specific goals. 23 24 MR. MURPHY: Now, the structure that was mentioned 25 is very similar to what's in the backfit rule. Backfit

requires the necessary to achieve adequate protection. 1 2 Backfits are allowed if there is a substantial 3 increase in the overall protection, and the costs are 4 justified by the degree of protection afforded. 5 And then finally, backfits are not allowed if they can't pass the backfit rule. The backfit rule essentially 6 7 establishes the three-region area. 8 The safety goals help us define the bottom line. DR. APOSTOLAKIS: What would the safety goals be 9 10 in that? 11 MR. MURPHY: The safety goals are here. 12 DR. APOSTOLAKIS: There? 13 MR. MURPHY: At the bottom, yes. 14 The safety goals are lower in adequate DR. KRESS: protection and that defines your three regions. 15 16 MR. MURPHY: You have an area of adequate 17 protection. Between, underneath that, we must comply with. 18 Below that, you have an area in which the backfit rule 19 controls and you do it if it's cost/beneficial. 20 DR. APOSTOLAKIS: But right now, we really have 21 not specified the boundary between the first and second 22 regions? 23 MR. MURPHY: No. MR. HOLAHAN: Let's also be careful. The 24 25 Commission has not defined that adequate protection equals ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

some numerical value. 1 2 DR. APOSTOLAKIS: Yes, I agree, I agree. 3 MR. HOLAHAN: So it's hard to --:4 DR. APOSTOLAKIS: My thesis is that the safety 5 goals, as they are interpreted today, would not define any 6 of the boundaries. But they are not defined in any 7 boundary. 8 DR. WALLIS: That's the problem I have. When you 9 talk about -- when it says the risk to the population should 10 not exceed .1 percent or something, that's a pretty clear 11 thing, and it says should not exceed. It's a clear one 12 boundary. It's not two regions, three regions; it's one 13 criterion. 14 And you should be above it. I mean, you should 15 not cross this threshold. It's not a goal to be aimed at; 16 to me, it's a statement of acceptability. 17 DR. KRESS: It doesn't say "must not." DR. WALLIS: It's equivocation to say that it's 18 19 not. 20 DR. APOSTOLAKIS: But that boundary, though, is 21 not there. That's another point. It is not there at all. 22 DR. WALLIS: Well, that's what I have a problem 23 with. When you say here's this fundamental statement of 24 philosophy, but it really doesn't matter, because we 25 interpret it some other way. ANN RILEY & ASSOCIATES, LTD.

225

Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034 MR. MURPHY: I think the way you interpret it at the bottom boundary is -- the way decisions are made is in terms of the rules. The backfit rule was developed using the safety goal as the basis for establishing where the breakpoint was cost/benefit analysis.

1

2

3

4

5

8

And to that extent, the safety goal has affectedthat bottom line.

DR. APOSTOLAKIS: How has it affected that?

9 MR. MURPHY: In the developing of a 2,000 per person rem and how the whole thing was put together. 10 There 11 is in the regulatory analysis guidelines, there is a plot, a 12 graph, a matrix, that shows you the relationship between core damage frequency and large early release frequency that 13 gives you an indication of whether or not there is a 14 substantial increase in safety involved in what you're 15 proposing, one of the requirements of the backfit rule. 16

17 So it enters in through that mechanism of getting 18 into it. The safety goals themselves are not part of the 19 regulations, but it focuses in on that bottom area.

Now, in the top area, I think there is a -- I'm losing my viewgraphs here -- a very good statement that came out of the SECY 99-246. And that was that risk estimates are important, but they're not the whole body of things that are considered as you get into this question of whether or not there's reasonable assurance of adequate protection.

DR. KRESS: Let me ask you a question about that, Joe. I agree with you on the statement.

1

2

3

4

5

But we have in 1.174, a line that represents the upper boundary and that if the lower boundary is the safety goal, you have a line that represents the upper boundary.

Is it inconceivable to think that that upper
boundary line could not be incorporated into an enhanced
definition of adequate protection that includes all these
things also? Is that beyond the pale?

MR. MURPHY: No, and I think, as you know, we had proposed looking for such a thing in the overarching safety . 12 principles.

And the Commission's guidance came back and said it's premature at this time. You need to get more experience with what you are doing.

And the way I interpreted their SRM, without reading it literally, you need to get more experience, and you --

DR. KRESS: But your point assumes that there is a three-region concept that ought to be policy, and there is some line up there that we're searching for, and whatever the value ought to be, whether it's the 1.174 value or not, it seems to me like it would be appropriate to incorporate that as an addition to the definition of adequate protection, not the sole definition, but in addition to it.

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

1 MR. MURPHY: Yes. See, I think what we can say is 2 that that structure -- we have a structure similar to what 3 the Committee talked about. We have that already in the 4 backfit rule.

We need to include the position, and perhaps we need to word it a little differently. Assume the 6/15/90 that basically says the safety goal is to find the bottom demarkation line between cost/benefit space and no change necessary.

10

DR. KRESS: I think we agree on that.

MR. MURPHY: And then finally is to take what the guidance is that we have from the Commission. As we get more experience, it may well be appropriate to consider the degree to which we can use risk analyses and defense-in-depth to better -- to provide a better definition of the upper limits.

And whether you want to call that upper limit adequate protection, or you want to say adequate protection is broader than this upper limit, but we can define the upper limit in a different way, which is --

21 DR. KRESS: I would certainly say something 22 broader that includes that.

23 MR. MURPHY: I think I would agree with that. I 24 think the Commission has given guidance to get more 25 experience with what we're doing, and to then come back and

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

1 try to do that. DR. KRESS: Do you might say eventually you might 2 3 get there, but you're just not ready yet? 4 MR. MURPHY: Yes, I think that was the direction 5 we have --6 DR. KRESS: You need to define that upper limit. 7 MR. MURPHY: At this point --8 DR. KRESS: But how can you -- the question I 9 would have is, how can you proceed to mis-conform the 10 regulations without that upper limit unless you use some ad 11 hoc value, which I am presuming is going to be 1.174, 12 because that's the only thing that's around right now. 13 DR. APOSTOLAKIS: Why are you using 1.174? DR. KRESS: That's 10⁽⁻³⁾, basically, CDF, and then 14 a LERF of $10^{(-4)}$, I think. 15 DR. APOSTOLAKIS: That's --16 17 DR. KRESS: I think the line is drawn on one of 18 your charts; isn't it? 19 MR. HOLAHAN: No. 20 DR. APOSTOLAKIS: There is not. 21 DR. KRESS: There ought to be a line at --22 MR. MURPHY: The line on the charts are 1.174. 23 DR. WALLIS: If I remember correctly, it doesn't 24 go any further than that. 25 DR. KRESS: I thought that was a line. It was ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036

(202) 842-0034

1

just the top of the chart.

2 MR. HOLAHAN: I think it's falling off the end of 3 the earth. The map just doesn't go further than that. 4 MR. MURPHY: The numbers are basically used for 5 the demarcation line, 1.174, roughly akin to the safety - 6 qoals. 7 DR. KRESS: There ought to be an upper line. 8 DR. APOSTOLAKIS: But I think it depends --9 DR. KRESS: I think you have to have limits. 10 DR. APOSTOLAKIS: Yes. 11 DR. KRESS: In order to do a proper, risk-informed 12 regulatory process. 13 DR. APOSTOLAKIS: And I think it is not 14 inconsistent with what you're saying, Joe, to change the 15 approach a little. 16 Instead of agonizing over what is adequate 17 protection, which, of course, is what he just showed us, 18 what does that mean? 19 Logically, it means, yes, risk insights, and defense-in-depth, and safety margins and whatever else you 20 need. 21 22 But by the very logical method, I can have definitions of inadequate protection. If any of these Ns is 23 24 above a certain limit, then I'm sure I don't have adequate 25 protection.

1 And if you think that way, then you are not 2 inconsistent with the Commission's SRM; you've satisfied Dr. 3 Kress because there is an unacceptable level of core damage 4 frequency the way we calculate it now, for which, if you 5 exceed -- I don't care what else you do -- adequate 6 protection is not there.

And you can say the same thing about defense-in-depth. We have been told many times that I don't care what the risk number is; if you don't have redundancy in this place, we're not going to accept it, and we try to justify that.

DR. WALLIS: You're talking to this community, and I think the first bullet up there really talks to the public. You've got to be able to tell the people what kind of adequate protection they're getting, why you think it's adequate, and what assurance you have.

Well, all our arguments here seem to be internal
on how does sort of a bureaucracy make decisions. But,
surely, the first question is, are you fulfilling your
public trust to make number one happen.

21 And if you can't provide a measure of it, how do 22 they know you're doing your job?

23 DR. APOSTOLAKIS: Again, these are two distinct 24 questions, in my view. And the center of -- or studies of 25 what strategic and international studies also ask the NRC to

232 define numerically, and what is adequate protection. 1 I think it would be very difficult right now to 2 3 define it numerically. However, it will not be as difficult 4 DR. KRESS: To do what I said. 5 6 DR. APOSTOLAKIS: To define inadequate protection. 7 DR. KRESS: Yes. DR. APOSTOLAKIS: Because that I can do in terms 38 9 of each measure, not the combination. 10 DR. KRESS: Yes. 11 DR. APOSTOLAKIS: And that will help me with 12 risk-informing the regulations. Is the airline industry, for example, using as a 13 14 sole criteria of adequate protection, the probability of 15 death per passenger mile? Probably not. It's a collection of things they are doing to make sure that flying is safe. 16 17 DR. KRESS: Absolutely. DR. APOSTOLAKIS: So the lack of a numerical 18 19 measure is not something unique to us. 20 DR. WALLIS: What do you tell them when they ask 21 this straightforward question? Tell us why you have 22 reasonable assurance of adequate protection. 23 DR. KRESS: You tell them we do this --DR. WALLIS: In two sentences. 24 25 DR. KRESS: You tell them we mean all these ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

1 regulations, we do all this training. 2 DR. WALLIS: Yeah, but that is a circular 3 argument. 4 DR. KRESS: I know, but then --DR. WALLIS: Anything you do is okay. 5 6 DR. KRESS: Then you also tell them we keep the :7 CDF below this number, and we keep the LERF below this : 8 number, and that is what I --9 DR. APOSTOLAKIS: Other things, safety margins. 10 Then your criteria have nothing to do with the real 11 failures, the design criteria. And all these things, you 12 have multiple, successive barriers that a Commission --DR. KRESS: You say all those things. 13 DR. APOSTOLAKIS: Yeah. 14 15 DR. KRESS: It is all adequate protection. 16 DR. WALLIS: They are means to an end. They are 17 means to an end. What is the end? 18 DR. APOSTOLAKIS: Adequate protection. 19 DR. WALLIS: And how do you know you have got 20 that? You know what I mean. 21 MR. MURPHY: Our regulations are not geared to 22 just being adequate protection, because virtually every 23 regulation I can think of has been more than that. It has been justified using the backfit rule and cost benefit 24 25 range, which means it has been cost beneficial to take it ANN RILEY & ASSOCIATES, LTD.

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

further on down, if you will, in this three regions than just whatever that list limit that you were just talking about that might be part of an adequate protection definition. So mostly we are below that.

1

2

3

4

5

6

7

8

9

10

This really is an indication as to where to stop on the safety goal.

DR. APOSTOLAKIS: See, if you follow, though, it just occurred to me, if you follow my line of thinking, then it seems to me you can define a limit above which --

DR. KRESS: Much closer to the macro.

DR. APOSTOLAKIS: Above which -- sorry -- there is inadequate protection, but you cannot use CDF and LERF to define how safe is safe enough. Because the mere fact that the CDF is maybe 9 -- 10 to the minus 5 does not guarantee that this agency will say this is safe enough, because there are other things that the agency is looking at.

DR. KRESS: Well, you can define it as being a
region below which you no longer have to do cost benefit.
No longer do I have to do the --

20 DR. APOSTOLAKIS: If your CDF was all inclusive, 21 right now we know it isn't, --

DR. KRESS: I would use CDF and LERF. I would use CDF and LERF. And I would also have in the policy statement that policy is to have a balance between those two, and I would actually have that as part of the policy statement.

You know, rather than as part of the subsidiary objective, I would actually incorporate both of those in there and say there is a policy that we will balance these. Balance, of course, not being equal, it is being some value of each to meet the LERF.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

DR. APOSTOLAKIS: I think it is the value of the CDF and LERF, plus a whole host of other regulations.

DR. KRESS: The presumption is always there that you meet all the regulations. That presumption is always in there, even with the safety goals, and that you do all the training and the inspection and all the other things. You always have that, I have always that presumption in there.

DR. APOSTOLAKIS: I mean if --

DR. KRESS: If you don't meet those, why you are going to get -- you are going to get --

DR. APOSTOLAKIS: Right. That doesn't help very much in the sense that if we have a policy statement that goes along the lines we are discussing, then the staff would want to use the statement.

20 DR. KRESS: Oh, I would have no objection to 21 having those statements in.

DR. APOSTOLAKIS: But if the other regulations are part of the statement, a cyclical argument again. You are not supposed to touch those. And if you want to eliminate some of them, --

DR. KRESS: Yeah, I think that does give you a 1 problem, yeah. 2 DR. APOSTOLAKIS: 3 That gives you --4 DR. KRESS: Yeah. 5 DR. APOSTOLAKIS: It seems to me that inadequate protection in terms of individual metrics would be easier to 6 7 define. 8 DR. KRESS: It would certainly help process a lot. 9 DR. APOSTOLAKIS: And it would help in 10 risk-informing the regulations. 11 DR. WALLIS: Who is getting the assurance? The 12 assurance is being given to whoever is being protected. So 13 it seems to me that that person has to have some say in what 14 is reasonable. 15 MR. MURPHY: Well, as this is used, this is the 16 legal requirement, the finding that is made when we license 17 a plant, that there is reasonable assurance, there is no 18 undue risk to the health and safety of the public. But the 19 reasonable assurance here is by the person in the NRC making 20 the decision to take a licensing or regulatory action. 21 DR. APOSTOLAKIS: We, ourselves, wrote a letter 22 agreeing with the certification of AP600. We had reasonable 23 assurance, I suppose. We had better. In fact, --DR. WALLIS: Well, it is also a moving target. 24 Ι 25 mean as society gets safer, as the other accidents become ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014

> Washington, D.C. 20036 (202) 842-0034

less likely.

1

2

3

4

5

6

7

8

DR. APOSTOLAKIS: That's right.

DR. WALLIS: It is generally happening. Aircraft are safer and so on, then maybe this is a moving goal.

MR. MURPHY: The safety goal policy statement stated that in a qualitative term that there should be minimum impact on life and health, I think. That is interpreted as a tenth of a percent.

9 DR. KRESS: Unfortunately, that tenth of a percent 10 is a moving target because both the accident rates are 11 changing and the cancer rates are changing.

12 DR. APOSTOLAKIS: See, I just remembered 13 something. We are arguing here in terms of the three regions, Joe, thinking about having in mind CDF and LERF and 14 15 so on. Maybe that is not the right context, because now I 16 remember when the U.K. Health & Safety Executive published their report last year, which I don't know whether it has 17 been adopted, they gave three regions for a quantity that 18 19 was independent of the system.

They said the individual risk from any hazardous activity in the United Kingdom should be, if it is greater than 10 to the minus 4 for the general public, for a member of the general public, it is unacceptable. And if it is less than 10 to the minus 6, it is in a region where it is broadly acceptable, and in between you have this cost

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

benefit region.

1

So if you define now the high level goals like individual probability of death or some societal measure, I think they use 50 or more deaths, you free yourself from issues of adequate protection is the combination of all the regulations we have, plus core damage frequency and so on, because this is now a very high level policy statement, it refers to individual risk.

9 DR. KRESS: I think we have that already in the 10 qualitative.

DR. APOSTOLAKIS: But it is, again, a goal. It is a goal and a single value. It doesn't tell you what is acceptable or unacceptable, clearly unacceptable.

DR. KRESS: Well, we have it as a goal, we don't have it as a limit yet.

DR. APOSTOLAKIS: But I think we are downplaying that because we are not really -- we are going in a direction that does not utilize the health effects. We are using CDF and LERF.

DR. KRESS: Well, I think -- you and I disagree a little there. I think LERF is a good surrogate for health effects. I have no problem with that as a surrogate.

23DR. APOSTOLAKIS: Any kind of health effects?24DR. KRESS: The one we have is a good surrogate25for early fatalities. It is not a good surrogate yet for

land contamination. 1 2 DR. APOSTOLAKIS: Right. 3 DR. KRESS: It is not a good surrogate for -- it 4 can be, but just have a different value. 5 DR. APOSTOLAKIS: That's right. 6 DR. KRESS: So it is a good surrogate, and I have 7 no problem using -- in fact, I think it is a good thing to use because it focuses on design issues as opposed to siting 8 9 issues, which you can deal with elsewhere, and then 10 emergency response issues. But I do --11 DR. APOSTOLAKIS: But LERF can be a policy 12 statement, can't it? 13 DR. KRESS: I think a policy statement --14 DR. APOSTOLAKIS: A surrogate. 15 DR. KRESS: I have no problem with using the high 16 level goals as they are, and then, as a subsidiary, saying 17 that these high level goals can be achieved by a proper 18 balance between LERF and CDF, where LERF is a surrogate for 19 them. I have no problem with doing that way, as long as it 20 is in there somewhere as guidance. 21 DR. APOSTOLAKIS: But when you say appropriate 22 balance, then how would you define the three regions -- the two values? 23 24 DR. KRESS: I would have three regions on LERF and 25 three regions on CDF, each of them -- each of them would

239

have a policy objective associated with it.

1

DR. APOSTOLAKIS: So each one would have an unacceptable region?

DR. KRESS: Yeah, and they would be consistent. You start with LERF, CDF is incorporated in LERF. You put three regions on LERF and then you say, what balance do I want to have now between CDF and LERF? And you start with one and then you make the other regions consistent with it. But it is perfectly reasonable to do it that way.

10DR. APOSTOLAKIS: I understand. At least we can11try.

DR. KRESS: And, in fact, you would tie that then 12 13 to your -- this is, in essence, a definition of 14 defense-in-depth with respect to quantifiable uncertainty. And I like the way they presented, I think Tom King 15 16 presented a look at this balance, plus looking at individual 17 sequences to see if there was a balance there. And that, to 18 me, ought to be a regulatory policy, a regulatory objective, 19 and it ought to be part of the policy statement. Then you 20 have something to work to.

DR. APOSTOLAKIS: Well, maybe that is what Joe means over there, as experience is gained. Maybe after the initial --

24DR. KRESS: That may be. Yeah, I am assuming that25is what that means. So I don't know whether the time is

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

ripe now, or they need to think about it some more and do it later or not.

I think the point that Dr. 3 MR. MURPHY: Apostolakis made is very good, that by recognizing that 4 5 adequate protection or reasonable assurance and adequate 6 protection has many more things to be considered that just 7 quantitative risk analysis. Can we use our experience, as 8 we try to risk-inform things, as we look at the past ʻ9 analyses that have been done, can we use this in some way to 10 come to a better definition of at least a portion of what 11 contributes to that big thing called reasonable assurance of 12 adequate protection? I can see some merit in doing 13 something like that.

14 I have a feeling this presentation is getting away 15 from me.

16

17

24

25

1

2

[Laughter.]

DR. KRESS: Sorry about that.

MR. MURPHY: What I had on a slide that I don't want to talk about where somebody says something fast is generalized versions of the five principles. I think they flow -- no, they don't flow very --

22 DR. APOSTOLAKIS: Generalized versions means 23 wordsmithing it, too.

> MR. MURPHY: I mean these words. DR. APOSTOLAKIS: Okay. Good. So we may want to

1 change some of the words. Now, plant performance should be monitored. Is that what the oversight process is supposed 2 3 to do? 4 MR. MURPHY: Yeah. 5 DR. APOSTOLAKIS: Do you have any opinion as to 6 what the objective of this oversight process is that we are 7 monitoring? What are we trying to preserve? 8 MR. MURPHY: Trying to preserve? I think you are .9 trying to find out what is happening. 10 DR. APOSTOLAKIS: I mean why are we --11 MR. MURPHY: I think you are trying to find out 12 what is happening. 13 DR. APOSTOLAKIS: What is happening meaning? 14 MR. MURPHY: When you go to use -- what this says 15 is that if it is possible to come up with a rule and make 16 this a part of the safety goal policy statement, that if you state something, you are going to use this policy statement 17 18 to develop a regulation, to handle an area, you would prefer to have it such that there is a way of tracking performance 19 20 against that rule. It is performance-based regulation. 21 It is a reality check. DR. WALLIS: 22 MR. MURPHY: Yeah. It is just a call for 23 performance-based regulation. 24 MR. HOLAHAN: I think the other thing that we sort 25 of skipped of is these are generalized principles, you know, ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036

(202) 842-0034

from the versions expressed in Req. Guide 1.174. 1 In the Req. Guide the call for performance monitoring is for the 2 3 licensee to do the monitoring. Okay. The purpose of the 4 licensee doing the monitoring is to assure that the 5 assumptions made in the analysis are still, you know, 6 verified to the extent that you can. And then the staff's 17 oversight process is to see, in fact, that those things are 8 taking place.

But most of the monitoring that we think about is the things that the licensee does, not the things that the staff does.

DR. KRESS: I don't -- yeah, I don't see Principle Number 4 as being the same animal as the other principles. It is a different animal.

MR. MURPHY: No. It is.

15

16

25

DR. KRESS: And I wouldn't have it in my

17 principles. I would have something like an acceptable level 18 of risk will be maintained, and an acceptable balance will 19 be maintained between prevention and mitigation. Those are 20 principles that, you know, I would --

MR. MURPHY: That is a good suggestion.
DR. KRESS: Yeah, and I get rid of Number 4.
DR. APOSTOLAKIS: These are principles for
changes.

DR. KRESS: Yeah.

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

244 MR. MURPHY: Yeah. 1 MR. HOLAHAN: It is a principle for change. As a 2 3 matter of fact, in Reg. Guide 1.174, part of the argument about why we should control, you know, the size of changes 4 is that you want to maintain some, you know, some balance, 5 6 that you don't want the whole 99 percent of the risk to be 7 associated with one kind of issue. 8 DR. KRESS: And I would have something -- words in 9 there. 10 MR. MURPHY: Yeah, I think that is a good 11 suggestion. 12 DR. WALLIS: You have principles and you have 13 regulations, so that they should be enforced, that is --14 this doesn't have to be a principle, it is just --15 MR. MURPHY: No, again, these are principles in a 16 policy statement that is intended to set up --17 DR. WALLIS: You don't have to have a surrogate to 18 say we will have regulations and we will make sure they are 19 enforced, that is obvious. 20 DR. APOSTOLAKIS: But this tells you, though, Graham, that you have no defense-in-depth, for instance. 21 22 DR. WALLIS: Well, that is all right. But this other thing about the balance between regulations and the 23 24 last one is that you check that they really do it, that is so obvious. Otherwise, that is implementation of a 25

principle, it is not a principle. 1 2 DR. KRESS: These are principles of appropriate 3 regulation or something. I don't know what the title. DR. WALLIS: It is something else. 4 5 DR. KRESS: What these principles are. DR. WALLIS: It is way far from a safety goal. 6 7 DR. APOSTOLAKIS: I understand the staff is revising 1.174. Are you revising, updating 1.174? 8 9 MR. HOLAHAN: There are a couple of areas in which 10 we have committed to update 1.174, but they are not major 11 Although, I can see you are tempted to wordsmith changes. 12 the document. DR. APOSTOLAKIS: No, but the first --13 14 MR. HOLAHAN: Can I quote you on that? 15 DR. APOSTOLAKIS: The first principle, though, 16 Gary, I sort of agree with Dr. Wallis, it is kind of an 17obvious to say it is my principle that the licensees will 18 comply with the regulation. 19 MR. HOLAHAN: Well, if you quote the whole 20 principle as it is in 1.174, what it says is you either meet 21 the regulation or you use a process --22 DR. APOSTOLAKIS: Yeah, right. 23 MR. HOLAHAN: -- like the exemption process or a 24 proposed rule change in order to assure that wherever you 25 are going, you will continue to meet the regulations. ANN RILEY & ASSOCIATES, LTD.

Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

	246
1	DR. KRESS: Yeah, but that doesn't
2	DR. APOSTOLAKIS: That is sort of
3	DR. KRESS: Yeah, that doesn't translate well to
4	the overall.
5	DR. APOSTOLAKIS: We discussed that in the past.
6	MR. MURPHY: Well, let me get to what I thought
7	was going to be the controversial part.
- *8	DR. KRESS: It probably will be.
9	MR. MURPHY: The treatment of core damage
10	frequency is a fundamental goal. In your May 11, '98
11	letter, the ACRS recommended that I thought you had
12	recommended that core damage frequency be elevated as a
13	fundamental goal, but when I went back and read your letter
14	carefully, I found that your recommendation
15	DR. APOSTOLAKIS: Good idea.
16	MR. MURPHY: Yes, it is. Was that the elevation
17	as a fundamental goal be scrutinized.
18	DR. APOSTOLAKIS: You know how many hours we spend
19	here over each word?
20	[Laughter.]
21	MR. MURPHY: Yes. And I think the difference
22	between those words is significant.
23	DR. APOSTOLAKIS: You should come here on
24	Saturday.
25	MR. MURPHY: So I think we have scrutinized it.
te.	ANN RILEY & ASSOCIATES, LTD. Court Reporters
	1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034
	(202) 042-0034

9

We also have done something else that I would recommend, and let's go back and read the '86 policy statement. It is an excellent piece of work. It has a lot of things in it. Ιt is very forward-thinking for its time, amazingly so when you look back at it from this standpoint.

It has the following statement in it in terms of core damage frequency, that the Commission has as its 8 objective providing reasonable assurance while giving 9 appropriate consideration to the uncertainties involved that 10 a severe core damage accident will not occur at a U.S. 11 nuclear power plant.

12 Rather than try to raise a frequency as a 13 fundamental goal, I think it would be better to take this 14 word, with some editing to get the words so that they fit 15 into the body of the text better, but get this thought as a qualitative goal, and retain the 10 to the minus 4 CDF as a 16 17 subsidiary objective.

18 DR. KRESS: I wouldn't object to that, except I 19 still think you need, in a risk-informed world, limits. And when it becomes a goal, it is a type of limit, but it is not 20 21 the type of limit I think you need.

22

1

2

3

4

5

6

7

MR. MURPHY: No, I --

23 DR. KRESS: So I think you need to say 10 to the 24 minus 4 is the goal. The limit is, even as a subsidiary, I 25 don't mind where it shows up, as long as it shows up

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

248 1 somewhere, as a limit you have some other number which --2 MR. MURPHY: My feeling is -- we don't disagree in -3 principle. My feeling is that we need the goal right now, -4 the lower line, if you will. Do we need a limit? Yes. But 5 I personally think it is premature to do it. 6 DR. APOSTOLAKIS: But what you are saying, I 7 thought, Joe, was that you don't want the number to be in 8 the policy statement. Can we accommodate what Dr. Kress *3*9 wants by putting it in a lower level document? 10 DR. KRESS: Reg. Guide or something? In a Reg. 11 Guide. 12 DR. APOSTOLAKIS: Yeah. Because then you can 13 change that later. 14 DR. KRESS: That is why I was asking you about the 15 influence of policy statements before. I think as long as 16 it has the force of guiding the regulations, I don't care 17 whether it is a policy statement or not. 18 DR. APOSTOLAKIS: Yeah. But I tend to agree with 19 I don't -- I think you miscalculated, this is not a you. 20 controversial issue. I mean if the Commission has a 21 statement, which I must admit I don't remember, maybe 22 changing a few words would probably satisfy the original 23 intent. But we can also state some -- give some numbers 24 somewhere else. 25 DR. KRESS: But that statement is not in there as

1 . a primary goal, it is still a subsidiary, even the 2 qualitative one. MR. MURPHY: Well, as it is in the goal now, it is 3 a paragraph, in the writing it is not called a goal or 4 anything, basically, all it does is elevate that. 5 6 DR. KRESS: Yeah, these guys are proposing to 7 elevate that statement, which would -- to me, is probably a . 8 good source. <u></u>9 DR. APOSTOLAKIS: I think it is fine. 10 MR. MURPHY: And then keep the 10 to minus 4 as 11 a --12 As a subsidiary. DR. KRESS: 13 MR. MURPHY: As I will get to later, to do this, I 14 believe that it has to be coupled with a subsidiary goal in LERF. 15 16 DR. APOSTOLAKIS: Yes. 17 MR. MURPHY: And I will get to that in a minute. 18 DR. WALLIS: I rather like this qualitative goal, 19 It goes back to what Gary was saying, you know, I too. 20 don't think the question of independence is quite right, but 21 you can make statements which are qualitative, which then 22 have to be interpreted, and that interpretation may vary 23 from year to year as you know more. MR. MURPHY: 24 Yes. 25 DR. WALLIS: So you can change the lower level ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

stuff. But you are still meeting your goal because it is still valid.

1

2

23

24

25

MR. MURPHY: Yeah. The treatment of 3 uncertainties. Uncertainties are right now discussed at 4 5 some length in the policy statement. It is more than most 6 of us remember, I think, where we thought that it was a 7 discussion that said use mean values and that was it. In 8 fact, there is much more than that in the policy statement, 9 but I think it needs to be updated to include the discussion 10 of uncertainties that are in the quidance there provided in 11 Req. Guide 1.174, effectively bring the discussion of 12 uncertainties up to the state of the art.

DR. APOSTOLAKIS: Now, an interesting question 13 14 here is when the Commission selected this approach of 1/10th 15 of 1 percent, why did they do that? Did they do it -- first 16 of all, I think that is true that they wanted the 17 contribution to risk from nuclear power to be small, but 18 small may mean, you know, 1/10th, not necessarily 1/10th of 19 1 percent. Was the reason they chose that 1/10th of 1 20 percent, interesting enough, is a number that appears in the 21 policy statement? I thought we tried to avoid numbers, but 22 this is a number.

DR. KRESS: That is the number in there, yeah.

DR. APOSTOLAKIS: But, anyway, is the reason why they chose such a small number, I guess 1/10th of 1 percent

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

1 sounds better than one-thousandth, because they knew that there were a lot of uncertainties on the assessment side? 2 3 This has nothing to do with our ability to 4 estimate core damage frequency -- I mean how do we know 5 that, is it stated somewhere? 6 DR. SEALE: It has to do with the fact that to one 7 significant figure a person lives to be a hundred years old 8 and then he dies. DR. APOSTOLAKIS: Yeah. 9 10 DR. SEALE: And that the risk from nuclear power 11 should be about 10 percent of the cumulative risks from 12 everything else. 13 DR. WALLIS: 1/10th of a percent. 14 DR. SEALE: 10 percent. 15 DR. WALLIS: Oh, you mean taking a hundred. 10 16 percent is a lot. 17 MR. MURPHY: There was a study --18 DR. SEALE: But 10 percent of --19 DR. APOSTOLAKIS: Wait a minute, if it is 1/10th 20 of 1 percent per year, why is it more for a hundred years? 21 DR. WALLIS: No, that is a bogus argument. This 22 is from accidents, too. I mean you die from old age, that 23 is not an accident. DR. SEALE: I know, but it is essentially the risk 24 25 of nuclear power is --ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

252 1 DR. APOSTOLAKIS: 1/10th of 1 percent. 2 DR. SEALE: 1/10th of 1 percent. 3 DR. WALLIS: I think this is a political, I think 4 OSHA does the same -- I think OSHA has a tenth of 1 percent. 5 It is a political thing. OSHA has the same --6 DR. APOSTOLAKIS: When they selected that number, 7 were they --It is politically acceptable. 8 DR. WALLIS: 9 DR. APOSTOLAKIS: -- going to allow for the fact that there are uncertainties in the assessment. 10 11 DR. WALLIS: No, it is politically acceptable is what it is. 12 13 DR. APOSTOLAKIS: How do you know? 14 MR. SIEBER: I think there is some substance to 15 that. There was a paper written in the 1970s, a doctoral 16 thesis at MIT, which you may be able to find, that 17 establishes that number for risks incurred that come from outside forces where the participant can't see or anticipate 18 19 it, it is one in a thousand. But it is a good paper and it 20 has some basis. 21 CHAIRMAN POWERS: From MIT and it is a good paper. MR. BARTON: That is not an oxymoron. 22 23 CHAIRMAN POWERS: I didn't say that. 24 DR. APOSTOLAKIS: A very pleasant surprise to see 25 that some people do read those papers. ANN RILEY & ASSOCIATES, LTD.

Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

DR. KRESS: But, basically, it was a consensus 1 agreement that that is --2 3 DR. SEALE: Yeah. 4 DR. APOSTOLAKIS: You guys still don't understand 5 -- answer my question. I understand it is consensus. But is it -- I mean if the Commission and the community were 6 :7 convinced that the estimates of health effects from PRAs were with high confidence, would they still choose 1/10th of 8 29 1 percent? This is critical. 10 CHAIRMAN POWERS: It is certainly my understanding 11 that the health effects from PRAs are trips and falls, 12 because of the large mass. 13 [Laughter.] 14 DR. KRESS: I am glad you showed up, Dana. 15 DR. SEALE: In principle, George, you don't want 16 to start arguing about whether it is a factor of 3 or a 17 factor of 2 or whatever, it is 10 percent or a factor of 10. 18 DR. APOSTOLAKIS: But the reason why -- I 19 understand that. The reason why I am raising the issue 20 because if -- is that if the 1/10th of 1 percent was based 21 simply on political reasons and did not include anything 22 about the assessment, then the whole burden on quantifying uncertainties is on the assessor. 23 24 DR. SEALE: Sure. 25 DR. APOSTOLAKIS: Because the regulator, the ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

÷,

policy maker has not given me any -- I don't know, 1 relaxation there. 2 DR. KRESS: I think you have got a legitimate 3 point there, George, and I think it is a good question. 4 My 5 own personal opinion is they intended that to be a mean value given what they knew about the ability to assess the 6 7 risk. Now, that is an opinion. DR. APOSTOLAKIS: Oh, that is a very different 8 9 interpretation. 10 DR. KRESS: Yeah, that is an opinion. 11 MR. MURPHY: Let me try to share a couple of 12 thoughts with you. 13 DR. APOSTOLAKIS: Okay, yeah. 14 MR. MURPHY: It derives from a statement that is 15 in the policy statement, the real safety goal, the 16 qualitative safe goal, the Commission's first qualitative 17 safety goal is that the risk from nuclear power plant 18 operation should not be a significant contributor to a 19 person's risk of accidental death or injury. I think that 20 is a statement where uncertainty did not enter into it. 21 DR. KRESS: Well, you could think uncertainty 22 there, and what you would do is just say, what is the 23 uncertainty in the average -- in the death rate, normal death rate? 24 25 MR. MURPHY: I think -- yeah, but I think when you ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036

(202) 842-0034

came down -- that qualitative statement did not consider uncertainty. When you pick a number to go with the quantitative health objective, and, yeah, uncertainty enters into that. And remember that this policy statement was begun I believe around '76 -- it was '77. It was published as a draft for comment in '83 and got issued in '86.

1

2

3

-4

5

6

24

25

7 There were many, many debates as to whether that 8 meant 1 percent, or a tenth of a percent. I don't remember 9 any other numbers being debated, but I remember those two 10 numbers being debated at length.

DR. KRESS: On the treatment of uncertainty, your proposal is to update the discussion that is in 1.174 and make it --

14 MR. MURPHY: Yeah, what the discussion says now is 15 that it is important that you understand the uncertainties. 16 That is in the existing policy statement. It says to use 17 the mean value for a comparison, but you should calculate a distribution. You should recognize there are things we have 18 19 that are not in the distribution, and where you believe 20 those things are important, you should do sensitivity 21 studies to try to get some handle in your own mind as to what those importances are and factor this into the decision 22 23 process.

And that is, I think there are better ways of getting the message across now. There is a nice discussion

in 1.174 that can be converted at a high level and put into the policy statement. But I don't think it will, you know, it is not anything fundamentally different than what you have heard before, it is just updates. What is there is actually pretty good.

1

2

3

4

25

.6

7

24

25

I almost hate to put this one up.

DR. KRESS: Yeah, because -- okay, go ahead.

MR. MURPHY: Defense-in-depth. 8 The current policy 9 statement, again, addresses this in some detail. It talks 10 about the mandate, and that is the word that is in the 11 policy statement, of maintaining both prevention and 12 mitigation. It is, defense-in-depth is one of the five 13 principles from Reg. Guide 1.174 that we have talked about 14 earlier, so we are already talking about that. And, of 15 course, they note there are ongoing discussions on the 16 subject.

What I propose to do at this point, and this could change again, depending on whatever the ACRS does in its discussions on defense-in-depth, is to incorporate the statement on defense-in-depth that is in the Commission's White Paper into the policy statement or some, perhaps a shortened version of it. And if you don't remember what is in the White Paper, that is it.

DR. KRESS: Yeah, I --

MR. MURPHY: This is a direct quote.

DR. KRESS: Yeah. 1 DR. WALLIS: I like this because it gives you much 2 3 more of an idea of how much defense-in-depth you might have 4 if you could evaluate it. MR. MURPHY: 5 Yeah. 6 DR. WALLIS: So you are beginning to evaluate it 7 rather than just making it some kind of a principle. 8 DR. KRESS: I thought you were going to incorporate the definition of defense-in-depth that is in 9 the White Paper also. 10 11 MR. MURPHY: The definition actually is a 12 footnote. 13 DR. KRESS: I know, it was a footnote. 14 MR. MURPHY: I don't know how to make footnotes in viewgraphs. 15 I'm sorry, that is the problem. But, yeah, I 16 would take along with it the definition from the White 17 Paper. 18 DR. KRESS: Okay. 19 CHAIRMAN POWERS: Unlike the rest of the panel, I have no enthusiasm for this whatsoever, because I think it 20 21 does not make clear in its presentation that a major 22 thinking in the defense-in-depth is addressing the questions 23 of things that are not in the PRA, and the possibility that 24 the PRA is itself completely incorrect. 25 DR. APOSTOLAKIS: Well, to the extent practicable

it says.

1

2

3

5

12

13

14

18

CHAIRMAN POWERS: But, you see, if I am operating on the basis of I like defense-in-depth because it is a way 4 of defending myself against the hubris that I might actually be able to calculate something real, and then justifying it : 6 based on the calculation is undoing me.

7 DR. APOSTOLAKIS: And I take the opposite view. Ι . 8 think this sides with you, because it starts with the : 9 premise that the structuralist approach is the one we take 10 and then we use risk to evaluate some of the elements of the 11 defense-in-depth, and go the other way.

I have a view that combines both your DR. KRESS: views. I think there are two kinds of defense-in-depth.

DR. APOSTOLAKIS: What kind?

15 DR. KRESS: There is the defense-in-depth that one 16 does when one expresses a regulatory objective that I want 17 balance between prevention and mitigation.

DR. APOSTOLAKIS: Right.

19 DR. KRESS: And balance in terms of the 20 contribution to risk of the various sequences and balance to 21 the uncertainties in various sequences. We heard that with 22 Tom King the other day. That is one kind of defense-in-depth and it deals with what you can quantify 23 24 with a PRA and it is quantifiable uncertainties and so forth. 25

·1 Then I think there is another kind of 2 defense-in-depth which is called -- I don't know what the 3 uncertainties are, or they are unquantifiable, or they are very -- or they are too big for -- too big to be acceptable. ٤4 5 Then I would put sufficient attention to preventing • 6 initiation, to intervention before things go too far, to .7 providing diagnosis, and to mitigate the hazard vector, : 8 whatever it is. That is another kind of -- you put 9 attention on all those and that is where you can't quantify 10 the uncertainty. I think both of those are elements of 11 defense-in-depth and they ought to be both be part incorporated in the policy statement, and it handles both 12 13 your problems if you deal with it as two things instead of 14 one. 15 DR. APOSTOLAKIS: It sounds promising but I will 16 have to think a little bit more about it. 17 DR. WALLIS: Well, it is difficult, though, 18 because we always get the question, how much 19 defense-in-depth is enough? 20 DR. APOSTOLAKIS: See, you don't get that guestion 21 if you follow Dana's approach. 22 DR. KRESS: You don't get with the first part. 23 DR. APOSTOLAKIS: There is no how much. 24 DR. WALLIS: I mean you have an infinite amount. 25 DR. APOSTOLAKIS: Yes. ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

1 DR. WALLIS: You can't -- you have got to stop 2 somewhere. 3 DR. APOSTOLAKIS: Yes. <u>`4</u> MR. MURPHY: Do we have enough on defense-in-depth :5 or do you want to discuss it further? 6 DR. APOSTOLAKIS: No, I don't think we need to 7 discuss it further. 8 DR. KRESS: That is a subject we are going to talk 9 about more later. 10 MR. MURPHY: Okay. Frequency of a large release 11 of radioactive material. In the policy statement, the '86 12 policy statement, there was a charge from the staff to 13 consider a general performance guideline of 10 to the minus 14 6 per reactor year for a large early -- for a large release 15 of radioactive material, and asked us to define what that 16 large release was. 17 We tried several definitions over time, and in 18 1993 we came to the conclusion that we were unable to 19 develop an adequate definition that would fit with the 10 to 20 the minus 6 quideline. At that time we requested permission from the 21 22 Commission to terminate such activities and that permission 23 was granted. However, in looking at it, as I said, if you 24 are going to have a subsidiary to go on core damage 25 frequency, it seems that you need a subsidiary goal on LERF

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

to balance, for defense-in-depth purposes to balance the 1 two. And as the ACRS has noted, a LERF of 10 to the minus 5 2 3 is consistent with the QHO. It is also consistent with the regulatory analysis guidelines and with Reg. Guide 1.174. 4 This is a OHO which is not 5 DR. WALLIS: site-specific, it is the same factors in the middle of a 6 ^{*}7 city or out in the prairie somewhere? 8 MR. MURPHY: Well, it is individual risk of 5 9 times 10 to the minus 7. 10 DR. WALLIS: But if someone happens to be on the 11 borders of the plant or something? 12 DR. KRESS: No. 13 DR. WALLIS: Plants have more people on the 14 borders. It is the -- for the individual risk 15 MR. MURPHY: 16 it is specified in the policy statement as being the average 17 individual within one mile of the plant. 18 DR. WALLIS: One person? 19 MR. MURPHY: The average individual, yes. 20 DR. WALLIS: Does it say how many people are 21 there? 22 MR. MURPHY: It does not talk about societal risk. 23 It is average, it is individual risk. DR. WALLIS: Clearly, this is --24 25 DR. KRESS: You calculate the total number of ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

deaths within one mile and divide by the number of people 1 2 living in one mile. DR. APOSTOLAKIS: You are not allowed to say that 3 4 there are no people within one mile, so it is really 5 individual risk. 6 MR. MURPHY: Yeah. 7 DR. APOSTOLAKIS: It is the same thing as assuming 8 that there is a guy there all the time. 9 DR. KRESS: Yeah, absolutely. 10 DR. WALLIS: It is very different from the goal. 11 DR. KRESS: It is a little different than saying it is a guy there all the time. It is saying there is a 12 guy, part of him is here, and part of him is here, and part 13 14 of him is here. 15 [Laughter.] 16 MR. MURPHY: Yeah. It is said in terms of the --17 DR. KRESS: It is true, because you would calculate it by the wind rows. 18 19 DR. APOSTOLAKIS: Is there a document where the 20 way LERF is calculated is clearly described? 21 DR. KRESS: Yes. 22 DR. APOSTOLAKIS: Which one? DR. KRESS: Gosh, I forget what the document was. 23 24 They had -- I think it was the Brookhaven document, where 25 they calculate LERF. ANN RILEY & ASSOCIATES, LTD.

Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

CHAIRMAN POWERS: Yeah, it is an appendix in 1 2 1.174. 3 DR. KRESS: An appendix. DR. APOSTOLAKIS: Oh, it is an appendix. 4 MR. KING: No, it is a reference in 1.174, it is a 5 reference. There is a NUREG/CR on it. 6 7 DR. KRESS: I would not disagree with this 8 position except I still think eventually you have got to 9 have limits as well as goals for LERF. 10 DR. APOSTOLAKIS: Well, the three region thing is 11 up in the air, I don't think we agreed on it. 12 DR. KRESS: The three region, yeah. MR. MURPHY: Yeah, and clearly all I am talking 13 14 about right now is the lower boundary line. 15 DR. KRESS: The lower, yeah, right. 16 MR. MURPHY: And, yeah, I think we have talked 17 about the upper warning, you know, how I feel about it. Ι think it is a good idea, I still think it is premature, but 18 19 we have beat that one to death. 20 DR. APOSTOLAKIS: It is still not clear to me, 21 Joe, that these goals are really the boundary, I mean the 22 lower limit, the three region approach. You may be right but I am not sure, I am convinced. But my specifying a 23 goal, --24 25 DR. KRESS: I think they certainly are the lower ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

264 boundary. I am not sure we arrived at the appropriate and 1 right values for the lower boundary because I don't --2 :3 DR. APOSTOLAKIS: Yeah, 10 to the minus 4 is too high. 4 5 DR. KRESS: It may be too high. DR. APOSTOLAKIS: It is too high. 6 7 DR. KRESS: Yeah, I mean, but that is what is in the safety goals. 8 9 DR. APOSTOLAKIS: I will tell you what the limit 10 is, the upper limit is 10 to the minus 3 and the lower 10 to 11 the minus 5. 12 DR. KRESS: It could very well be. 13 DR. APOSTOLAKIS: For CDF. 14 DR. KRESS: I mean I think both of them are open to question, right. 15 16 DR. APOSTOLAKIS: And they are not risk limits. MR. MURPHY: Okay. What we are relying on mostly 17 18 is the guidance that came out of this June 15, 1990 SRM in 19 terms of how we would define the use of the existing safety 20 goals. And we are just trying to take that guidance and put 21 it back into them. 22 DR. WALLIS: It is interesting to me that all the 23 numbers you have quoted throughout have always been rounded 24 off to a factor of 10. 25 MR. MURPHY: I think it is safe to say in most ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

applications with PRA, my own view is you should --1 DR. WALLIS: Also, there is .1 percent, all the 2 3 numbers seem to be. MR. MURPHY: All the things should be in the order 4 of --5 6 DR. WALLIS: If we had 11 fingers, it would be 7 different. :8 [Laughter.] 9 MR. MURPHY: Why would that be? 10 DR. APOSTOLAKIS: I think the world would be 11 different, so maybe --12 CHAIRMAN POWERS: Actually, I believe that the 13 virtues of the Babylonian system, a base 60 system, have 14 been frequently cited. 15 DR. WALLIS: Binary, because then you could be 16 much more accurate, precise. 17 CHAIRMAN POWERS: I think the belief is the base 18 60 system is there are so many even divisors in it. 19 DR. WALLIS: I am not being facetious, it gives us 20 an idea of the beast we are dealing with, and we are making 21 decisions on a factor of 10. That is a pretty gross type of 22 factor. 23 MR. MURPHY: The uncertainties we have and our ability to do the risk analysis, I don't think a factor of 24 25 10 is --ANN RILEY & ASSOCIATES, LTD. Court Reporters

265

1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034 DR. WALLIS: Ten miles, too. I mean --

1

2

3

4

5

6

7

DR. KRESS: There is a technical basis for the 10 miles, believe or not, even though it is a rounded off number.

MR. MURPHY: Let me move on to societal risk.

DR. WALLIS: What happens if you go metric, does it become 10 kilometers?

8 MR. HOLAHAN: 6.23 kilometers, or is it 16 -- 16, 9 I guess.

10 MR. MURPHY: The qualitative latent cancer safety 11 goals and the QHOs are expressed in terms of a fractional 12 It considers the population within 10 miles of the impact. 13 plant. Initially, that started out as 50 miles and after 14 public comment on the '83 version of the safety goals, it 1.5was changed to 10 miles. The regulatory analysis 16 guidelines, on the other hand, considered integrated dose up 17 to 50 miles.

18 The reason for the choice of the 10 miles was that 19 it focuses attention on the area where the dose is usually 20 the highest. I am not a health physicist, but I think they 21 use the phrase "critical population," and so I think this is 22 appropriate.

DR. WALLIS: Well, 10 is really a surrogate for all the people who were irradiated within a thousand miles of Chernobyl. It doesn't -- there is no implication that 10

1 miles is a limit, it is simply a surrogate for all distances. 2 3 Yeah. But, see, what we have done MR. MURPHY: 4 is, in studies like NUREG-1150, we have looked at the risk 5 as a function of distance. And there is a knee in the curve : 6 that starts at around 8 miles and ends at around 12, if 7 anyone would like --° 8 DR. KRESS: That was a technical basis, I was 9 told. 10 MR. MURPHY: Yeah. 11 DR. SEALE: And you have to get to 10 miles before 12 you can effectively mount any kind of evacuation or before 13 you can do anything. 14 MR. MURPHY: The regulatory analysis guidelines 15 use 50 miles, those results have a large uncertainty and we 16 are required as part of the regulatory analysis to consider 17 what the impact of that uncertainty is. 18 I will talk more about this, but the main point I 19 want to make is that I see no reason to change either one of 20 these two documents, even though they are not totally consistent in the distance. The 10 mile zone seems to be 21 22 appropriate for the safety goals. The qualitative goal states that the societal risk to life and health should be 23 24 no more than -- should not be a significant addition to 25 other societal risk, so its percentage is roughly ANN RILEY & ASSOCIATES, LTD.

267

Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

1 appropriate in terms of the QHO. However, what is left out 2 of that is an overall societal impact. And we need to 3 consider --DR. KRESS: Like total number of deaths, for :4 5 example would be your measure of --6 MR. MURPHY: Person-rem deaths. 7 DR. KRESS: Yeah, or person-rem. 8 MR. MURPHY: The overall impact is. But that 9 raises its own questions. And what we find when we try to think of how to set a reasonable goal on that is that a 10 11 significant proportion of the population dose is calculated, 12 it comes not from cloud patches, but from ground shine and 13 ingestion. 14 DR. KRESS: Assuming you don't evacuate. Assuming you don't --15 MR. MURPHY: Well, that is assuming some portion 16 17 of the population evacuates. As I will get to, the 18 calculations, and I am talking now specifically on 19 NUREG-1150, are based on the EPA protective action guides. 20 They assume that a significant part of population evacuates, 21 99 percent, that those that evacuate, evacuate at a given 22 speed. It is based on analysis of other evacuations. The 23 99 percent itself is based on an analysis of evacuations. DR. KRESS: Now, those people, the dose to those 24 is from --25 ANN RILEY & ASSOCIATES, LTD.

268

Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

MR. MURPHY: Primarily from cloud. 1 Is primarily cloud. 2 DR. KRESS: 3 MR. MURPHY: Well, it depends on when they left 4 and when they didn't. Some of them are able to outrun the 5 cloud and they don't get anything, if they evacuate early 6 enough. 7 DR. KRESS: Then they don't get anything. 8 MR. MURPHY: Right. 9 DR. KRESS: All right. But once again --MR. MURPHY: In others, there is a distribution in 10 11 terms of who leaves when. 12 DR. KRESS: It is if you come back. It is if you 13 come back and don't relocate that you get this ground shine. 14 MR. MURPHY: Right. Now, in terms of relocation, 15 the assumption is that if you get a dose, and this is based 16 on the EPA protective action quidelines, if you get a dose 17 -- if your first year dose would exceed 2 rem, or any 18 succeeding year would exceed half a rem, that you would be 19 relocated. That was the assumption that was built in and 20 that is the assumption in the protective action quidelines. 21 The key thing about evacuation and relocation is 22 they are both totally outside the control of the NRC. Those 23 are not NRC functions, they are functions primarily of the 24 state governments in most states. We have an additional problem that the current 25 ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036

(202) 842-0034

level 3 PRA tools have significant weaknesses that limit 1 their utility of predictions at significant distances from 2 the plant. 3 DR. APOSTOLAKIS: So now you are allowing the 4 5 ability of the assessment tool to do something to have an : 6 impact on your goal. °7 MR. MURPHY: No. I am saying --8 DR. APOSTOLAKIS: Well, you are saying I can't : 9 calculate it, therefore I don't need a land contamination. 10 MR. MURPHY: That is not the conclusion I want you 11 to draw. 12 DR. APOSTOLAKIS: But why do have the third bullet then? 13 14 MR. MURPHY: I want you to understand that the 15 present techniques are weak. That does not mean do it or don't it. 16 17 DR. APOSTOLAKIS: That it the problem, the rule 18 should be independent of that, should it not? 19 MR. MURPHY: Yeah. The safety goal, for instance, 20 if you read the '86 statement, it is clear, as I interpret 21 it, at least, it applies -- it applies to shutdown 22 conditions. It applies to all -- it just talks about overall risk. Whether or not we could calculate it at the 23 24 time or didn't, didn't matter. It sets a limit. It sets a 25 goal that we should shoot for.

The same thing in terms of land contamination, it also, whether we need it or not, should not be particularly affected by the fact that we -- weak tools. But if we have weak tools, we need to do something about it, if we think this is important. And so that reason it is here.

1

2

3

4

5

25

DR. WALLIS: Having weak tools is the biggest justification for doing research, because if you need those tools, you don't have them.

÷9 MR. MURPHY: You got it. You look at the next 10 viewgraph. What I want to do, we have considered how to 11 handle this. In light of the way the safety goal policy statement is structured, in light of the fact that we derive 12 most of our authorization from the Atomic Energy Act, which 13 14 really doesn't address the environment, we would like to add -- but there are other laws that, of course, do, that 15 16 influence our various activities.

We are recommending that we add a qualitative goalfor protecting the environment.

DR. KRESS: Do you have any idea what that might be at the moment?

MR. MURPHY: I haven't come up with words yet. It would be not much more than that statement alone. It would be at a very high level, something like what is in the strategic plan.

DR. KRESS: Now, one of our concerns about

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

societal impact had to do with the fact that the two goals as they exist now are both individual risk goals.

MR. MURPHY: Yeah.

DR. KRESS: In the implementation. 4 We were 5 concerned that there ought to be a goal on either total 6 deaths or land contamination, one or the other of those. 7 And we considered whether or not total deaths were incorporated in the regulations anywhere, and they are, of 8 course, in the siting rules, for one place. The siting . 9 10 rules limit the population densities and things like that.

But if that is a regulatory objective, and it does show up in our regulations in a number of places, limiting the total number of deaths, shouldn't it be in the policy statement as one of the Commission's policies, to limit the number of total deaths? That could be a qualitative statement also.

17

23

24

25

1

2

3

MR. MURPHY: Yeah.

DR. KRESS: But, you know, I was of the feeling you might want to -- in terms of protecting the environment, that is one thing, that is a land -- to me, that is a land contamination. I think you might want to think about a qualitative statement on total deaths also.

MR. MURPHY: I don't have any major objection to it. What I am concerned about is, do I really want to get siting policy in a safety goal policy statement?

DR. KRESS: That is a legitimate question.

2 MR. MURPHY: And that is perhaps the thing that troubles me the most as I think about it. But should I have 3 -- you know, the overall impact is something worth 4 5 considering. As I say, I have a problem right now, I have a double problem. One is the tools I have are very weak. 6 7 Those of you who are familiar with it, the assumption in NUREG-1150 was that when a puff release occurs, it goes in 8 9 one direction forever.

10

25

1

DR. KRESS: Absolutely.

11 MR. MURPHY: The overall impact of that is hard to 12 discuss, but I know it doesn't represent reality. I know 13 that the wind persistence data from the United States 14 indicates that there is almost no place in the United States 15 where the wind persistence in one direction for six hours is 16 greater than 50 percent. And I know that in valley sites 17 and river sites, and ocean sites, there tends to be a 18 predominant flow either up and down a valley or in and out 19 the sea. And so the wind rows is very particularized in 20 which way it goes. So this may -- so the plume, instead of 21 going long-way this way, may be going back and forth. And 22 what the overall effect of that is, whether there is 23 conservative or non-conservative, quite frankly, I don't know. But I do know it doesn't model reality. 24

DR. KRESS: It depends on the wind rows and the

1 population distribution probably.

MR. MURPHY: So we need to do more analysis. And what we are suggesting is that we do more analysis and we do develop improved tools, but that has to be done in consideration of the regular prioritization process we have in our planning and budgeting process.

Beyond that, we can say that we have land
contamination considered already in the regulatory analysis
guidelines. That is based on NUREG-1150, and, as I said, we
think those things are -- they are the best we have, but
they are weak.

12 Overall societal impact, the only question you 13 have is, do you want to limit it somewhere? And I will give 14 you an example of what I mean. In NUREG-1150, we have two 15 sets of numbers. We have considered population dose 16 person-rem out to 50 miles. We have also considered it to 500 miles. Now, with this meteorological model, I am not 17 sure I believe anything with that 500 miles. 18 I think the weaknesses in that are extremely great. But, in fact, half 19 20 the dose came from greater than 50 miles when you did that calculation. 21

> Now, what does this come from? DR. KRESS: That dose is not a lot.

22

23

24

25

MR. MURPHY: Yeah, but what this came from was giving a large number of people extremely small doses. And,

you know, whether you should credit something like that, or even consider something like that is something that we need to decide. I think it takes a little careful determination as to what an appropriate distance for consideration is, what the critical population is, what you should be worried about. And so to the extent that you can, although I would agree with George, a societal question does not derive from the tools that calculated it, but when you try to set a limit, it seems you would want to set some -- or a goal, you ought to have a goal that you have some capability of trying to determine whether you meet it or not.

1

2

3

4

5

6

7

8

9

10

11

24

25

12 DR. KRESS: My view of that, Joe, is that NRC 13 should ask itself the question, should I be concerned about 14 giving a large number of people a small dose? And small 15 being enough to do some damage, but maybe not kill them. Of 16 course, they ought to be concerned with that. The question 17 is, can you develop a LERF, for example, that deals with 18 early fatalities that already incorporates that goal, how 19 small it has to be and how many people? Maybe you have 20 already bounded it with the LERF you have.

21 MR. MURPHY: Okay. You may need, without thinking 22 this thing through, you may need, for want of a better word, 23 an ERF.

DR. KRESS: Yeah, an ERF.

MR. MURPHY: Or, you know, at least get the

"early" out of it.

1

2

3

4

<u></u>5

6

7

8

9

DR. KRESS: Yeah. And my feeling there --MR. MURPHY: So can consider late releases.

DR. KRESS: My feeling there is in order to judge whether the LERF you have deals appropriately with things like early deaths, land contamination, total person-rem out to real far or not, you need some common metric to compare how much the regulatory agency values not having those things happen.

10 You need a loss function for each of them 11 expressed in dollars some way. It is not easy to do. And 12 loss functions are generally very subjective things. But 13 you need some way to compare each of them and say, well, I 14 value this land thing more than I do this, therefore, it 15 ought to be our LERF goal. Or I value this early fatalities 16 more and it ought to be our LERF goal.

I suspect when you did that, you would come up with a LERF on early fatalities as being the one that controls, but I don't know that because I have never seen the exercise done.

21 MR. MURPHY: The other thing that -- and we have 22 not discussed this in-house, so it is a personal opinion, I 23 would like to see the things we have expressed in things 24 that are under the control of the NRC. And when I get into 25 all the emergency actions, protective actions, you know, I

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

am getting beyond it, and that leads me back to the LERF or whatever, some sort of release guideline, so I tend to agree with you very much on that.

DR. KRESS: I would put it all in terms of LERF because it is under your control.

1

2

3

. 4

5

6 CHAIRMAN POWERS: Can I ask you a question in 7 another context? NRC has suggested that doses, the cleanup 8 of sites to dose levels on the order of 20 millirem, all 9 pathways, all sources is adequate. Can't that give you a 10 good capping on how far out to carry to your dose dispersion 11 calculations?

12 MR. MURPHY: I don't think I can't answer your 13 question, Dana.

14 CHAIRMAN POWERS: In another context, Commissioner 15 Diaz has acquainted me with one of his own assessments and 16 that is that at doses below 100 millirem, we simply can't 17 distinguish the effects from natural effects, and that might 18 give you even another capping on how far you disperse, you 19 carry your dispersal calculations.

MR. MURPHY: So the calculations that we did in 1150 are based on EPA protective action guides which allow -- say, you would relocate if you would get less than 2 rem in the first year, and a half rem per year thereafter, or a half rem in any year thereafter. These are quite different than the numbers you were just quoting.

CHAIRMAN POWERS: Yes.

1

2

3

MR. MURPHY: What would actually happen --CHAIRMAN POWERS: I think I am looking at a different question. 4

I think you have a different 5 MR. MURPHY: 6 question, but in terms of what, it would -- how it enters 7 into this, I just had the one set of data that was 8 calculated using one set of assumptions. Now, obviously, it 9 is like a yo-yo, you know, if I push down and get low dose, 10 I get large land contamination. If I get low land contamination, I get large dose. 11

CHAIRMAN POWERS: I guess I didn't follow that at 12 all. 13

14 MR. MURPHY: What I am saying is if I allow people 15 in -- if I want to minimize the amount of land that is 16 interdicted by setting a high goal for that, then I get a 17 higher population dose. If I get a lower population dose, 18 then the amount of land will go up. We have picked a point 19 that is based on the EPA protective action guides as we did 20 our calculation. I don't know what would happen in a real 21 accident.

22 CHAIRMAN POWERS: Well, I think you are addressing 23 a different question than I was --

24 MR. MURPHY: Okay, maybe I didn't understand your question. 25

CHAIRMAN POWERS: I was really coming to this, do we go out to 50 miles or 500 miles? And when do we stop, and when do we quit giving large populations minuscule doses and then imputing from the linear hypothesis some health hazard? And it seems to me that if you said I carry it out until I fall down to 25 millirem from all sources --6

1

2

3

4

5

7

8

9

10

DR. KRESS: Which may be plant and site-specific. Well, since it is a dose, it would be, depending on the wind rows and the calculation, --

CHAIRMAN POWERS: Percent always depends on that.

DR. KRESS: So it wouldn't be one fixed number, it 11 12 would depend on the site.

CHAIRMAN POWERS: True. 13 I mean I think that --14 certainly, if I lived next to a plant, I would be happiest 15 if you took your analysis and considered my site and not 16 somebody else's site, and whatnot. And that is a way of 17 capping it.

18 DR. WALLIS: The reality, it seems to me, if you 19 look at the Chernobyl experience, you can get some evidence 20 for what actually happened in terms of land contamination, 21 and how many -- for how many years the sheep in Scotland 22 could not be eaten and things like -- this is actually a matter of record, not hypothesis. You might use this 23 24 reality to get you some kind of a basis for decision making. 25 CHAIRMAN POWERS: Well, unfortunately, what you

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

280 1 have to do is go back and actually look at the contamination, because European countries have interdictions 2 3 of the food supplies on a more restrictive basis than the NRC has ever considered. 4 DR. WALLIS: But you could probably translate to 5 6 the United States standards. 7 CHAIRMAN POWERS: In which case, the sheep would 8 never have been interdicted in Britain. : 9 DR. KRESS: This would help you get the loss 10 function I was talking about, you know, how much does it

11 | cost you?

12 CHAIRMAN POWERS: Joe, can you complete this in 13 the next three minutes?

14MR. MURPHY: If I can complete it -- well, it15depends how many questions I get, but --

16DR. KRESS: Well, I have got at least one on this17one.

MR. MURPHY: Yeah. Temporary changes in risk, the existing safety goal. This is out of the '86 policy. The statement I quoted earlier, the Commission's first qualitative safety goal is the risk from nuclear power plant operation should not be a significant contributor to a person's risk of accidental death or injury.

24 We raised a question earlier whether -- how we 25 should consider temporary changes in risk, as changes from

configuration control and that sort of thing. I think, if we are looking at that qualitative statement, I think in principle the temporary risks are already covered.

DR. KRESS: In principle, but that principle doesn't translate into anything useful in this case.

1

2

3

4

5

6

7

8

24

25

MR. MURPHY: Now, taking it from there and trying to get that into an implementation is going to take some time.

9 DR. KRESS: Yeah. And in order to do it, I think 10 you need a cap on the temporary risk, and I will tell you 11 why, even though you have a statement in there. The total 12 CDF, as you note, is an annualized average over the lifetime 13 of the plant.

14 A temporary change is a here and now thing that 15 certainly adds into that, as you say, but you cannot account 16 for it in your calculations as CDF because you don't know, 17 it is never accounted for because you don't know how big it is going to be, how long it is going to be, or how many of 18 19 these you are going to have. And the idea would be, with a 20 cap, is to say, well, I don't want -- I have a got a CDF calculation that doesn't include it, I don't want these 21 22 things to add more than, say, 10 percent more to my CDF. 23 Pick out a number, 10 percent would be a good quess.

Then I look at historical records and maybe if I just look at how many shutdowns I have and say, I cannot

have more than X number, N number of these temporary spikes because I have only two of them each shutdown or something. This is just experience. Therefore, I have a number for how many spikes I expect. I have a CDF for the plant and I don't want these spikes to add more than 10 percent more to the CDF. That gives you an integral of the cap DT that you cannot exceed as a temporary risk, and it is a cap. And I think that is a reasonable way to approach this, and I think you do need a cap on temporary risk in order to incorporate it properly into the risk-informed system.

1

2

<u>,</u>3

4

5

6

7

8

9

10

17

11 MR. MURPHY: I suspect several of us have various 12 reactions. Let me try one first and then ask Gary if he has 13 one.

When you do what you said, I don't disagree in principle with what you said, but recognize that all the spikes aren't up, some of the spikes are down.

DR. KRESS: I would ignore the down ones.

18 MR. MURPHY: I wouldn't. I would take the 19 integral and say if the day to day variation in risk, how 20 well does that -- as actually happens by looking at the 21 configuration controls, how does that compare with my average? Then I would look at that and say, are any spikes 22 23 high enough that they raise this question that the risk was a significant contributor to a person's risk as he goes 24 25 about his daily life? So this considers the variation of

> ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

the risk at the plant. The hardest part of it may be consideration that the individual's risk from other causes changes on a daily basis, too, and how you factor that kind of thing in.

Gary.

1

2

3

4

5

6

7

8

9

12

MR. HOLAHAN: Yeah, I would like to say I agreed with some of what I heard, but I am not sure I agreed with any of it. I am not very enthusiastic about having any sorts of limits or goals on temporary risks. I think that 10 the spikes, ups and downs, need to be included in the 11 analysis. Okay. To a certain extent we do that now. We include, you know, unreliability and unavailability of equipment, you know, it is averaged in the PRA. 13

14 The difficulty I see is there is a temptation to 15 take, you know, the highest spike and compare it to some 16 goal. But I think Joe said it correctly, you know, remember 17 the safety goal is derived from, you know, 1/10th of 1 18 percent of accidents. But the risks of accidents go up and down. As a matter of fact, the accident risk is dominated 19 20 by automobile accidents, automobile fatalities, and those 21 definitely go up and down.

22 As a matter of fact, right now, sitting on the 23 fourth floor of this building, I suspect our automobile risk is exceedingly low. Okay. But it snows sometimes and you 24 25 go out on the road, obviously, the risks go up and down.

And if you want to control the peaks, you have got to compare peaks to peaks, okay, and not peaks to averages. I think it is meaningless to say at one point in time the reactor risk peaked up, you know, by a factor of 10 and that it would be compared to something. Well, should it be compared to drunk driving or driving while you are talking on the cell phone? What do you compare it to?

8 If you start comparing it to the averaged 9 automobile fatalities, I think you have -- all of a sudden, 10 you know, doing the wrong arithmetic. So I think you should 11 put it in the analysis, calculate the mean values and 12 compare mean values to mean values. And I think that is 13 taking care of the arithmetic all right.

MR. KING: I kind of like the idea of a cap on risk, but I don't think you need to change the policy statement to implement such a thing in a Reg. Guide or anyplace else. So I agree with Joe's.

DR. KRESS: Yeah.

1

2

3

4

5

6

7

18

MR. KING: And at that, I don't think we have settled internally exactly how we are going to deal with changes and risks, but I do agree, we don't need to do anything to the policy statement to let us do that.

DR. KRESS: I think this is an issue having to do with risk management in outages. I think that is where it belongs, in some sort of rule there. And I agree, it

shouldn't -- it doesn't belong in a policy statement.

MR. MURPHY: Let me share one --

MR. HOLAHAN: I would like to correct my statement. We are sitting on the second floor, but the automobile risk isn't any higher on the second floor than it was on the fourth.

[Laughter.]

1

2

3

4

5

6

7

8 MR. MURPHY: Let me just mention, at least three 9 or four years ago OECD did a study of the use of, for want 10 of a better word, risk meters, or that type of device in the 11 U.K., and a report was published. And as that report 12 recalled the results of that, particularly for the Torness 13 Plant in Scotland, they used a philosophy that basically 14 said the instantaneous spike that you are talking about, and 15 then comparing that to the width, that if the spike was a 16 factor of 3, you could stay there one-third of the year. If 17 the spike was a factor of 10, the maximum time you could 18 stay there was 1/10th of a year, or 30 days. And if the 19 spike was a factor of a hundred, you could stay there for no 20 more than three days and they set a limit on a spike of a 21 hundred.

22 DR. KRESS: That is almost kind of like -- that is 23 almost what I was saying.

24 MR. MURPHY: Yeah. They also set a limit that 25 said here is your instantaneous PRA -- I mean here is your

average PRA, your annual average, and you take all the spikes, you record all the changes in the plant as you go along, as you run this device, and at the end you integrate it, and the integration has to be within a factor of 2 of the annual average, or a factor of 3 -- a factor of X, I forget the number. And that was the way that they used it is in terms of setting a goal for how you would use this system.

1

2

3

4

5

6

7

8

.9

12

And with that, I think I am done, Dana.

DR. KRESS: Well, we thank you, Joe. Unless there are more questions, --

DR. WALLIS: I want to know what happens next.

DR. KRESS: Well, we -- our plans I think at this time are to possibly write a letter in March on this proposal and just basically tell them what we think about their positions on each one of these issues. You know, we have expressed some opinions here. We have to discuss it among ourselves and come to some committee.

19DR. WALLIS: Is this something that goes to the20Commission and the Commission will make a decision?

DR. KRESS: It is going to the Commission at the end of March, I understand.

DR. WALLIS: Does it go out to the public?
 MR. MURPHY: We have to give the Commission a
 paper on modifications of the safety goal policy statement

ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036 (202) 842-0034

by the end of March. 1 DR. WALLIS: Does it go to the public? 2 3 DR. KRESS: No, it is going to the Commission. DR. SEALE: Not at this time. 4 5 The Commission will make a decision DR. WALLIS: 6 of what they think is in the public interest without 7 consulting the public. 8 MR. MURPHY: We will get the Commission's advice. 9 What we are calling for is that after we get permission to 10 go forward, we go change the policy statement. And that 11 draft then would circulate for public comment. DR. WALLIS: It would? 12 MR. MURPHY: Yes. 13 14DR. SEALE: It is in the Federal Register. 15 DR. WALLIS: I thought it was. 16 MR. MURPHY: I would think there would be more than the Federal Register, we would probably need to have a 17 18 workshop or two on the subject. 19 DR. SEALE: The first decision is whether or not 20 you want to open a can of worms. 21 CHAIRMAN POWERS: At this point I think I am going 22 to bring this session to a close and we can go off the 23 record. 24 [Whereupon, at 4:37 p.m., the meeting was recessed 25 to reconvene at 8:30 a.m., Friday, February 4, 2000.] ANN RILEY & ASSOCIATES, LTD. Court Reporters 1025 Connecticut Avenue, NW, Suite 1014 Washington, D.C. 20036

(202) 842-0034

287

REPORTER'S CERTIFICATE

This is to certify that the attached proceedings before the United States Nuclear Regulatory Commission in the matter of:

NAME OF PROCEEDING: MEETING: 469TH ADVISORY COMMITTEE ON REACTOR SAFEGUARDS (ACRS)

CASE NO:

PLACE OF PROCEEDING: Rockville, MD were held as herein appears, and that this is the original transcript thereof for the file of the United States Nuclear Regulatory Commission taken by me and thereafter reduced to typewriting by me or under the direction of the court reporting company, and that the transcript is a true and accurate record of the foregoing proceedings.

Jon Hundley

Official Reporter Ann Riley & Associates, Ltd.



UNITED STATES NUCLEAR REGULATORY COMMISSION ADVISORY COMMITTEE ON REACTOR SAFEGUARDS WASHINGTON, D. C. 20555

January 24, 2000 (REVISED)

SCHEDULE AND OUTLINE FOR DISCUSSION 469TH ACRS MEETING **FEBRUARY 3-5, 2000**

THURSDAY, FEBRUARY 3, 2000, CONFERENCE ROOM 2B3, TWO WHITE FLINT NORTH, ROCKVILLE, MARYLAND

- 8:30 8:45 A.M. 1)
 - Opening Remarks by the ACRS Chairman (Open)
 - Opening statement (DAP/JTL/SD) 1.1)
 - 1.2) Items of current interest (DAP/NFD/SD)
 - 1.3) Priorities for preparation of ACRS reports (DAP/JTL/SD)
- 8:45 10:45 A.M. 2)
 - Technical Aspects Associated with the Revised Reactor Oversight Process and Related Matters (Open) (JJB/MVB/MTM)
 - Remarks by the Subcommittee Chairman 2.1)
 - 2.2) Briefing by and discussions with representatives of the NRC staff regarding the technical aspects associated with the revised reactor oversight process, including the updated significance determination process, technical adequacy of the current and proposed plant performance indicators, and related matters.

Representatives of the nuclear industry will provide their views, as appropriate.

10:45 - 11:00 A.M. ***BREAK***

- 3)
- 11:00 12:00 Noon Proposed Final Amendment to 10 CFR 50.72 and 50.73 (Open) (MVB/NFD)
 - 3.1) Remarks by the Subcommittee Chairman
 - 3.2) Briefing by and discussions with representatives of the NRC staff and the Nuclear Energy Institute (NEI) regarding the proposed final amendment to 10 CFR 50.72, "Immediate Notification Requirements for Operating Nuclear Power Reactors," and 50.73, "Licensee Event Report System."

12:00 - 1:00 P.M. ***LUNCH***

- 4) 1:00 - 2:30 P.M. Proposed Regulatory Guide and Associated NEI Document 96-07, "Guidelines for 10 CFR 50.59 Safety Evaluations" (Open) (JDS/JJB/MME)
 - Remarks by the Cognizant ACRS member 4.1)

Briefing by and discussions with representatives of the NRC staff and NEI regarding the status of development of proposed Regulatory Guide, which endorses guidance in NEI 96-07 associated with the implementation of the revised 10 CFR

2:30 - 2:45 P.M. ***BREAK***

5)

6)

4.2)

2:45 - 4:15 P.M. Proposed Revision of the Commission's Safety Goal Policy Statement for Reactors (Open) (TSK/GA/PAB)

50.59 process.

- Remarks by the Subcommittee Chairman 5.1)
- Briefing by and discussions with representatives of the NRC 5.2) staff regarding proposed revision of the Commission's Safety Goal Policy Statement for reactors and related matters, including industry views.

Representatives of the nuclear industry will provide their views, as appropriate.

4:15 - 5:15 P.M. Break and Preparation of Draft ACRS Reports Cognizant ACRS members will prepare draft reports for consideration by the full Committee.

5:15 - 7:15 P.M. 7) Discussion of Proposed ACRS Reports (Open) Discussion of proposed ACRS reports on:

- 7.1)
- Low-Power and Shutdown Operations Risk Insights Report (GA/MTM)
- 7.2) Technical Aspects Associated with the Revised Reactor Oversight Process (JJB/MVB/MTM)
- Proposed Final Amendment to 10 CFR 50.72 and 50.73 7.3) (MVB/NFD)
- 7.4) License Renewal Process (MVB/RLS/NFD)
- 7.5) Response to Follow-up Questions Resulting from the ACRS Meeting with the Commission on November 4, 1999 (DAP/NFD/SD)

FRIDAY, FEBRUARY 4, 2000, CONFERENCE ROOM 2B3, TWO WHITE FLINT NORTH, ROCKVILLE, MARYLAND

8:30 - 8:35 A.M. Opening Remarks by the ACRS Chairman (Open) (DAP/SD) 8)

9) 8:35 - 10:30 A.M. Impediments to the Increased Use of Risk-Informed Regulation and Use of Importance Measures in Risk-Informing 10 CFR Part 50 (Open) (GA/TSK/AS)

Remarks by the Subcommittee Chairman 9.1)

9.2) Briefing by and discussions with representatives of NEI as well as invited experts regarding impediments associated with the increased use of risk-informed regulation and use of importance measures in risk-informing 10 CFR Part 50, and related matters.

Representatives of the NRC staff will provide their views, as appropriate.

10:30 - 10:45 A.M. ***BREAK***

10) 10:45 - 11:30 A.M.

Proposed Final Revision of Appendix K to 10 CFR Part 50 (Open) (GBW/PAB)

- 10.1) Remarks by the Subcommittee Chairman
- 10.2) Briefing by and discussion with representatives of the NRC staff regarding the proposed final revision of Appendix K, "ECCS Evaluation Models," to 10 CFR Part 50, "Domestic Licensing of Production and Utilization Facilities."

Representatives of the nuclear industry will provide their views, as appropriate.

11) 11:30 - 11:45 A.M.

Subcommittee Report (Open) (GA/MTM) Report by the Chairman of the Reliability and Probabilistic Risk Assessment Subcommittee regarding matters discussed during the December 15-16, 1999 meeting.

Representatives of the NRC staff will provide their views, as appropriate.

Report of the Joint ACRS/ACNW Subcommittee (Open) 12) 11:45 - 12:00 Noon (TSK/GA/MTM) Report on matters discussed during the January 13-14, 2000 meeting of the Joint ACRS/ACNW Subcommittee.

LUNCH 12:00 - 1:00 P.M.

NRC Safety Research Program Report to the Commission (Open) (GBW/MME)

- 13.1) Remarks by the Subcommittee Chairman
- 13.2) Discussion of the annual ACRS report to the Commission on the NRC Safety Research Program.

Representatives of the NRC staff will provide their views, as appropriate.

3:00 - 3:15 P.M. ***BREAK*** 3

1:00 - 3:00 P.M.

13)

14)	3:15 - 3:30 P.M.	Reconciliation of ACRS Comments and Recommendations (Open) (DAP, et al./SD, et al.) Discussion of the response from the NRC Executive Director for Operations to comments and recommendations included in recent ACRS reports and letters.
15)	3:30 - 3:45 P.M.	<u>Future ACRS Activities</u> (Open) (DAP/JTL/SD) Discussion of the recommendations of the Planning and Procedures Subcommittee regarding items proposed for consideration by the full Committee.
16)	3:45 - 4:30 P.M.	Report of the Planning and Procedures Subcommittee (Open) (DAP/JTL) Report of the Planning and Procedures Subcommittee on matters related to the conduct of ACRS business.
17)	4:30 - 5:30 P.M.	Break and Preparation of Draft ACRS Reports Cognizant ACRS members will prepare draft reports for consideration by the full Committee.
18)	5:30 - 7:15 P.M.	 <u>Discussion of Proposed ACRS Reports</u> (Open) Discussion of proposed ACRS reports on: 18.1) Impediments to the Increased Use of Risk-Informed Regulation and Use of Importance Measures in Risk- Informing 10 CFR Part 50 (GA/TSK/AS) 18.2) Technical Aspects Associated with the Revised Reactor Oversight Process (JJB/MVB/MTM) 18.3) NRC Safety Research Program (GBW/MME) 18.4) Response to Follow-up Questions Resulting from the ACRS Meeting with the Commission on November 4, 1999 (DAP/NFD/SD) 18.5) Low-Power and Shutdown Operations Risk Insights Report (GA/MTM) 18.6) Proposed Final Amendment to 10 CEP 50 72 and 50 73
		 18.6) Proposed Final Amendment to 10 CFR 50.72 and 50.73 (MVB/NFD) 18.7) Proposed Revision of the Commission's Safety Goal Policy Statement for Reactors (TSK/GA/PAB) 18.0) Expression Proposed Revision (MV/D) (MIED)
		 18.8) License Renewal Process (MVB/RLS/NFD) 18.9) Proposed Final Revision of Appendix K to 10 CFR Part 50 (GBW/PAB)
SATURDAY, FEBRUARY 5, 2000, CONFERENCE ROOM 2B3, TWO WHITE FLINT NORTH, ROCKVILLE, MARYLAND		

19) 8:30 - 2:00 P.M.Discussion of Proposed ACRS Reports (Open)(12:00-1:00 P.M. - LUNCH)Continue discussion of proposed ACRS reports listed under Item 18.

20) 2:00 - 2:30 P.M. <u>Miscellaneous</u> (Open) (DAP/JTL) Discussion of matters related to the conduct of Committee activities and matters and specific issues that were not completed during previous meetings, as time and availability of information permit.

NOTE:

- Presentation time should not exceed 50 percent of the total time allocated for a specific item. The remaining 50 percent of the time is reserved for discussion.
- Number of copies of the presentation materials to be provided to the ACRS 35.

G DRIVE:INTRODUCTORY INTRODUCTORY STATEMENT BY THE ACRS CHAIRMAN 469TH MEETING, FEBRUARY 3-5, 2000

THE MEETING WILL NOW COME TO ORDER. THIS IS THE <u>FIRST DAY</u> OF THE 469TH MEETING OF THE ADVISORY COMMITTEE ON REACTOR SAFEGUARDS. DURING TODAY'S MEETING, THE COMMITTEE WILL CONSIDER THE FOLLOWING:

- (1) TECHNICAL ASPECTS ASSOCIATED WITH THE REVISED REACTOR OVERSIGHT PROCESS AND RELATED MATTERS
- (2) PROPOSED FINAL AMENDMENT TO 10 CFR 50.72 AND 50.73
- (3) PROPOSED REGULATORY GUIDE AND ASSOCIATED NEI DOCUMENT 96-07, "GUIDELINES FOR 10 CFR 50.59 SAFETY EVALUATIONS"
- (4) PROPOSED REVISION OF THE COMMISSION'S SAFETY GOAL POLICY STATEMENT FOR REACTORS
- (5) PROPOSED ACRS REPORTS

THIS MEETING IS BEING CONDUCTED IN ACCORDANCE WITH THE PROVISIONS OF THE FEDERAL ADVISORY COMMITTEE ACT.

DR. JOHN T. LARKINS IS THE DESIGNATED FEDERAL OFFICIAL FOR THE INITIAL PORTION OF THE MEETING.

WE HAVE RECEIVED NO WRITTEN STATEMENTS FROM MEMBERS OF THE PUBLIC REGARDING TODAY'S SESSIONS. WE HAVE RECEIVED A REQUEST FROM A REPRESENTATIVE OF NEI FOR TIME TO MAKE ORAL STATEMENTS REGARDING PROPOSED REVISION OF THE SAFETY GOAL POLICY STATEMENT. A TRANSCRIPT OF PORTIONS OF THE MEETING IS BEING KEPT, AND IT IS REQUESTED THAT THE SPEAKERS USE ONE OF THE MICROPHONES, IDENTIFY THEMSELVES AND SPEAK WITH SUFFICIENT CLARITY AND VOLUME SO THAT THEY CAN BE READILY HEARD. I WILL BEGIN WITH SOME ITEMS OF CURRENT INTEREST.

Modifications to the Reactor Safety Goal Policy Statement

Presentation to ACRS

Joseph A. Murphy Office of Nuclear Regulatory Research February 3, 2000

Reactor Safety Goal Policy Statement

Background

- SECY -99-191 informed the Commission of progress in developing recommendations regarding modifications to Safety Goal Policy Statement and proposed feasibility study of overarching safety principles.
- Related SRM stated staff should provide a recommendation regarding the policy statement, but disapproved study of the feasibility of developing overarching principles.

Relationship Between Safety Goals and Regulations

- Regulations establish requirements which enable the agency to conclude there is no undue risk to the public health and safety.
- Policy statements provide a high level expression of the safety philosophy and expectations of the agency.
- Safety Goal Policy Statement, coupled with the PRA Policy Statement, provides a foundation for risk-informed regulation of reactors.
- Safety Goal Policy Statement provides the overall targets for safety when considering modification to existing regulations or the addition of new regulations.

Changes to Reflect Current Policy

Proposed Recommendations

- Incorporate five principles from R.G. 1.174 (generalized to reflect broader usage) into Regulatory Implementation portion of the policy statement.
- Incorporate positions taken in 6/15/90 SRM that safety Goals establish a level of safety considered safe enough and that they represent a risk level to strive for, utilizing the provisions contained in the Backfit Rule.
- Provides foundation for risk-informed regulation.

Five Generalized Principles

- Plants are expected to meet current regulations and any applicable exemptions.
- The defense-in-depth philosophy should be maintained.
- Sufficient safety margins should be maintained.
- Where changes in risk might occur, increases in risk or core damage frequency should be small.
- Plant performance should be monitored.

Treatment of Core Damage Frequency as a Fundamental Goal

Proposed Recommendations

- Elevate qualitative statement in policy statement presented below to status of a qualitative goal (with editing).
 - "...the Commission intends to continue to pursue a regulatory program that has as its objective providing reasonable assurance, while giving appropriate consideration to the uncertainties involved, that a severe core damage accident will not occur at a U.S. nuclear power plant."
- Retain CDF of 10⁴/RY as a subsidiary objective and include it in the policy statement.
 - Coupled with LERF, provides practical implementation guidance for QHOs.

Treatment of Uncertainty

Staff Recommendation

- Uncertainty is discussed at some length in policy statement.
- Update discussion of uncertainty in policy statement to reflect the guidance provided in R.G. 1.174.

Defense in Depth

- Current policy statement discusses importance of prevention and mitigation.
- Defense in depth included in five principles from R.G. 1.174
- Note ACRS/ACNW ongoing efforts.
- Incorporate statement on use of Defense in depth from Commission's White Paper

Defense in depth

White Paper

"Risk insights can make the elements of defense-in-depth more clear by quantifying them to the extent practicable. Although the uncertainties associated with the importance of some elements of defense may be substantial, the fact that these elements and uncertainties have been quantified can aid in determining how much defense makes regulatory sense. Decisions on the adequacy of or the necessity for elements of defense should reflect risk insights gained through identification of the individual performance of each defense system in relation to overall performance."

Safety Goal Structure

ACRS in 5/11/98 letter stated:

"The current Policy Statement specifies only a single goal for each objective...An upper limit and a goal define three regions. For risk levels above the upper limit, immediate action should be taken. For risk levels between the upper limit and the goal, the possibility of reducing the estimated metric should be investigated, taking into account costs and benefits. For risk levels below the goal, no action would be required"

Safety Goal Structure and Adequate protection

Backfit Rule

- Structure proposed by ACRS is similar to framework in Backfit Rule (50.109)
 - Backfits required if necessary to ensure adequate protection (a)(5)
 - Backfits allowed if substantial increase in overall protection and costs are justified by increased protection (a)(3)
 - Backfits not allowed because cannot pass tests above.
- Safety Goals help define lower limit since they were used in deriving the Regulatory Analysis Guidelines.

Safety Goal Structure

Adequate Protection

 SECY-99-246 noted "risk estimates serve as an important measure of plant safety, but do not embody the full range of considerations that enter into the judgment regarding adequate protection. The judgment regarding adequate protection derives from a more diverse set of considerations, such as acceptable design, construction, operation, maintenance, modification, and quality assurance measures, together with compliance with NRC requirements including, license conditions, orders, and regulations"

Safety Goal Structure

- Consistent with 10/28/99 SRM, premature to define "reasonable assurance of adequate protection" quantitatively.
- Structure similar to that proposed by ACRS exists.
- Include position in 6/15/90 SRM as discussed above regarding 'safe as safe enough".
- As experience is gained, may be appropriate to consider degree to which risk analyses and defense-in-depth can be used to provide better definition of the upper limit.

Frequency of Large Release of Radioactive Material

Staff Recommendation

- Delete reference to "general performance guideline" since the effort to examine that was terminated in 1993.
- Propose to incorporate a LERF subsidiary goal of 10⁻⁵ per reactor year.
- Eliminates uncertainties associated with Level 3 analysis and is based on activities within control of licensee.

Societal Risk

Considerations

- Qualitative latent cancer safety goal and QHO expressed in terms of fractional impact.
- Population within 10 mi. considered.
- Regulatory Analysis Guidelines consider integrated dose to 50 mi.
- Choice of 10 mi. focuses attention on area where dose is usually the highest.
- Use of 50 mi in R.A.G. may yield results with large uncertainty, and this uncertainty should be discussed in the regulatory analysis.

Societal Risk

Recommendations

- 10 mile zone is appropriate for safety goal.
- Qualitative goal states societal risks to life and health should not be a significant addition to other societal risks.
- Expressing the QHO as a percentage is consistent with the qualitative goal.
- Overall societal impact needs to be evaluated.

Land Contamination and Overall Societal Impact

- Significant portion of population dose comes from ground shine and ingestion. Strongly affected by protective measures.
- Calculations in NUREG-1150 based on EPA Protective Action Guides. Relocation if projected 1st year dose exceeds 2 rem or any succeeding year exceeds 0.5 rem.
- Current Level 3 PRA tools have significant weaknesses that limit utility of predictions at significant distances from the plant.

Land Contamination and Overall Societal Impact

Recommendations

- Add qualitative goal on protecting the environment. Note CDF and LERF provide a level of protection.
- Land contamination is considered in Regulatory Analysis Guidelines, based on NUREG-1150 results and in EISs.
- Development of improved tools will be considered in the planning and budgeting process.

Temporary Changes in Risk

• The existing safety goal states

- The Commission's first qualitative safety goal is that the risk from nuclear power plant operation should not he a significant contributor to a person's risk of accidental death or injury.
- Temporary changes are covered in principle.
- Clarify applies to temporary changes as well as annual average risk.



ACRS PRESENTATION

REVISED REACTOR OVERSIGHT PROCESS PILOT PROGRAM RESULTS AND LESSONS LEARNED

WILLIAM DEAN ALAN MADISON MICHAEL JOHNSON GARETH PARRY

FEBRUARY 3, 2000

AGENDA

- INTRODUCTION
- PILOT PROGRAM RESULTS READINESS FOR START OF IMPLEMENTATION
- DEFINING PRINCIPLES AND ASSUMPTIONS
- PERFORMANCE INDICATORS
- SIGNIFICANCE DETERMINATION PROCESS
- ASSESSMENT PROCESS

PILOT PROGRAM RESULTS - READINESS FOR IMPLEMENTATION

- PIs and Baseline Inspection provide a sound framework for providing oversight of licensee performance to assure that reactor safety is maintained
- NRC assessments and actions more objective, understandable, and predictable to industry and public
- Focus on risk significant issues has reduced unnecessary regulatory burden
- Revised oversight process adequate to support initial implementation at all plants
- The staff will implement an ongoing self-assessment process

FRAMEWORK DEFINING PRINCIPLES AND ASSUMPTIONS

Thresholds can be set, beyond which only minimal NRC interaction is warranted.

• Revised Oversight Process

- Defined, objective threshold
- PI "Green"
- SDP "Green"
- Current Process
 - Subjective threshold
 - Minor violation

- Adequate assurance of performance needs both PIs and inspection results.
 - Revised Oversight Process
 - Integrates PIs with inspection findings
 - Continual assessment
 - Current Oversight Process
 - Relies on inspection findings
 - PIs have minor role and used broadly
 - Assessments every 18-24 months

- Performance in crosscutting areas will be inspected or inferred through both PIs and inspection findings.
 - Revised Oversight Process
 - Assesses performance in cornerstones
 - Considers cross cutting issues causes of problems in cornerstones
 - Directly inspects PI&R, certain aspects of human performance, reviews SCWE
 - Recent changes
 - Current Oversight Process
 - Assesses performance <u>of</u> functional areas
 - Looks for issues crossing functional areas
 - Addresses PI&R in SALP letter

- The oversight process will be indicative within the licensee response band.
 - Revised Oversight Process
 - Risk-informed Baseline Inspection Program (indicative)
 - Supplemental (diagnostic)
 - Increased oversight based on Action Matrix
 - Current Oversight Process
 - Core Inspections and regional initiative inspections diagnostic
 - Initiative inspections loosely based on SALP score

PERFORMANCE INDICATORS

THRESHOLDS

- Used to identify performance levels below which increased NRC interaction is warranted; no ranking or trending of performance
- Green-white threshold identifies outliers/nominal performance
 - --- Based on data from 1995 to 1997
 - --- Identified about 5% of plants per year
 - --- Will be reevaluated using historical data
- IE and MS Yellow and red thresholds based on increase in risk
 - --- Yellow corresponds to ΔCDF of about 10⁻⁵
 - --- Red corresponds to $\triangle CDF$ of about 10⁻⁴

PERFORMANCE INDICATORS

SET OF PIS

- Based upon framework: cornerstones and attributes of licensee performance
- Selected from those currently in use or readily available
 --- Minor modifications to simplify, clarify, or customize
- Improvements made continuously
- Benchmarking showed indicators identified poor performers
- Benchmarking showed SSAs provided no new information

PERFORMANCE INDICATORS

ONGOING WORK

- Consistency of PI Definitions
- Guidance on Programmatic Issues
- Definitions and Guidance for Some Indicators
- Impact of Multi-Unit Sites or Indicators on Site-wide Indicators
- Continued Review of Indicators In Self-Assessment Program
- Risk-Based Indicators/Industry-Wide Performance

SDP Principal Objectives

Significance Characterization

 To characterize the significance of inspection findings arising from deficient licensee performance, using risk metrics where appropriate

Communication

 To clearly communicate the staff's bases for its characterization of the significance of deficient licensee performance

SDP Development/Refinement Plant Specific Reactor Safety SDP

- Plant-specific worksheets are developed from information directly available to the staff (e.g., IPEs)
- Site visits to be conducted with each licensee to obtain comments and any recommended worksheet changes
- Each reactor safety SDP should be tested against the licensee's PRA for general consistency of results

All SDPs

 A feasibility study using actual issues is performed on all SDPs prior to initial implementation

SDP Ongoing Work

- Site-visits and consistency testing for reactor safety SDP are expected to continue through April 2000
- Containment SDP expected to be developed and ready in April 2000
- Shutdown issues screening tool expected to be developed and ready in April 2000
- External events screening tool development in progress with target date April 2000

ASSESSMENT PROCESS

- Provides improved objectivity (subjective judgement is not a central aspect)
- Provides increased predictability through the use of established thresholds for performance and an "Action Matrix" that identifies planned regulatory response
 - Predictability versus rigidity
 - Process for addressing deviations
- Provides opportunity for licensee response/input prior to final NRC determination of issue significance and regulatory response ("due process")

Internal Survey

Background & Purpose

Purpose: Solicit first-hand insights from pilot plant participants

-End-of-pilot survey sent to regions (11/99) -Responses from 94 individuals who directly participated in pilot *-Inside NRC* released information from survey (1/00)

Results

-Regional administrators (Views: significant improvement, more objective, improved consistency) Concerns: documentation threshold, inspection of cross-cutting issues, and SDP

-Individual participants (Views: more objective, PIs in appropriate areas, and effective training) Concerns: timely identification of declining performance, documentation threshold, and SDP

Actions

-Considered during internal and external lesson learned workshop

-Factored into actions planned for completion prior to and post initial implementation

-Results to be released to internal and external stakeholders

Draft Final Rule

. :

Modification of Event Reporting Requirements

10 CFR 50.72 and 50.73

Objectives

Section 50.72 provides immediate reporting of significant events where:

- Immediate NRC action may be required to protect the public health and safety or
- The NRC needs timely, accurate information to respond to heightened public concern

Section 50.73:

- Identifies the types of events and problems believed to be significant and useful to the NRC's effort to identify and resolve threats to public safety
- Is designed to provide information needed for engineering studies of anomalies, trend analysis of occurrences, and identification of accident precursors

Current rulemaking:

- Clarifies requirements
- Reduces unneccessary burden, consistent with risk considerations
- Is consistent with NRC program improvements

Principal Changes

Outside the Design Basis of the Plant

System Actuation

Invalid Actuation

Required Initial Reporting Times

Reporting of Historical Problems

Late Surveillance Tests

Outside the Design Basis of the Plant

In the proposed rule, we recommended deleting this criterion

Significant events would be captured by the following criteria:

- Event or condition that could have prevented the fulfillment of the safety function of structures or systems that are needed to: shut down, maintain safe shutdown conditions, remove residual heat, control radioactive releases, or mitigate accidents.
- Plant in an unanalyzed condition that significantly degraded plant safety
- Principal safety barrier seriously degraded
- Condition or operation prohibited by the plant's technical specifications
- Independent trains or channels inoperable due to a single cause or condition
- <u>A proposed new criterion</u> component in a degraded or non-conforming condition, such that its ability to perform its specified safety function is significantly degraded and the condition could reasonably be expected to apply to other similar components in the plant

Outside the Design Basis of the Plant (continued)

The draft final rule takes the following approach:

- The requirement to report a condition outside the design basis of the plant is deleted
- The new criterion is modified to address concerns raised in the comments and to more precisely address NRC needs
 - As modified, the criterion requires reporting any event or condition that required corrective action for a single cause or condition in order to ensure the ability of more than one train or channel to perform its specified safety function.
 - Events of this type indicate a condition where the NRC needs to consider taking action to ensure the cause or condition is adequately addressed at the reporting plant and/or other plants as appropriate.

4

Outside the Design Basis of the Plant (continued)

Additional guidance regarding the new criterion:

- The "reporting clock" starts when it is determined that corrective action is required for a single cause or condition in order to ensure the ability of more than one train or channel to perform its specified safety function.
- A written LER is due within 60 days. No telephone notification is required.
- This criterion involves corrective actions for significant conditions adverse to quality, under Criterion XVI, Appendix B.
- It does not include cases which merely involve checking of multiple trains or channels.
- The combination of removing the design basis criterion and adding this criterion is estimated, on balance, to result in fewer reports.

5

System Actuation

The proposed rule recommended reporting actuation for a list of systems provided in the rule to provide consistent reporting for actuation of a few standby systems that are risk-significant

Federal Register notice requested public comment, including three alternatives

The draft final rule includes a modified list of systems that provides for:

- Consistent reporting for the named systems, which are risk-significant
- A net reduction in reporting

In the future, as part of the effort to "risk-inform" 10 CFR Part 50, there may be an opportunity to develop plant-specific lists of systems of the most risk-significant systems in accordance with NRC-approved methods and criteria.

Invalid Actuation

In the proposed rule we recommended eliminating telephone notifications for invalid actuations and retaining the requirement for written LERs for these events.

Most commenters opposed any reporting of spurious actuations.

The draft final rule takes the following approach:

- The requirement to provide a telephone notification under §50.72 (i.e., within 8 hours) for an invalid actuation is eliminated.
- The requirement to report these events under §50.73 is retained. However:
 - The licensee has the option of providing a telephone notification.
 - The telephone notification may be made at any time within 60 days.

7

Required Initial Reporting Times

The draft final rule takes the following approach:

- One-hour reporting is required for:
 - Declaration of an emergency class
 - Deviation from the technical specifications under 10 CFR 50.54(x)
- Four-hour reporting is required for:
 - Unplanned transients (ECCS injection, required shutdown, critical scram)
 - Planned news release or notification to another government agency
- Eight-hour reporting is required for other §50.72 events
- Sixty-day reporting is required for reports submitted under §50.73.
- Three redundant criteria are deleted from §50.72

Reporting of Historical Problems

In the proposed rule we recommended using a three year cutoff for two specific types of events Public comment recommended:

- Expanding the idea to other types of events
- Reducing the cutoff to two years

The draft final rule:

- Expands the idea to all reports under 50.72 and 50.73
- Uses a cutoff time of three years to better support performance indicators

Late Surveillance Tests

This change will eliminate reporting of late surveillance tests if the equipment, when tested, was still functional

Such events do not involve an impact on the capability to perform a specified safety function

Schedule

- 02/03/00 Complete briefing of ACRS
- 02/08/00 Complete briefing of CRGR
- 03/10/00 Provide final rule and guidelines to Commission
- 04/07/00 Provide final rule and guidelines to OMB for approval
- 06/23/00 Publish final rule
- 09/23/00 Effective date



STATUS OF 10 CFR 50.59 GUIDANCE

February 3, 2000 Eileen M. McKenna

Office of Nuclear Reactor Regulation

1.

Background

- Final Rule approved June 22, published October 4, 1999 (64 FR 53582)
- Rule revisions become effective 90 days after approval of guidance
- RG is expected to be endorsement of NEI 96-07 (revision)

Current Status

- Draft revisions submitted in 1999 and reviewed by NRC
- Revised NEI 96-07 submitted for NRC endorsement January 18, 2000
- NRC letter with staff comments to be issued early February; meeting with NEI planned for February 9 to discuss open issues
- Commission briefing scheduled for February 29
- Publish draft RG for public comment April 2000

Changes to Rule Requirements

- Organization and format
- Definitions (change, facility, departure from method...)
- Screening capability (using definitions)
- Evaluation criteria ("minimal" increases, design basis limits, departure from methods of evaluation)
- Other Clarifications and Conforming changes

OPEN ISSUES

- Fire Protection plan (and facility) changes
 - GL 86-10 license condition (plan in FSAR, use 50.59)
 - proposal is to use license condition on its own w/o 50.59
 - staff concern is with other process aspects (records, bases)
- Methods
 - clarifications needed on "essentially the same"
 - guidance on plant-specific "approvals"
- Design Basis limits for fission product barriers
 - "subordinate" limits concept not accepted
 - staff concerns with "95/95 DNB" as the fuel DBL
- Screening on design function (examples)


OPEN ISSUES (continued)


• Numerical values


- staff has reached general agreement with the proposal (but some clarifications needed)


- Relationship to Maintenance Assessments


 NEI proposed that "changes associated with maintenance" be covered by maintenance rule (a)(4) assessments, not 50.59
 details of proposal still under review
 - details of proposal still under review













































Operability Determination

- Is a well defined process
 - Focus on system ability to perform a safety function
 - Industry knows how to perform
- Supports Technical Specifications and basis for operational decisions
 - One analysis, highly focused and consistent



What is the issue?

- Reporting degraded components
 - 50.73(a)(2)(ii)(C)
 - Not part of the initial rule proposal
 - Added to final rule issued for comment
- Significantly increases burden
 - Must have a backfit analysis
- Requirement is vague and will be a disaster in implementation


Data Collection?

"A component being in a degraded or non-conforming condition such that the ability of the component to perform its specified safety function is significantly degraded and the condition could reasonably be expected to affect other similar components in the plant"

- ANPR--No longer require reporting...outside design basis.
- FRN--ensure design basis...would continue to be reported

Examples in 1022 do not make sense

- Licensee would have looked at similar components
- Would be addressed in corrective action program
- System safety function not affected--else would have been reported under other criteria
- Not clear what this is trying to do



We are confused

- The industry needs more information
- Can the staff develop clear examples for NUREG 1022?
- Will the staff hold a public meeting and explain how this will work?
- Can we see the backfit analysis that justifies this new requirement?

Remove degraded components and----

- The draft rule improves clarity
 - Worked by regional staffs and operators
- Provides a clear focus and nexus to safety
 - One that can be understood
 - Uses consistent operability determination process
- Would eliminate unnecessary reports
- Could be a great end to an 8 year effort

What next--three options

- Eliminate the requirement
- Separate the degraded component issue from the current rulemaking effort
 - Justify specifically
 - Do the needed backfit analysis
- Stop the process and address event reporting as part of effort to harmonize part 50